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GENERAL INTRODUCTION
Coronary artery disease
Coronary artery disease is one of the leading causes of morbidity and mortality world-
wide(1). Common risk factors for atherosclerosis include high blood pressure, high cho-
lesterol levels, smoking, obesity, diabetes mellitus and a family history of cardiovascular 
disease (2). Atherosclerosis of the coronary artery wall, results in vessel lumen narrow-
ing, limiting the ability to increase blood flow and supply of oxygen to the myocardium 
at instances of increased demand. This often presents with angina pectoris, a clinical 
syndrome characterized by discomfort of the chest, provoked by physical or emotional 
stress and relieved by rest or nitroglycerin. In case a developed atherosclerotic lesion 
suddenly ruptures, acute luminal thrombosis causes partial or complete occlusion of 
the coronary artery resulting in ischemia of the myocardium. The term acute coronary 
syndrome (ACS) refers to the group of clinical symptoms compatible with acute myocar-
dial ischemia.
Usual care of stable angina
The current guidelines recommend exercise electrocardiography (XECG) as first line di-
agnostic test for patients with suspected coronary artery disease (3, 4). While considered 
cost effective, the XECG is also known for its modest diagnostic accuracy(5-8). Stress 
myocardial perfusion imaging (SPECT) and stress echocardiography have a better di-
agnostic accuracy for detecting obstructive coronary artery disease(9). However, these 
stress imaging tests also have practical and logistical drawbacks, are relatively expensive, 
are not 100% accurate, and only reserved for patients with higher probability of disease 
(3, 4). Equivocal stress test results lead to multiple testing, including invasive angiogra-
phy (ICA). The greatest advantage of ICA is high spatial resolution and the possibility of 
directly performing an intervention if needed. However, a US registry reported that only 
37% of ICAs resulted in (mechanical) treatment illustrating that the non-invasive work-
up fails as a gatekeeper to ICA (10). Since publication of the results of the COURAGE and 
FAME trial there is growing consensus that (surgical) revascularization does not benefit 
every patient with angiographic CAD, but should be reserved for those with objective 
myocardial ischemia. Invasive angiography, without proper ischemia testing, leads to 
over-treatment(11, 12).
Cardiac CT
Cardiac CT has emerged as an alternative modality for investigation of suspected CAD. 
It has been increasingly used over the past years, and rapid technological developments 
have led to improvement of spatial and temporal resolution. With the introduction of 
64-slice CT scanners high diagnostic accuracy has been achieved and the reliability to 
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detect and particularly to exclude significant CAD against ICA has been confirmed in 
numerous studies(13, 14).
A cardiac CT examination often starts with a CT assessment of the calcium score. With 
a non-contrast enhanced scan calcium deposition can be detected and quantified non-
invasively using the Agatston method (15). Calcium scores are highly associated with 
the degree and severity of CAD, and thus assist in predicting the probability of future 
cardiac events(16-18). While calcium imaging is still mostly used for risk stratification in 
asymptomatic individuals, the high sensitivity and negative predictive value, makes it 
an excellent diagnostic examination to rule out coronary artery disease in the evalua-
tion of chest pain, avoiding contrast media and reducing costs and radiation exposure 
(19). Registry studies repeatedly showed that in low to intermediate risk patients with a 
negative calcium scan, severe CAD is rare(8, 20, 21).
During coronary computed tomography angiography (CCTA) radiodens iodinated 
contrast medium is injected into the vascular system of the patient to enhance the lumen 
of the coronary artery, revealing the presence and degree of atherosclerosis. It has a high 
sensitivity and negative predictive value for the detection of angiographic stenoses (22, 
23), thereby allowing for reliable exclusion of coronary artery disease (3). However, it is 
limited in its ability to assess the hemodynamic importance of CAD. Because anatomical 
lesion severity is a poor predictor of hemodynamic significance, functional evaluation of 
intermediate stenoses is recommended for therapeutic decision making(3, 24). CT myo-
cardial perfusion imaging (CT-MPI) could complement the anatomical information from 
CCTA by providing functional information and prognostic relevance. During myocardial 
hyperemia by adenosine infusion the myocardial blood flow can be measured from the 
differences in contrast inflow between normally and hypo-perfused myocardium (25). 
It has been validated in single center studies and shown to have diagnostic accuracy 
at least comparable to SPECT, with similar radiation dose and with the advantage of 
providing information on coronary stenosis. Hereby it can function as a gatekeeper for 
ICA in patients without hemodynamically significant CAD (25-29).
Aims
The aim of this thesis was to investigate the optimal diagnostic strategy for patients pre-
senting with stable angina and unstable angina and ACS. A better diagnostic strategy, 
ultimately leads to a better outcome for patients with suspected CAD.
OUTLINE OF THE THESIS
Chapter 2 gives an overview of current use of cardiac CT, including the acquisition 
methods, evaluation of images, and the potential clinical applications of cardiac CT.
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The first part of this thesis focuses on cardiac CT in stable angina patients. We designed 
and performed the multicentre, randomized controlled CRESCENT trial to evaluate 
a cardiac CT work up, consisting of a calcium scan and selective CT angiography with 
standard functional testing in patients with suspected CAD. The results are presented in 
chapter 3. In a sub analysis of this trial (chapter 4) we investigate the gender differences 
in the performance of cardiac CT compared to functional testing. Chapter 5 shows the 
results of the randomized controlled IsoCOR trial comparing two contrast media with 
different osmolarity. The hypothesis was that if iso-osmolar contrast media is injected 
with a comparable iodine-delivery rate to low-osmolar contrast media, the coronary 
opacification is similar as with low-osmolar contrast media.
The second part of this thesis provides information on CT myocardial perfusion imag-
ing in stable angina patients. In chapter 6 we investigate the diagnostic value of trans-
mural perfusion ratio for the detection of hemodynamically relevant coronary artery 
stenosis compared to quantified myocardial blood flow. In chapter 7 we present the 
results of the multicenter randomized controlled CRESCENT-II trial comparing a tiered 
cardiac CT protocol, consisting of the selective performance of a CT-calciumscan, CT-
angiography and CT-myocardial perfusion imaging, with functional testing in patients 
with suspected coronary artery disease.
The third part of the thesis focuses on CT angiography in unstable angina and acute 
coronary syndromes. In the randomized BEACON trial (chapter 8 )we investigated 
whether a diagnostic strategy supplemented by early coronary CT angiography was 
superior to contemporary standard optimal care (SOC) encompassing high-sensitivity 
troponin assays (hs-troponins) for patients with suspected acute coronary syndrome in 
the emergency department. In chapter 9 we describe the sex-associated differences in 
the performance of coronary CT angiography in an emergency setting. In chapter 10 we 
assessed the image quality of coronary CT angiography performed during office hours 
and outside office hours in the emergency department.
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INTRODUCTION
Cardiac CT allows for practically motion-free imaging of the heart and detailed visualiza-
tion of the coronary arteries. Over the past decade noninvasive coronary angiography 
by cardiac CT has become a valuable technique for the diagnostic triage of patients with 
(suspected) coronary artery disease in various settings.
Data Acquisition and Evaluation
Cardiac CT scan modes
A fundamental step in the technical development of cardiac CT has been the removal 
of the physical connection between the rotating and stationary scanner elements. 
So-called slip-ring technology allows transfer of energy and data between the rotat-
ing tube-detector and the stationary unit without cables that necessitate unwinding 
after a few scanner rotations. Continuous rotation allows continuous data acquisition, 
which was crucial for the development of cardiac CT. The first widely applied scan mode 
for cardiac imaging using multislice CT systems was the spiral scan mode. A spiral CT 
scan is performed using continuous table advancement and data acquisition. From the 
table’s perspective the path of the rotating elements has the shape of a helix or spiral, 
hence the name spiral or helical CT. By expanding the number of detector rows cover-
age speed could be improved significantly. While a 4-slice cardiac CT scan required up 
to 40 seconds, 64-slice CT systems and beyond can complete the acquisition in a few 
heart beats or less, which allows for a much more comfortable breath-hold. While the 
spiral scan mode with retrospective ECG synchronization is a very robust technique it 
has the drawback of a relatively high radiation exposure. In an effort to reduce radiation 
exposure the axial scan mode was re-introduced, though with continuous scanner rota-
tion, and has by now become the default scan mode. Scanners with sufficient detector-
collimation width to cover the entire heart do not require movement of the table during 
the examination.
ECG-Synchronization
For most scanners the width of the combined detector rows is insufficient to cover the 
heart at once. Therefore several stacks of data need to be acquired over several heart 
cycles to image the complete heart (figure 1). In order to create a comprehensible CT 
angiogram the acquisition or reconstruction of images needs to be synchronized to the 
heart cycle. Displacement of the coronary arteries varies throughout the cardiac cycle 
and is generally least during mid-diastole or end-systole. Therefore, ECG-synchronization 
is important both to create images without motion artifacts as well as phase consistency 
between images acquired during different heart cycles. There are two approaches to 
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acquire ECG-synchronized CT images. The original spiral CT protocols used only retro-
grade ECG-gating, which implies that after the acquisition of CT data a recorded rhythm 
tracing was used to select phase-consistent data to reconstruct images. This approach 
requires that each table position is scanned for the duration of at least one heart cycle. 
The advantage is that retrospectively any cardiac phase can be reconstructed. The 
downside is that the radiation dose to the patient is fairly high. The alternative approach 
is prospective ECG-triggering, in which case the data acquisition (and radiation expo-
sure) is limited to a pre-specified window within the heart cycle based on the live ECG 
trace. The axial scan mode is performed using prospective ECG triggering: each set of 
images is acquired in sequence, triggered by the ECG, with repositioning of the table in 
between scans. Nowadays, ECG-gated spiral scans can be combined with prospectively 
ECG-triggered variation of the roentgen tube output to lower exposure during phases 
that are not expected to be needed for image interpretation. Alternatively, contempo-
rary axial scan protocols can be performed with an extended exposure window to allow 
for reconstruction of more cardiac phases.
Axial source images 3D CT angiogram
Figure 1. ECG-gated spiral CT image reconstruction. Overlapping data is acquired during a spiral CT scan. 
Using the recorded ECG, images are reconstructed from phase-consistent data acquired during each con-
secutive heart cycle. Together the reconstructed images from several heart cycles become a complete 3D 
data set of the heart during a single phase of contraction.
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Temporal Resolution
While the scan time refers to the duration of the entire CT acquisition, the temporal 
resolution relates to the time needed to acquire a single image. The temporal resolution 
is comparable to the shutter time of a camera, and needs to be as short as possible 
to avoid motion blurring on the images. The fundamental temporal resolution of CT is 
determined by the rotation speed of the system, the image reconstruction algorithm, as 
well as the number of tube-detector units on the scanner. Standard partial scan recon-
struction algorithms require approximately half of a rotation of projection data to create 
an image, so the temporal resolution is about half of the rotation time of the scanner. 
Alternatively, multisegmental reconstruction algorithms combine scan data from con-
secutive heart cycles to reconstruct images. Theoretically, the temporal resolution could 
be a fraction of the number of cycles combined (generally between two and four). In 
reality the effective temporal resolution is improved to a lesser magnitude, depending 
on the heart rate in relation to the scanner rotation time. Another limitation of multiseg-
mental reconstruction algorithms is the requirement that each table position needs to 
be scanned during at least two or more heart cycles. For this reason these algorithms are 
generally only applied in case of a fast heart rate. For slower heart rates the table speed 
would need to be lowered, which would prolong the scan time and increase the radia-
tion exposure. Depending on the rotation speed currently available single-source CT 
scanners offer a temporal resolution between 140 and 200 ms. To improve the relative 
temporal resolution modification of the heart rate by beta-blockers is common practice, 
and essential in patients with a faster heart rate. Alternatively calcium channel block-
ers or sinus node blockers may be used. Dual-source CT scanners are equipped with 
two tube-detector units mounted at an angular offset of 90°. Instead of a 180° rotation 
dual-source CT can acquire the same number of projections from a 90° rotation, which 
improves the temporal resolution by a factor of two (75-83 ms) independent of the heart 
rate. In the vast majority of patients with an acceptable heart rate current CT technol-
ogy allows virtually motion-free imaging of the coronary arteries during phases of the 
heart cycle where the displacement of the heart is small, i.e., the mid-diastolic phase just 
before atrial contraction and/or the end-systolic phase.
Radiation Exposure
CT cannot be performed without exposure to roentgen, which is potential harmful for 
patients. The radiation dose of a cardiac scan generally exceeds that of non-ECG-synchro-
nized CT scans. ECG-gated spiral CT requires multiple sampling to ensure availability of 
data at each table position during at least one entire heart cycle. Additional contributing 
factors to the relatively high radiation dose of cardiac CT are the need for fast rotation 
and thin detector collimation, and the location of the coronary arteries deep inside the 
chest. The actual radiation dose a patient receives during a given examination varies 
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substantially, and is determined by the scanner type, patient characteristics (body size) 
and the scan protocol. Initially, more powerful CT scanners resulted in a gradual increase 
in radiation doses associated with cardiac examinations. Without dose saving measures 
the dose of a 64-slice CT coronary angiogram varies between 8 and 20 mSv [1–4].
General measures to reduce the radiation exposure include narrowing of the scan 
range, lowering of the tube voltage, and lowering of the tube current, particularly in 
smaller patients (table 1) [1,5]. Contemporary scanners with powerful roentgen gen-
erators allow for imaging at tube potentials as low as 70 or 80kV in smaller patients. 
In patients with a regular heart rhythm ECG-triggered tube modulation is an effective 
means to reduce total dose for spiral CT acquisitions, without sacrificing image quality [1] 
(figure 2).With prospectively triggered axial scanning image acquisition (and radiation 
exposure) is limited to the phase of interest, which significantly reduces patient dose. 
Iterative reconstruction techniques, which largely replaced filtered back projection 
over the past few years, improve image quality with effective reduction of image noise. 
Iterative reconstruction techniques lead to dose reductions, when usual noise levels 
are accepted while images are acquired at lower tube current settings. The most recent 
generations of dual-source CT scanners have the capability of performing a prospec-
tively ECG-triggered high-pitch spiral CT scan. This scan mode allows for complete data 
acquisition covering the entire heart within a single heart cycle, despite a maximum 
detector collimation of 5-7 cm. This scan protocol avoids potential stack artifacts that are 
typically seen for scans acquired over several heart cycles, but also further decreases the 
radiation dose. Because only a single heart-phase can be acquired, and a longer period 
within the heart cycle is needed to acquire all images, a low heart rate is important for 
good image quality. In general practice, state-of-the-art CT scanners perform coronary 
CT angiography at an average radiation exposure below 5 mSv. Using more cutting-
edge technology the radiation dose can be less than 1 mSv in selected patients.
Table 1. Dose-reduction measures.
General tube current reduction
Geometry dependent (attenuation-based) tube current modulation
Tube voltage reduction
Tighter scan ranges
Table speed adjusted to the heart rate
ECG-triggered roentgen tube output modulation
ECG-triggered axial scan mode
ECG-triggered high-pitch spiral scan mode
Anatomic tube modulation
Iterative reconstruction algorithms (indirectly)
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Image Reconstruction and Post-processing
As mentioned before images are acquired or reconstructed using ECG synchronization, 
and depending on the scan protocol different phases can be reconstructed afterwards, 
which may be helpful in case of motion artifacts. Images can be reconstructed using the 
filtered back-projection, or using the more recently introduced iterative reconstruction 
algorithms, which have become more or less the current standard. The slice thickness 
is adjustable, but generally selected in accordance with the detector width at around 
0.4-0.75 mm. Overlapping slices can be reconstructed to improve the (subjective) 
longitudinal spatial resolution. The smoothness or sharpness of the images can be 
adjusted by using different reconstruction filters (kernels). Generally the field of view for 
the reconstruction is planned to include the entire heart. Given the fixed image matrix 
dimensions, reconstruction of a larger field of view will reduce the spatial resolution of 
the images.
50%
RR-interval
ECG-Triggered tube modulation
Continuous scanning
Prospective ECG-triggering
Figure 2. ECG-triggered tube modulation. Originally, tube output would be continuous during the data 
acquisition. Using ECG-triggered tube modulation the roentgen tube output can be alternated during the 
heart cycle. Based on the previous heart cycles the anticipated phase for reconstruction is predicted, at 
which time the tube output is elevated to the nominal level. For the remaining of the cycle the tube current 
is maintained at a very low level. For prospectively ECG-triggered, axial CT imaging the table is stationary 
during data acquisition. After each consecutive acquisition the table moves to the next position, which 
generally requires the time of two heart cycles, during which time no roentgen is emitted.
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To facilitate the evaluation of the large numbers of CT images postprocessing tools 
have been developed (figure 3). Cross-sectional images through the CT angiogram can 
be created in any position or orientation. These multiplanar reformations (MPR) can be 
flat cross-sectional planes, or they can be created along the (tortuous) trajectory of a ves-
sel to demonstrate the entire course of that vessel in a single image. Thin-slab maximum 
intensity projections (MIP) are 2D displays of the highest attenuation values, usually 
contrast medium, calcium or metal, within a given slab. It provides greater overview of 
the vessel with better contrast between the lumen and the surrounding tissues. Because 
of the higher attenuation of metal and calcium, MIP is less effective in case of stented or 
severely calcified vessels. These postprocessing tools can be very helpful in combination 
with the axial source images, to assess the coronary lumen and detect coronary artery 
disease. Although not intended for the initial coronary evaluation three-dimensional 
(3D) volume-rendered images are an attractive means to summarize and communicate 
findings. Dedicated postprocessing tools have been developed for specific applications, 
including quantification of stenosis, differentiation of atherosclerotic plaque compo-
nents, myocardial enhancement or contractile function.
CORONARy LUMENOGRAPHy
Detection of Coronary Stenosis
With the introduction of 64-slice CT systems coronary CT has emerged rapidly as a reli-
able diagnostic modality to detect coronary artery disease. (figure 4). Multiple studies 
comparing CT angiography with invasive angiography have shown that for the assess-
ment of individual coronary segments, the sensitivity to detect significant coronary ar-
tery stenosis is around 94%. Calcified coronary disease causes blooming artifacts on CT, 
which increases the apparent stenosis severity of a lesion. CT angiography cannot assess 
the hemodynamic severity of CAD. Depending on the selected stenosis threshold the 
reported specificity of coronary CTA for detecting hemodynamically significant stenosis 
is 64-90%. The negative predictive value of CT has been consistently high in all stud-
ies, with a pooled average of 98%. Because of the excellent negative predictive value, 
coronary CTA is very effective for ruling out obstructive coronary artery disease [6,7,8].
Generally, the confidence and accuracy to assess stenosis is better in larger branches and 
in the absence of extensive coronary calcification (figure 5). Additionally, obesity decreases 
the signal to noise and the ability to assess coronary obstruction. An irregular heart rate, in 
particular atrial fibrillation, causes discontinuity between the consecutive acquisitions and 
negatively affects interpretation of the images, although contemporary technology does 
provide sufficient image quality in selected cases. As discussed previously image quality is 
better in patients with a low heart rate, for single-source CT preferably below 60–65/minute.
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The development of contemporary CT systems with up to 320 detector rows for fast 
coverage, or double source-detector configuration for optimal temporal resolution, 
have improved the diagnostic performance of coronary CT further. However, to perform 
CTA with an optimal visualization of the coronary arteries it requires experienced opera-
tors, readers and sufficient preparations. Nitroglycerin expands the coronary lumen and 
beta-blockers improve image quality by reducing the heart rate. The challenge to rule 
out coronary artery disease is more difficult in patients with a high calcium burden, or 
otherwise higher pre-test probability of coronary artery disease. Because the spatial 
resolution of coronary CTA is lower than for invasive angiography, angiographic disease 
is classified in categories of diameter stenosis: normal in the absence of plaque, <25%, 
25-49%, 50-69%, 70-99%, and occluded [9].
Figure 3. Image postprocessing. Use of different postprocessing tools in the same data set, which shows 
multiple calcified lesions in the left anterior descending coronary artery (LAD)(b and e). A complete 3D 
reconstruction of the heart (a) shows the highly calcified lesions in the LAD (arrows). Only a small section 
of the LAD can be visualized on a single axial slice (d), while multiplanar reformations can be created to 
demonstrate a longer section of the vessel (c). Curved multiplanar reformations (b) and maximum intensity 
projections (c) can be used to show the entire vessel in a single image. Panels (f–h) show cross-sections 
of the LAD at the proximal reference, the suspected stenosis and the distal reference level (arrowheads), 
respectively. D, diagonal branch; MO, marginal branch.
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Coronary CTA is unable to directly assess the functional severity of coronary artery 
disease. To determine whether a lesion detected by cardiac CT causes ischemia may 
require a subsequent stress test or invasive FFR. Recently, CTA derived FFR (CTA-FFR) was 
introduced, which is a new technique that applies computational fluid dynamics to a coro-
nary/myocardial model derived from the cardiac CT exam. Without the need for additional 
scans or stress medication (adenosine) aorta-coronary pressure gradients under simulated 
Figure 4. Severe coronary stenosis. CT shows a severe stenosis of a large obtuse-marginal branch (MO) of 
>70% (arrow). Maximum intensity projection of the circumflex artery (Cx) and the MO showing the severe 
stenosis (arrow) (b). Invasive angiography showing the left coronary system and stenosis (arrow)(c).
Figure 5. CT angiography shows an occluded 
left circumflex coronary artery, which appears to 
consist of thrombus on top of a partially calcified 
plaque. The plaque contains plaque with low at-
tenuation values as well as spots of calcium. The 
vessel is also outwardly remodeled, all of which 
are features associated with rupture-prone 
plaque.
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hyperemia can be calculated throughout the coronary artery tree (figure 6). The good di-
agnostic performance of CTA-FFR in comparison with conventional invasive FFR has been 
demonstrated in several trials [10,11]. On-site performed CTA-FFR have recently become 
available, which also shows promising performance in single center studies[12,13].
Clinical Applications
Coronary CTA is characterized by an excellent negative predictive value for confident ex-
clusion of coronary stenosis, especially in patients with a low to intermediate probability 
of coronary artery disease. Based on the 2013 ESC guidelines on stable coronary artery 
disease coronary CTA is suitable for patients with a low to intermediate probability of 
disease (15-50% using the Genders prediction rule [14]) and an equal alternative com-
pared to functional testing, under the condition that the patient is a suitable candidate 
for CT and if adequate technology and local expertise is available. (Class IIa, level of 
evidence C). [15] In addition, coronary CTA can be used for patients with inconclusive 
functional test results (Class IIa, level of evidence C). The ACC/AHA guidelines for stable 
ischemic heart disease consider coronary CTA as an alternative diagnostic option when 
functional testing is not possible or leads to inconclusive test results (Class IIa).
Figure 6. CTA shows moderate re-stenosis after 
placement of a bio-resorbable scaffold in the left 
anterior descending coronary artery (LAD) (A). 
The three-dimensional rendering of the CTA-
derived fractional flow reserve (FFR) simulation 
displays calculated FFR values as a color map (B). 
While a change in shading from blue to green 
over the treated LAD indicates a change in FFR 
values, the distal CTA-FFR does not drop below 
0.80, and is therefore not regarded as hemody-
namically significant.
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Use of coronary CTA recommended by current ESC Guidelines
•	 Coronary	CTA	should	be	considered	as	an	alternative	to	stress	imaging	techniques	
for ruling out stable coronary artery disease in patients within the lower range of 
intermediate PTP for stable CAD in whom good image quality can be expected (class 
IIa, level of evidence C).
•	 Coronary	CTA	should	be	considered	in	patients	within	the	lower	range	of	interme-
diate PTP for stable coronary artery disease after a non-conclusive exercise ECG or 
stress imaging test, or who have contraindications to stress testing in order to avoid 
otherwise necessary invasive coronary angiography, if fully diagnostic image quality 
of coronary CTA can be expected (class IIa, level of evidence C).
•	 Coronary	calcium	detection	by	CT	is	not	recommended	to	identify	individuals	with	
coronary artery stenosis (class III, level of evidence C).
•	 Coronary	CTA	is	not	recommended	in	patients	with	prior	coronary	revascularization.	
(class III, level of evidence C)
•	 Coronary	CTA	is	not	recommended	as	a	'screening'	test	in	asymptomatic	individuals	
without clinical suspicion of coronary artery disease (class III, level of evidence C).
•	 Coronary	 CTA	 should	 be	 considered	 as	 an	 alternative	 to	 invasive	 angiography	 to	
exclude ACS when there is a low to intermediate likelihood of CAD and when cardiac 
troponin and/or ECG are inconclusive (class IIa, level of evidence A).
After publication of these guidelines a few comparative effectiveness trials have been 
published (table 2). The pragmatic PROMISE trial randomized an impressive 10.003 
patients with new stable chest pain between CT angiography and functional testing 
(mostly nuclear imaging) for evaluation of suspected coronary artery disease. The study 
demonstrated that there was no difference in adverse cardiac events after 2 years. [16] 
Although after CT more patients underwent invasive angiography and more were re-
vascularized, the number of invasive angiograms without obstructive coronary artery 
disease was reduced. In the SCOT-HEART trial, the addition of coronary CTA to standard 
care was investigated in 4146 patients with stable angina. [17] The investigators demon-
strated improved certainty of the diagnosis of angina pectoris caused by ischemic heart 
disease, but no effect on frequency of the diagnosis of angina due to coronary artery 
disease. After 1.7 years, there was a close to statistically significant 38% reduction in 
hard events in favor of patients in the CT group. The smaller CRESCENT trial randomized 
350 patients between cardiac CT, consisting of a calcium scan and selective coronary 
CTA, and functional testing [18]. This study showed that after CT, more patients reported 
complete relief of anginal symptoms and resulted in fewer adverse events. CT was 
more often able to confidently rule out coronary artery disease and therefore the final 
diagnosis was reached faster, requiring fewer downstream noninvasive tests without a 
significant increase in invasive angiograms.
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Besides diagnosing stable CAD, coronary CTA also has a role in suspected acute coro-
nary syndromes in the emergency department, which has been investigated over the 
recent years (table 3). The CT-STAT trial compared coronary CTA with nuclear imaging as 
initial test in the management of patients with acute chest pain. They reported a 54% 
reduction in time to diagnosis and 38% lower costs of ED care with CT [19]. The ACRIN-
PA trial demonstrated that low-risk patients could be safely discharged with early CT 
angiography twice as often, and CAD was more likely to be diagnosed with CT. [20] The 
ROMICAT2 trial showed a reduction in length of hospital stay and a 4-fold higher dis-
charge rate from the ED after CT. [21] The results of these trials contributed to a class IIa 
recommendation (level of evidence A) for the use of coronary CTA in low-intermediate risk 
patients with non-conclusive ECG and biomarker results to avoid invasive angiography. 
[22] Since these trials were completed, the introduction of high sensitivity-troponin has 
changed standard care at the ED considerably and may reduce the efficiency benefits of 
CT substantially, as was demonstrated recently in the BEACON trial. [23] It showed that 
CT was safe, less expensive, with less subsequent diagnostic testing. However, CT did 
not identify more patients with significant CAD requiring revascularization and did not 
reduce the length of stay nor allowed more expedited discharge. The role of coronary 
CTA may shift towards the assessment of patients with low-elevated troponin levels, 
which become more frequent with the use of more sensitive troponin assays.
Table 2. Randomized controlled trials comparing coronary CTA and standard care in stable chest pain
PROMISE (2015) SCOT-HEART(2015) CRESCENT (2016)
N 10003 4146 350
Risk D&F: 53 ± 21% ASSIGN 10-year CHD risk: 
17 ± 12%
D&F: 45 ± 29%
Follow up (yrs) 2.1 1.7 1.2
USA Scotland The Netherlands
CT Standard Standard+ 
CT
Standard CT Standard
Additional testing 25%* 53%*
Cath angiography 12.2% 8.1% 12% 13% 12% 11%
Revascularizations 8.8%* 3.9%* 11.2% 9.7% 9% 7%
Adverse events** 3.3% 3.0% 14% 15.7% 3%* 10%*
Total cost (€) 369* 440*
Mean cumulative 
radiation dose (mSv)
12.0* 10.1* 6.6 6.1
* Significant results ** PROMISE including all-cause death, nonfatal MI, hospitalization for unstable angina 
and major procedural complications. SCOT-HEART including all-cause death, non-fatal MI and stroke and 
hospitalizations for chest pain. CRESCENT including all-cause death, non-fatal MI and stroke, late revascu-
larization procedures (>90days) and unplanned cardiac ED evaluations.
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Imaging of Stents
The high roentgen attenuation of the metal in standard coronary stents causes artifacts 
that complicate evaluation of the coronary lumen within the stent, particular close to 
the stent struts. The magnitude of these artifacts vary depending on the material and 
the stent design, i.e., the strut thickness [24]. The effect on visualization of the in-stent 
lumen is most severe in smaller stent [25]. Comparative studies have shown a very 
reasonable accuracy for in-stent stenosis in comparison to conventional angiography, 
although a substantial number of stent were excluded because of insufficient image 
quality [26–28]. Accuracy is better in larger stent and is more accurate for detection 
of occlusion compared to stenosis [29]. Guidelines recommend CT angiography after 
coronary stenting in symptomatic patients and in asymptomatic patients with a prior 
left main stent with a diameter ≥ 3mm [9]. On an individual basis CT can be considered 
to rule out severe obstruction of stents in larger proximal coronary branches of bypass 
grafts [30]. Even more than in nonstented patients acquisition of high-quality data, with 
application of dedicated filters for image reconstruction is recommended to achieve 
interpretable image quality (figure 7). Recently bioresorbable scaffolds have been in-
troduced. The metal-free struts allow unrestricted coronary CT angiography both at the 
time of implantation, as well as after resorption (figure 8).
Bypass Graft Imaging
Because of their large diameter, limited calcification and relative immobility bypass 
grafts, and particularly saphenous vein grafts, are well visualized by CT, although surgical 
material may cause artifacts (figure 9). Even with earlier generations of CT graft occlu-
Table 3. Randomized controlled trials comparing coronary CTA and standard care in acute chest pain
ACRIN (2012) ROMICAT II (2012) BEACON (2016)
N 1370 985 500
Risk TIMI score 0-2 Low–intermediate risk Average GRACE 83
USA USA The Netherlands
Troponin assay Conventional Conventional High-sensitivity
CT Angio Controls CT Angio Controls CT Angio Controls
ACS diagnosis 1% 1% 9% 6% 9% 7%
ED discharge 50%* 23%* 47%* 12%* 65% 59%
Cath angiography 5% 4% 12% 8% 17% 13%
Revascularizations 3% 1% 6% 4% 9% 7%
Length of stay (hrs) 18* 25* 23* 31* 6.3 6.3
1-month MACE 0% 0% 0.4% 1.2% 10%** 9%**
Total cost $4026 $3874 €337* €511*
* significant results; ** including revascularizations. Acute coronary syndrome (ACS); emergency depart-
ment (ED); major adverse cardiovascular events (MACE)
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sion or patency can be differentiated with very good accuracy. Current CT technology 
detects graft occlusion, as well as significant stenosis with an accuracy of approximately 
95% (table 4) [31-35]. However, ischemic symptoms in patients after bypass surgery can 
be caused by obstruction of bypass grafts, or by progression of disease in the native 
coronary arteries. Longer after surgery obstruction of the non-grafted coronary arteries 
or distal coronary run-offs is in fact more likely than graft failure as the cause of recur-
rent complaints [36]. Therefore, evaluation cannot be limited to the bypass grafts alone, 
but should include the coronary arteries as well. The latter however proves to be more 
complicated due to often diffuse coronary disease and excessive presence of coronary 
Figure 7. Diagnostic value of CT coronary angi-
ography. Pretest and post-test probability of sig-
nificant coronary artery disease after CT coronary 
angiography, confirmed by catheter coronary 
angiography. In the low-to-intermediate pretest 
probability group CT virtually excludes signifi-
cant coronary artery disease, while a positive CT 
scan increases the probability of coronary artery 
disease to 68 and 88% for low and intermedi-
ate pretest probability patients. (Adapted from 
Meijboom et al. [6].)
Figure 8. CT stent imaging. Two patent stents in the left anterior descending coronary artery (LAD). The 
different intensity of the stent struts on CT suggests they are stents of a different type. A septal branch 
is preserved after stenting. A third stent has been implanted in the left circumflex branch (LCX). The low-
density material within the stent suggests occlusion (arrow). Distally the LCX is opacified, likely due by col-
lateral supply.
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calcification [37]. Although results have improved using contemporary technology: 
sensitivity and specificity of approximately 90%, diagnostic performance is still inferior 
to the published results in patients without previous bypass graft surgery [32,33,35].
Because of the chronic nature of atherosclerotic disease in these patients luminal 
obstruction may be diffuse and extensive. Occluded grafts may exist for years without 
causing symptoms because of maintained coronary flow or development of collateral 
vessels [38]. Even more than in nonsurgical patients, functional information concern-
ing the presence and localization of ischemic myocardium is important to identify the 
culprit coronary or graft lesion. As a consequence CT is often not fully conclusive in pa-
tients presenting with symptoms late after surgery. It can be of use in specific situations 
when one is (exclusively) interested in the condition of the bypass grafts. CT imaging 
of the grafts can be performed prior to catheterization to shorten the time spent in the 
catheterization laboratory, particularly when the location of the grafts is challenging or 
unknown.
Figure 9. Bioresorbable scaffold in the left ante-
rior descending artery (LAD). Remnant platinum 
markers (arrowheads) indicate the location of the 
previous scaffold placement. After the proximal 
marker noncalcified plaque results in a <50% ste-
nosis (a). A patient with a previous bioresorbable 
scaffold placement from the proximal circumflex 
artery (Cx) into the marginal obtuses (MO) side 
branch. There is some intima hyperplasia visible 
causing stenosis up to 50%. A metal stent was 
placed distally from the bioresorbable scaffold. 
(b) 
Table 4. Diagnostic performance of CT to detect significant bypass graft disease.
N Excl.(%) Sens.(%) Spec.(%) PPV(%) NPV(%)
Pache et al. [24] 31 6 98 89 90 98
Malagutti et al. [25] 52 0 99 96 95 99
Ropers et al. [26] 50 0 100 94 76 100
Meyer et al. [27] 138 0 97 97 93 99
Onuma et al. [28] 54 2 100 91 74 100
Number of patients (N), exclusion rate (Excl.), sensitivity (Sens.), specificity (Spec.), positive predictive value 
(PPV) and negative predictive value (NPV) to detect >50% luminal obstruction.
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IMAGING OF CORONARy ATHEROSCLEROSIS
Coronary Calcium
Because of the roentgen attenuating properties of calcium in comparison to other tis-
sues, calcium can be imaged without the need for contrast medium. While most clinical 
data has been gathered using electron-beam CT, calcium imaging can be performed with 
MSCT using either prospectively ECG-triggered scanning or retrospectively ECG-gated 
image reconstruction [35,36]. Finding calcium is evidence of coronary atherosclerosis. 
Most patients with flow-limiting disease have a positive calcium score. In symptomatic 
patients the positive predictive value of a positive calcium score for the presence of 
coronary stenosis is about 50%, and without symptoms even lower. The absence of coro-
nary calcium does not exclude the presence of (noncalcified) atherosclerosis, although 
severe coronary artery disease will be unlikely in this case.
The (semi-)quantitative amount of coronary calcium is a surrogate measure for the 
total coronary plaque burden. Several studies have shown that the coronary calcium 
score [37] predicts adverse coronary events independently of conventional risk factors 
[38–42]. The St Francis Heart Study showed that the calcium score outperformed the 
Framingham Risk Score for the prediction of coronary events [39]. According to pub-
lished guidelines calcium scoring is reasonable to better classify patients at an inter-
mediate risk of cardiovascular events [43]. Patients with an Agatston score below 100 
have a annular CV risk well below 1% and can be considered low-risk. Those with a score 
>400 have a CV risk equal to for instance diabetics and are entitled to more intensive 
preventive treatment. Whether this will reduce their risk, and whether calcium scoring 
as such improves clinical outcome still needs to be established.
The current ESC guidelines state that a “zero” calcium score cannot be used to rule 
out coronary artery stenosis in symptomatic individuals, especially when young and 
with acute symptoms (class III, level of evidence C). However, for asymptomatic adults 
at intermediate risk for CAD or with diabetes and 40 years of age and older, the use of 
coronary calcium scanning should be considered for CV risk assessment (class IIa, level 
of evidence B).
Contrast-Enhanced Plaque Imaging
On contrast-enhanced CT scans noncalcified plaque can be identified in addition to cal-
cified lesions (figure 10). In comparative studies with IVUS CT detects most of the plaque 
in the proximal coronary vessels, particularly when some calcium is present [44,45]. 
Because the outer vessel wall is poorly defined, with user-dependent measurements 
affected by display settings, plaque quantification remains difficult [46,47]. Measured 
CT attenuation (Hounsfield units) within plaques has been compared with histology and 
IVUS [46,48–51]. Calcified plaques have a significantly higher attenuation than noncalci-
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Figure 10. Graft imaging. Three-dimensional 
reconstruction of a CT angiogram of a patient 
with a left internal mammary artery graft (IMA) 
connected to the middle segment of the left 
anterior descending coronary artery (LAD) and 
a venous graft from the ascending aorta with 
an anastomosis to a diagonal branch (D), a pos-
terolateral branch and a posterior descending 
branch (not shown). While the grafts are well 
visualized, assessment of the native coronary 
arteries, particularly the LAD, is more compli-
cated.
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fied plaques. Differentiation of lipid-rich and fibrous plaque, or hypo- and hyper-echo 
dense plaques has proven to be more difficult. Lipid-rich plaques have significantly 
lower attenuation values, but with significant overlap with measured values in fibrous 
plaques, particularly between studies. Similar to IVUS studies, CT has shown that culprit 
plaques in patients with an acute coronary syndrome tend to be larger with positive 
vessel remodeling. Unstable lesions contain smaller overall quantities of calcium, but 
with a more spotty distribution, as well as more low-density plaque in comparison to 
stable coronary plaques [52–56]. Recent years more research is conducted into high-risk 
plaques in coronary CTA. High risk plaque features are considered to be:
•	 low	attenuation	(HU)	plaques,	defined	as	<30	HU	corresponding	with	plaques	with	a	
lipid core
•	 Positive	remodeling,	defined	as	a	remodeling	index	>1.1,	which	is	calculated	as	the	
ratio of the diameter of the plaque relative to diameters of the average proximal and 
distal reference diameters
•	 Spotty	 calcification,	 defined	 as	 calcification	 measuring	 <3mm	 in	 diameter	 sur-
rounded by non-calcified plaque
•	 Napkin-ring	sign,	defined	as	a	ring	of	peripheral	high	attenuation	surrounding	a	low	
attenuation (necrotic) core
Further research and technical developments are necessary to develop CT-based plaque 
analysis in the future. [56,57,58].
SUMMARy
•	 ECG-synchronized	 cardiac	 CT	 allows	 noninvasive	 visualization	 of	 the	 heart	 and	
coronary arteries. Beta-blockers are often used to lower the heart rate and minimize 
motion artifacts.
•	 Contemporary	 scanner	 technology	 and	 scan	 protocols,	 combined	 with	 operator	
awareness, can reduce the radiation dose of cardiac CT considerably.
•	 The	diagnostic	accuracy	of	coronary	angiography	using	the	latest	generation	CT	is	
good in comparison to conventional catheter angiography, and permits exclusion of 
significant coronary obstruction in the majority of patients. Challenges in coronary 
CT imaging include calcified vessels, stents, small vessel pathology, arrhythmia, 
tachycardia, and obese patients.
•	 Coronary	CT	 is	 considered	 a	diagnostic	 option	 in	patients	with	 chest	pain,	 a	 low-
intermediate probability for coronary artery disease, particularly when exercise tests 
are unavailable or nonconclusive. Other applications include the triage of patients 
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with recent/acute chest pain at low to intermediate risk without ECG changes or 
elevated blood markers.
•	 Coronary	calcium	scoring	can	improve	risk	stratification,	and	may	be	considered	for	
individuals at intermediate risk. Imaging of noncalcified plaque by CTA is a field of 
intensive research and expectations.
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ABSTRACT
Aims To compare the effectiveness and safety of a cardiac CT algorithm with functional-
testing in patients with symptoms suggestive of coronary artery disease (CAD).
Methods and Results Between April 2011 and July 2013 350 patients with stable 
angina, referred to the outpatient clinic of four Dutch hospitals, were prospectively 
randomized between cardiac CT and functional-testing (2:1 ratio). The tiered cardiac CT 
protocol included a calcium scan followed by CT angiography if the Agatston calcium 
score was between 1 and 400. Patients with test specific contra-indications were not 
excluded from study participation. By one year, fewer patients randomized to cardiac 
CT reported anginal complaints (p=0.012). The cumulative radiation dose was slightly 
higher in the CT group (6.6±8.7mSv versus 6.1±9.3mSv; p<0.0001). After 1.2 years, 
event-free survival was 96.7% for patients randomized to CT and 89.8% for patients 
randomized to functional-testing (p=0.011). After CT the final diagnosis was established 
sooner (p<0.0001), and additional downstream testing was required less frequently 
(25% vs 53%, p<0.0001), resulting in lower cumulative diagnostic costs (€369 versus 
€440; p<0.0001).
Conclusion For patients with suspected stable CAD, a tiered cardiac CT protocol offers 
an effective and safe alternative to functional-testing. Incorporating the calcium scan 
into the diagnostic workup was safe and lowered diagnostic expenses and radiation 
exposure.
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INTRODUCTION
Diagnostic testing of coronary artery disease (CAD) is annually performed in 20 million 
patients worldwide.(1) Despite concerns about accuracy (2), exercise ECG remains the 
first performed test in many parts of the world,(3-5) while stress imaging is reserved for 
patients with a higher probability of disease.(3) Cardiac CT has emerged as an alterna-
tive diagnostic test for CAD, characterized by an excellent negative predictive value for 
confident exclusion of CAD. Recently, two large randomized studies reported on the 
value of coronary CT angiography for evaluation of stable angina (6, 7). In the Computed 
Tomography versus Exercise Testing in Suspected Coronary Artery Disease (CRESCENT) 
randomized-controlled trial we assessed the effectiveness and safety of a tiered cardiac 
CT protocol, consisting of a calcium scan and selective performance of CT angiography, 
in comparison to functional-testing.
METHODS
Study Design
The CRESCENT trial is a pragmatic randomized-controlled trial comparing the clinical 
effectiveness of a tiered cardiac CT approach and a standard diagnostic workup using 
functional-testing. At four hospitals in the Rotterdam region of the Netherlands, 350 
patients with stable chest pain, who had been referred for evaluation of suspected CAD, 
were prospectively enrolled. The study was approved by the medical ethics committees 
of the central coordinating centre and participating sites. The CRESCENT trial is regis-
tered at the US National Institutes of Health (ClinicalTrials.gov), number NCT01393028.
Study participants
Patients aged 18 years or older with stable chest pain or angina equivalent symptoms 
potentially caused by obstructive CAD were study eligible. Exclusion criteria were 
known CAD or invasive angiography or stress test performed within the last year. Renal 
impairment, contrast allergy, atrial fibrillation, or other test specific contra-indications 
did not preclude study participation.
Study procedures
Participants who consented in writing were randomly assigned to CT or functional-testing 
in a 2:1 ratio because of the established performance of the standard protocol. After the 
standard outpatient clinic visit, all participants filled out the Seattle Angina Questionnaire 
(SAQ), EuroQol-5D-5L (EQ-5D) and Short-Form-36 (SF-36) for quality-of-life assessment, 
and a cost questionnaire. All subsequent testing was performed at the recruiting center.
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Patients were contacted after one year for ascertainment of trial endpoints and 
health status measurements (questionnaires). Performance and results of downstream 
diagnostic and therapeutic procedures were collected. All procedures were confirmed 
through review of medical records.
Cardiac CT strategy
For the CT algorithm, detailed in figure 2, all patients first underwent a calcium scan. 
Absence of calcium excluded CAD and required no further testing, except for patients 
with a high pre-test probability of CAD (>70% by Diamond and Forrester criteria (8)). 
Patients with a calcium score between 1 and 400 (and patients without calcium but a 
>70% pre-test probability), underwent contrast-enhanced coronary CT angiography 
to detect obstructive CAD. Those with CT contra-indications, a calcium score >400, or 
non-conclusive CT angiogram (non-interpretable or intermediate obstructive disease), 
underwent stress testing or invasive angiography at the discretion of the treating physi-
cian. CT angiography results were classified as normal or CAD<50%, low-risk CAD>50%, 
or high-risk CAD. High-risk CAD was defined as left main stenosis, three-vessel disease 
or proximal LAD stenosis (>50%). All recruiting sites had previous cardiac CT experience, 
and were equipped with 64-slice or more advanced CT technology, with radiation mini-
mizing measures depending on local practices and patients characteristics.
Functional-test strategy
Most patients randomized to standard care underwent a symptom-limited exercise ECG. 
The target heart rate was defined as 85% of the maximum predicted heart rate based on 
age. Based on exercise tolerance, ST-segment changes and symptoms the Duke Treadmill 
Score (DTS) was calculated to assist further management. Myocardial perfusion imaging 
or stress echocardiography were performed in case of contraindications to exercise ECG, 
or non-interpretable or equivocal results. All functional- imaging tests were interpreted 
for the presence of inducible ischemia, and assessed risk of adverse outcome applying 
established criteria for each respective test.(9, 10)
Both CT and functional tests were performed and interpreted by local physicians, who also 
made the subsequent clinical management decisions. Patients considered to be at high-risk 
based on test results and clinical interpretation, or those with refractory symptoms despite 
optimal medical treatment, were generally referred to invasive coronary angiography.
Outcomes
The primary outcome was the clinical effectiveness, defined as the absence of chest pain 
complaints after one year. Additionally, SAQ, SF-36 and EQ-5D questionnaire responses 
were compared between baseline and one year follow-up. Pre-specified secondary out-
comes included the diagnostic yield, defined as the proportion of patients undergoing 
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revascularization after invasive angiography. Efficiency outcomes included the time to 
diagnosis, defined as the period from presentation until the first test that led to the final 
diagnosis, or the final test that ruled out obstructive CAD. Downstream testing included 
all non-invasive testing (exercise-ECG, cardiac CT, stress echocardiography and perfusion 
imaging) and invasive angiography to detect CAD after the initial test. The diagnostic 
costs included all tests performed until one year. Average costs per test were based on 
a previously published cost analyses.(11) Based on the frequency of tests performed in 
each group, a formula for calculation of the overall downstream procedural costs was 
constructed, which allows recalculation using alternative procedural charges.
Survival analysis was based on a composite endpoint of all-cause mortality, non-fatal 
myocardial infarction, major stroke, unstable angina pectoris with objective ischemia 
and/or requiring revascularization, unplanned cardiac evaluations and late coronary 
revascularization procedures. Nonfatal myocardial infarction was defined as biomarker 
elevations in a concordant clinical context. Late revascularizations were defined as per-
formed beyond 90 days. Unplanned cardiac evaluations were defined as non-elective 
hospital visits and admissions for acute complaints suspected to be of a cardiovascular 
nature. Events were counted once for each patient in the hierarchical order listed above. 
Each suspected clinical endpoint and a random 10%-sample of the remaining patients 
were reviewed by two external, independent reviewers, blinded to randomization, with 
discordance resolved by a third reviewer.
The cumulative effective radiation dose (mSv) included all tests and interventions 
involving roentgen. For cardiac CT a conversion factor of 0.017 was used. For SPECT and 
catheterization conversion factors of 0.0085mSv/millibecquerel and 0.24mSv/Gy*cm2 
were used.(12, 13)
Statistical analyses
Insufficient funding prevented us from testing the original endpoint, which was the pro-
portion of patients undergoing catheter angiography followed by revascularization and 
required 1128 patients to demonstrate an 8%-points difference (alpha 0.05; power 0.80). 
For the alternative endpoint, 294 patients were required to demonstrate an 8%-points 
difference in reported chest pain (alpha significance level 0.05; power 0.80). The second-
ary power analysis was performed shortly after patient recruitment had started.
Continuous data are presented as means±SD or medians with interquartile ranges. 
Groups were compared using an independent-sample t-test or Mann-Whitney U-test for 
continuous variables, and chi-square or Fisher’s exact-test for categorical variables. Dif-
ferences in the SAQ-questionnaire mean scores between baseline and follow-up were 
analysed with a paired-t-test. The probability of event-free survival was estimated by 
Kaplan-Meier survival analysis with comparisons performed with the log-rank statistic. A 
Cox-proportional hazards model was employed to estimate the relative hazard of events 
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by randomized test strategy, deriving hazard ratios and 95% confidence intervals (CIs). 
A two-sided p-value of <0.05 was considered statistically significant. Statistical analyses 
were performed using SPSS (version 21, IBM Corp, Armonk NY, USA), according to the 
intention-to-treat principle.
RESULTS
Study population
Between April 2011 and July 2013, 463 eligible patients were approached, of whom 93 
(20%) declined participation and 20 (4%) were unable to provide written consent. Of 
the 350 enrolled patients, 242 were randomly assigned to CT and 108 to standard care 
based on functional-testing. All patients were included in the intention-to-treat analysis 
(figure 1). Overall, 293 of 350 participants (84%) had complete one-year follow-up. The 
original records for hospital visits and events were available in 347 of 350 (99%) patients. 
The mean age was 55±8 years, 55% were women, and most had an intermediate prob-
ability of CAD. While there were no significant differences in baseline characteristics, the 
estimated cardiovascular risk (SCORE) appeared slightly higher in the functional-testing 
group (table 1) (14). In 28 patients (8%) a final diagnosis of obstructive CAD was made 
by invasive angiography.
Figure 1. Patient flow diagram with disposition by randomized arm. Complete clinical follow-up defined as 
both clinical event information and questionnaires available at one year.
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Table 1. Patient characteristics
Cardiac CT
(n=242)
Functional testing
(n=108)
Mean age (years) 55±10 55±10
Female sex (%) 55 56
Systolic/diastolic blood pressure (mmHg) 138/84 138/84
Median body-mass index 28±5 28±5
History (%)
Coronary disease 0 0
Stroke 3.3 7.4
Peripheral artery disease 3.7 6.5
Atrial fibrillation 0.4 1.9
Renal impairment* 3.7 4.6
Renal failure* 1.7 1.9
Cardiac risk factors (%)
Current/past smoker 34 36
Hypertension 52 52
Dyslipidaemia 54 61
Diabetes mellitus 17 16
Family history of ischemic heart disease 38 37
Presenting chest pain symptoms (%)
Typical angina 24 23
Atypical angina 53 51
Non-anginal complaints 23 24
Pre-test probability (%)** 45±29 45±29
Median cardiovascular risk (SCORE***) 4.0(2.0;13.8) 6.0(2.0;12.0)
Baseline medications (%)
ACE inhibitor or AT II blocker 23 25
Beta-blocker 23 30
Calcium channel blocker 11 17
Aspirin or other antiplatelet agent 29 29
Statin or other lipid lowering medication 47 49
Vitamin K antagonists 3 7
Nitrates, oral or sublingual 7 12
Diuretics 11 9
Patient characteristics presented as mean±SD, percentage or median and interquartile range. There are 
no significant differences between both groups. Dyslipidaemia: total cholesterol >5mmol/L, low-density 
lipoprotein >3mmol/L, or on lipid-lowering medication. *Renal impairment: GFR<90 ml/min/1.73m2; renal 
failure: GFR <30 ml/min/1.73m2 **Diamond and Forrester criteria(8, 14). ***Estimated annual risk of cardio-
vascular death by Systematic Coronary Risk Evaluation.(14)
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Test results
In the functional testing group exercise ECG could not be performed in five patients 
(5%) because of left bundle branch block (n=2) or the inability to exercise (n=3). The 
exercise ECG was considered abnormal in 11%. In 50% of patients, including those with 
contra-indications to exercise ECG, further testing was required by myocardial perfusion 
imaging (29%), stress echocardiography (7%), cardiac CT (6%) and invasive angiography 
(11%).
In the CT group, the median calcium score was 4.0(0-61), and 100 patients had no 
detectable calcium. In 26 (11%) the calcium score was high (>400), for most of whom 
clinicians ordered further testing: nuclear imaging (n=8), stress echocardiography (n=3), 
exercise ECG (n=6), and invasive angiography (n=13). While CT angiography was indi-
cated for 117 patients, one scan was inappropriately performed in a patient with a high 
calcium score, while the scan was not performed in 9 patients (8%) with renal failure 
(n=4), severe contrast allergy (n=4), or anxiety (n=1). Significant stenosis was absent in 
75% of patients, 17% had >50% low-risk CAD, 6% had high-risk CAD, and 3% of the scans 
were non-diagnostic (figure 2).
Figure 2. Cardiac CT algorithm and results. Coronary calcium by Agatston method. Pre-test probability of 
coronary disease (CAD) by Diamond and Forrester criteria(8). High-risk CAD defined as left main stenosis, 
three-vessel disease or proximal LAD stenosis (all >50%).
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Clinical effectiveness
After one year fewer patients randomized to CT reported anginal symptoms in compari-
son to the functional-testing group (39% vs 25%, p=0.012), although the proportion of 
patients with similar or worsened symptoms was comparable (26% vs 29%, p=0.595)
(figure 3). For the SAQ-subscales, the CT group had a lower angina frequency at one 
year follow-up (p=0.012). Other SAQ-subscales showed a statistically non-significant 
trend toward more improvement over one year for the CT group (table 2). Quality-of-life 
improvement, measured with the five dimensions of the EQ-5D-questionnaire did not 
differ between the groups (p=0.759)(appendix 1). The mean VAS scale increased in the 
CT group from 67.6 into 72.5, and in the functional-testing group from mean 66.8 to 69.4 
(p=0.237). All SF-36-subscales were similar between both groups (appendix 2).
The diagnostic yield of invasive angiography, i.e. catheterizations followed by a revas-
cularization procedure, was 72% after CT, compared to 58% in the functional-testing 
group (p=0.469)(table 3). The prevalence of >50% coronary disease was similar between 
groups (8.8% CT, 6.5% functional-testing; p=0.384), as well as the proportion of high-risk 
CAD (4% and 3%, respectively (p=0.703), and the proportion undergoing revasculariza-
tion (table 3).
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Figure 3. Angina status one year after randomization.
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Table 2. SAQ results and subgroups at baseline (BL) and one-year follow-up (FU). The Seattle angina ques-
tionnaire consists of 17 questions. For every question points can be scored on an incremental scale. Every 
question contributes to one of the five SAQ-subscales. Scores are shown as means. A higher score indicates 
better angina health state.
Cardiac CT Functional-testing Improvement
BL FU p-value BL FU p-value CT FT p-value
Physical limitations 37.3 39.7 <0.0001 37.0 38.8 0.09 2.30 1.80 0.630
Angina stability 3.1 4.1 <0.0001 3.0 3.9 <0.0001 0.93 0.95 0.948
Anginal frequency 9.2 10.9 <0.0001 9.6 10.6 <0.0001 1.68 1.05 0.012
Treatment satisfaction 17.2 17.8 0.070 17.0 17.2 0.731 0.63 0.23 0.598
Disease perception 3.3 4.1 <0.0001 3.3 4.0 0.001 0.86 0.62 0.209
Total SAQ 64.7 75.0 <0.0001 63.6 73.1 <0.0001 10.28 9.47 0.668
Table 3. Diagnostic yield defined as proportion of invasive angiograms followed by revascularization
Cardiac CT
(n=239)
Functional-testing
(n=108) p-value
Invasive angiography 29 (12.1%) 12 (11.1%) 0.843
No CAD>50% 8 (3.3%) 5 (4.6%) 0.384
Low-risk CAD>50% 12 (5.0%) 4 (3.7%) 0.635
High-risk CAD>50% 9 (3.8%) 3 (2.8%) 0.703
Revascularization 21 (8.8%) 7 (6.5%) 0.384
Percutaneous coronary intervention 15 (6.2%) 7 (6.5%) 0.703
Coronary bypass graft surgery 6 (2.5%) 0 (0%) 0.092
Diagnostic yield 21/29 (72%) 7/12 (58%) 0.469
Days to revascularization 31 (18-67) 46 (30-198) 0.243
Late revascularization(>90 days) 3 (1.2%) 3 (2.8%) 0.144
Table 4. Adverse events
Cardiac
CT
(n=239)
Functional 
testing 
(n=108) p-value
All-cause death 2 (1%) 2 (2%) 0.413
Non-fatal myocardial infarction 1 (0%) 1 (1%) 0.564
Unstable angina 1 (0%) 1 (1%) 0.564
Non-fatal stroke 0 (0%) 1 (1%) 0.137
Late revascularizations 2 (1%) 2 (2%) 0.413
Unplanned cardiac evaluations 2 (1%) 4 (4%) 0.058
Acute chest pain at emergency department 1 (0%) 3 (3%) 0.057
Palpitations at emergency department 1 (0%) 1 (1%) 0.564
Total adverse events 8 (3%) 11 (10%) 0.004
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Diagnostic efficiency
For most patients the final clinical diagnosis was achieved on the same day in both 
groups, but more often in the cardiac CT group: median duration until final diagnosis 
0(0;0) days by CT and 0(0;44) by functional-testing (p<0.0001). Overall, 25% of patients 
randomized to CT underwent another test after the baseline test, compared to 53% in 
the functional-testing group (p<0.0001)(figure 4). Invasive angiography was similarly 
frequent after CT (12%) and functional-testing (11%, p=0.775). Although index testing 
costs were higher, cumulative diagnostic expenses were 16% lower for CT €369 versus 
€440, p<0.0001) (appendix 3).
Safety
Observed clinical events (19) included four deaths, two nonfatal infarctions, two cases 
of unstable angina requiring revascularization, one nonfatal major stroke, four late re-
vascularizations and six other unplanned cardiac evaluations, reported in 347 patients 
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Figure 4. Downstream testing. Proportion of patients requiring further non-invasive and/or invasive testing.
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(table 4). The unplanned evaluations in the emergency department included two cases 
of palpitations and four cases of acute chest pain, four (3.7%) in the standard care group 
and two after CT (0.8%, p=0.058). At an average follow-up of 446 days (1.2 years), event-
free survival was 96.7% for patients randomized to CT and 89.8% for patients random-
ized to standard care (p=0.011)(figure 5). The hazard ratio for adverse events was 0.32 
(95%CI 0.13-0.81) for the CT group compared with the standard care group (p=0.015).
Cumulative radiation dose
All but one patients in the CT group (99.6%), but only 46 of 108 (43%) patients assigned 
to standard evaluation received radiation exposure from an imaging test. Hence, the 
cumulative radiation dose was higher in the CT group (6.6 ± 8.7mSv) compared to the 
Number at risk
Days 0 100 200 300 400 500 600 664
Functional 108 104 101 98 58 42 33 0
Cardiac CT 239 236 234 228 137 89 69 0
Figure 5. Kaplan-Meier curves of event-free survival. Events counted once per patient in the hierarchical 
order of all-cause mortality, non-fatal myocardial infarction, major stroke, unstable angina with objective 
ischemia and/or requiring revascularization, unplanned cardiac evaluations and late revascularizations.
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standard care group (6.1 ± 9.3mSv, p<0.0001). The mean radiation dose from only the 
calcium score scan was 1.3 ± 1.1mSv, for a complete cardiac CT examination 4.1 ± 4.4mSv, 
for myocardial perfusion scintigraphy 14.0 ± 2.3mSv and for invasive angiography 14.0 
± 14.3mSv.
Calcium scan based rule out of coronary disease
In 98 patients (39%) CAD was ruled out based on a zero calcium score. During follow-
up none of these patients underwent further testing, and no adverse events occurred. 
Anginal symptoms were reported less frequently after a zero calcium scan, compared to 
when CAD was ruled out based on CT angiography or functional-testing (p=0.042). Only 
2 patients (2%) without calcium had a >70% pre-test probability of CAD. CT angiogra-
phy revealed single-vessel disease in one of these, eventually treated by stenting when 
symptoms persisted despite medical treatment.
DISCUSSION
This prospective, multicentre, randomized trial was designed to assess whether a tiered 
cardiac CT protocol based on calcium imaging and selective performance of CT angiog-
raphy would be effective and safe for the management of suspected CAD, in comparison 
to functional-testing. To improve the overall applicability patients with test-specific 
contra-indications were not excluded from study participation, and data were evaluated 
by an intention-to-diagnose approach. After cardiac CT more patients reported com-
plete relief of anginal symptoms after one year. Fewer adverse events occurred in the CT 
group. The cumulative radiation exposure was nearly 10% higher. Cardiac CT was more 
often able to confidently rule out CAD. Therefore the final diagnosis was reached faster, 
requiring fewer additional tests, and subsequently lower diagnostic expenses.
Diagnostic management of suspected coronary artery disease
Because prospective outcome data are sparse, diagnostic testing recommendations for 
stable CAD are predominantly based on technical performance studies, registry data 
and expert opinion, with discordant recommendations between guidelines.(3-5) In 
many centres the routine non-invasive diagnostic approach consists of stress testing, 
with the applied test modality depending on pre-test probability, patient characteris-
tics, local availability and expertise. The exercise-ECG is the most widely available and 
least expensive functional test, but has a modest diagnostic performance. Although 
functional imaging more accurately detects angiographic CAD, its superiority over the 
exercise ECG has not been convincingly demonstrated in prospective clinical trials.(15)
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Performance and safety
While the negative predictive value and ability to exclude CAD are high, coronary CT 
angiography has a tendency to overestimate both the angiographic and hemodynamic 
severity of CAD, which may necessitate further functional-testing for management deci-
sions. Because the prevalence of obstructive CAD is low in real-world populations with 
stable chest pain symptoms, cardiac CT could be an efficient and cost-effective first-line 
test (6, 8, 15, 16). In our study cardiac CT allowed immediate exclusion of CAD in 75% 
of patients, compared to 47% in the functional-testing group. While CT angiography 
does not assess the hemodynamic severity, excluding high-risk angiographic CAD often 
allows for reassured medical treatment without further testing required at that moment. 
While there was a notable numerical difference in the proportion of catheterizations 
followed by revascularization in favour of patients randomized to CT (72 vs 58%), this 
result did not reach statistical significance, and it is not possible to conclude whether 
this higher diagnostic yield affected clinical outcome. The proportion of patients with 
complete relief of angina was higher after CT. While this can be explained by a higher 
diagnostic performance of CT followed by more appropriate management of cardiac 
as well as non-cardiac conditions, perceived symptoms and further need for diagnostic 
tests may also be affected by differences in experienced reassurance of patients and 
physicians by the test results.
Importantly, cardiac CT appears a safe strategy. The total adverse event rate was in 
fact lower in the CT group, although these results should be considered of an explor-
ative nature given the population size and inclusion of softer endpoints. No statisti-
cally significant difference in the occurrence of death or myocardial infarction could be 
demonstrated between the two groups. The use of X-rays represents a drawback of CT, 
although by applying the calcium scan, contemporary CT equipment and dose reducing 
techniques, the cumulative exposure exceeded doses in the functional-testing group by 
no more than 10%.
Diagnostic efficiency
In this population with a relatively low CAD prevalence, the cardiac CT strategy achieved 
a conclusive diagnostic result much faster than functional-testing. In the functional-
imaging group, further testing was required twice more frequent. Contrary to our 
expectations, cardiac CT did not increase the rate of referral to invasive angiography. 
Despite higher initial costs, after one year the CT approach was less expensive, decreas-
ing overall diagnostic costs by 16% as calculated within our cost accounting system. 
Appendix 3 contains a formula for calculation of the overall downstream procedural 
costs based on frequency of performed tests, which allows recalculation using alterna-
tive procedural charges.
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Calcium imaging to rule out CAD
Calcium imaging is still mostly used for risk stratification in asymptomatic individuals. 
While data from high-risk symptomatic populations suggest a non-negligible rate of 
obstructive CAD in the absence of detectable calcium, (17) registry data from more 
representative lower-risk cohorts have repeatedly demonstrated that severe CAD is rare 
and no more than 1% of patients with a negative calcium scan ultimately undergo PCI or 
bypass graft surgery.(18, 19) Given the excellent negative predictive value of the calcium 
scan, perhaps better than any other test, we decided its incorporation was justified in 
the CT algorithm, thereby avoiding contrast medium in 39% of patients, as well as an 
overall reduction in radiation exposure and costs in the CT group. Although groups 
are small, our results show no indication that implementation of the calcium scan in 
patients with a low-intermediate probability is unsafe.
CRESCENT in light of recently published trials
Recently two randomized controlled trials were published that examined whether CCTA 
would be more clinically effective than standard care. The pragmatic PROMISE trial ran-
domized an impressive 10,003 patients between CT angiography and functional testing 
(67% nuclear imaging) for evaluation of suspected CAD, and reported no difference in 
adverse cardiac events after two years.(6) Although more patients underwent invasive 
angiography within the first 90 days, CT was associated with fewer invasive angiograms 
without obstructive CAD. Differences between our study and PROMISE include the use 
of calcium imaging in the CT strategy, and less frequent use of functional imaging in the 
control group (27% in CRESCENT vs approximately 90% in PROMISE).
In the SCOT-HEART trial, the addition of CCTA to standard care was investigated in 4146 
patients with stable angina.(7) The investigators demonstrated improved certainty, but 
no effect on frequency of the diagnosis of angina due to coronary heart disease if CCTA 
was included in the diagnostic evaluation. After 1.7 years there was a close to statisti-
cally significant 38% reduction in the composite endpoint of death related to coronary 
heart disease and myocardial infarction (p=0.0527). The design of SCOT-HEART differs 
from our study, or PROMISE, for the fact that CT did not replace functional testing, but 
was added to a standard care protocol with XECG for most.
The low prevalence of CAD and the generally benign clinical outcome of patients 
with stable chest complaints in these studies, has raised questions concerning the need 
for advanced and expensive imaging tests. In this respect our randomized trial, albeit 
much smaller in population size, adds to the evidence from PROMISE and SCOT-HEART 
by demonstrating that a tiered approach including calcium imaging can mitigate the 
potential risks and costs of cardiac CT, while achieving at least comparable performance 
in comparison to a functional test approach without predominance of stress imaging. 
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Contrary to previous trials we did not exclude patients based on contraindications to 
specific test, thereby widening the applicability of our results.
In all these trials with a relatively low CAD prevalence, the individual probability of disease 
was overestimated by conventional prediction rules.(6, 7) Depending on the criteria the 
disease prevalence in CRESCENT was 8%, while the predicted probability by the Diamond 
and Forrester method was 45%. Similarly, in PROMISE the average probability was 53%, 
while the observed disease prevalence was 8.8%. In 2013, which was after the study had 
started, the new ESC guidelines recommended a different prediction rule(3, 20). Retrospec-
tive implementation of these Genders criteria lowered the pre-test probability of CAD from 
45% to 37%, but still substantially overestimating the true observed disease burden.
In line with contemporary guidelines(3), in the CRESCENT trial patients with an-
giographically significant, but otherwise low-risk CAD on CT angiography were often 
treated medically before considering further testing or revascularization. This relatively 
conservative approach may have affected the downstream use of stress imaging, inva-
sive angiography and revascularization procedures in comparison to previous trials.
Limitations
Although it was not possible to blind caregivers and patients to the test results, participants 
were treated by multiple physicians without direct involvement in the study. Although 
our trial demonstrated benefit of cardiac CT on several aspects, the modest population 
prevented us from drawing firm conclusions on some of the other endpoints. The follow 
up rate of clinical questionnaires (SAQ, EQ-5D, SF-36) was slightly higher for the CT group 
(86% vs 78%, p=0.06), which may have influenced results. We compared cardiac CT to a 
functional strategy starting with exercise ECG in the majority of patients. Performance of 
the functional approach might have been different if stress imaging techniques had been 
applied more frequently. In addition, outcome of the diagnostic strategy is indirectly mea-
sured, based on the assumed benefit of therapeutic choices based on those test results. 
Although the study was performed at several sites, appropriateness of extrapolation of 
our results to other centres will depend on comparability of the clinical setting in terms of 
current diagnostic care, available technology, cost-accounting systems and therapeutic 
management attitudes. Further research is necessary to establish the value of cardiac CT 
in terms of hard endpoints and in comparison to other diagnostic strategies.
CONCLUSION
In the workup of suspected, stable coronary artery disease, cardiac CT represents a safe 
and effective diagnostic strategy in comparison to functional testing, with potential 
benefits in terms of cost-efficiency.
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APPENDICES
Appendix 1. EQ-5D results. VAS scale is the respondent’s self-rated health on a vertical, visual analog scale 
where the endpoints are labelled best and worst imaginable health state. A higher score indicates a better 
health state. Mean (± SD). P value of the improvement in the reported quality of life scale at one year follow-
up between the CT and functional-testing group.
Baseline One year follow-up p-value
Cardiac
CT
(n=219)
Functional 
testing 
(n=93)
Cardiac
CT
(n=208)
Functional 
testing 
(n=85)
Mobility 0.325
No problems walking about 116 (53%) 53 (57%) 132 (63%) 47 (55%)
Slight problems walking about 40 (18%) 18 (19%) 39 (19%) 25 (29%)
Some problems walking about 43 (20%) 16 (17%) 21 (10%) 9 (11%)
A lot of problems walking about 20 (9%) 6 (6%) 12 (6%) 4 (5%)
Confined to bed 0 (0%) 0 (0%) 4 (2%) 0 (0%)
Self-care 0.911
No problems with self-care 189 (86%) 79 (85%) 190 (91%) 74 (87%)
Slight problems washing or dressing 20 (9%) 7 (8%) 7 (3%) 8 (9%)
Some problems washing or dressing 7 (3%) 5 (5%) 8 (4%) 2 (2%)
A lot of problems washing or dressing 2 (1%) 2 (2%) 3 (1%) 1 (1%)
Unable to wash or dress 1 (0%) 0 (0%) 0 (0%) 0 (0%)
Usual activities 0.670
No problems with usual activities 96 (44%) 43 (46%) 118 (57%) 40 (47%)
Slight problems with usual activities 70 (32%) 21 (23%) 54 (26%) 26 (31%)
Some problems with usual activities 42 (19%) 18 (19%) 24 (12%) 16 (19%)
A lot of problems with usual activities 9 (4%) 11 (12%) 8 (4%) 2 (2%)
Unable to perform usual activities 1 (0%) 0 (0%) 3 (1%) 1 (1%)
Pain/discomfort 0.736
No pain or discomfort 43 (20%) 21 (23%) 74 (36%) 29 (34%)
Slight pain or discomfort 97 (44%) 37 (40%) 87 (42%) 30 (35%)
Moderate pain or discomfort 62 (28%) 27 (29%) 36 (17%) 20 (24%)
A lot of pain or discomfort 14 (6%) 6 (6%) 8 (4%) 6 (7%)
Extreme pain or discomfort 1 (0%) 2 (2%) 3 (1%) 0 (0%)
Anxiety/depression 0.623
Not anxious or depressed 110 (50%) 41 (44%) 118 (57%) 45 (53%)
Slightly anxious or depressed 76 (35%) 32 (34%) 63 (30%) 26 (31%)
Moderately anxious or depressed 26 (12%) 15 (16%) 14 (7%) 10 (12%)
Very anxious or depressed 6 (3%) 4 (4%) 9 (4%) 3 (4%)
Extremely anxious or depressed 0 (0%) 1 (1%) 4 (2%) 1 (1%)
Total EQoL 0.759
VAS scale 67.6 (±16.9) 66.8 (±19.5) 72.5 (±17.6) 69.4 (±19.1) 0.237
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Appendix 2. Short Form 36 results. SF-36 quality-of-life questionnaire subdivided into eight subscales. A 
higher score indicates a better health state. Mean (±SD). P-values for change in SF-36 subscale scores from 
baseline to follow-up between the CT and functional-testing group.
Baseline One year follow-up
Cardiac
CT
(n=219)
Functional 
testing 
(n=93)
Cardiac
CT
(n=208)
Functional 
testing
(n=85) p-value
Physical functioning 668 (±256) 640 (± 258) 717(±278) 775 (±223) 0.699
Role limitations due to physical health 194 (±168) 210 (± 177) 278(±163) 256 (±160) 0.136
Role limitations due to emotional 
problems
195 (±125) 196 (±121) 216(±119) 209 (±117) 0.941
Energy/fatigue 201 (±81) 190 (±91) 220 (±90) 219 (±80) 0.991
Emotional well being 337 (±92) 334 (±94) 347(±100) 359 (±82) 0.941
Social functioning 140 (±49) 140 (±53) 154 (±51) 162 (±43) 0.962
Pain 122 (±42) 123 (±45) 147 (±52) 152 (±47) 0.391
General health 218 (±86) 208 (±90) 223 (±95) 218 (±96) 0.209
Appendix 3. Downstream diagnostic costs
Total costs Cardiac CT Functional testing p value
Mean (SD) 369 (± 501) 440 (± 474) p<0.0001
Median (25th, 75 percentile) 270 (64, 270) 159 (106, 651)
Cost estimates (euros)¹  
Exercise tolerance test 106
Coronary calcium score 64
CT coronary angiography 206
Stress echocardiography 105
Single photon emission CT 545
Catheter-based coronary angiography 1,394
Appendix 3. Shows the cost estimates for diagnostic testing, based on Genders et al. (11) and the down-
stream procedural costs for standard care compared with CT. Results are shown in euros.
Formula for the calculation of the total diagnostic costs of a workup of patients with suspected CAD with 
functional-testing and the comprehensive cardiac CT workup:
-  Costs in functional-testing group = (0.94 * € exercise ECG) + ( 0.29 * € SPECT) + ( 0.06 * € CCTA) + ( 0.07 
* € Stress echo) + ( 0.11 * € Cath)
-  Costs in CT group = ( 1 * € CAC-score) + ( 0.46 * € CCTA) + ( 0.07 * € SPECT) + ( 0.05 * € exercise ECG) + ( 
0.01 * € Stress echo) + ( 0.12 * € Cath)
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ABSTRACT
Background - Cardiac CT represents an alternative diagnostic strategy for women with 
suspected CAD, with potential benefits in terms of effectiveness and cost-efficiency.
Methods and Results - the CRESCENT trial prospectively randomized 350 patients with 
stable angina (55% women; 55±10 years), mostly with an intermediate CAD probability, 
between cardiac CT and functional testing. The tiered cardiac CT protocol included a 
calcium-scan followed by CT-angiography if the Agatston calcium score was between 
1-400. Patients with test specific contraindications were not excluded from study partici-
pation. Gender differences were studied as a pre-specified sub-analysis. Enrolled women 
presented more frequently with atypical chest pain and had a lower pre-test probability 
of CAD compared to men. Independently of this differences, cardiac CT led in both sexes 
to a fast final diagnosis as compared functional testing, while the effect was larger in 
women (p-interaction=0.01). The reduced need for further testing after CT, compared 
to functional testing, was most evident in women (p-interaction=0.009). However, no 
gender interaction was observed with respect to changes in angina and quality of life, 
cumulative diagnostic costs, and applied radiation dose (all p-interactions≥0.097).
Conclusions – Cardiac CT is more efficient in women than men in terms of time to reach 
the final diagnosis and downstream testing. However, overall clinical outcome showed 
no significant difference between women and men after one year.
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INTRODUCTION
In industrialized countries, coronary artery disease (CAD) is the leading cause of death 
among women and associated with a worse outcome compared to men 1, 2. Due to a 
frequently different presentation of complaints ischemic heart disease is thought to be 
under-recognized in women 3, 4. The prevalence of vasospasm and microvascular angina 
is higher in women, which may partly explain the differences in symptoms between 
women and men 4. Conventional first-line non-invasive diagnostic tests are thought 
to be less accurate in women, further contributing to under-diagnosis, and potentially 
under-treatment 5, 6. On the other hand, women have higher rates of indeterminate ex-
ercise ECG results, but also more false positive results due to nonspecific ST-T changes. 
The lower sensitivity of nuclear imaging is thought to result from the smaller size of the 
female heart, while false-positive diagnoses may be introduced by breast attenuation 
artifacts 7, 8. Paradoxically, there appears to be an relative overuse of invasive angiog-
raphy (ICA) in women, perhaps fueled by the limited confidence in noninvasive tests, 
resulting in a rather low diagnostic yield for obstructive CAD 9, 10.
Cardiac CT is a non-invasive imaging modality with an excellent diagnostic accuracy 
for the detection of CAD in both men and women 11. Recently, three multicenter random-
ized trials showed that cardiac CT is at least as effective and safe as standard diagnostic 
testing for patients with suspected CAD 12-14.Given the uncertain diagnostic accuracy of 
functional tests in women, direct visualization of CAD by cardiac CT may be particularly 
effective in women.
In this pre-specified sub-analysis of the recently published CRESCENT trial (Calcium 
imaging and selective CT angiography in comparison to functional testing for suspected 
coronary artery disease), we investigated whether sex affects the effectiveness and 
safety of cardiac CT compared to standard functional testing in patients with symptoms 
suggestive of CAD.
METHODS
Study design and participants
CRESCENT is a multicenter randomized controlled clinical effectiveness trial. From 
the cardiology outpatient clinics at four hospitals in the Rotterdam region of the 
Netherlands, 350 patients with stable chest pain and suspected CAD were enrolled in 
the study. The study design, inclusion and exclusion criteria, and primary results have 
been reported previously 12. Briefly, all adult patients with stable chest pain or angina 
equivalent symptoms potentially caused by obstructive CAD were considered for study 
participation. Exclusion criteria were a history of known CAD, invasive coronary angi-
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ography or stress test performed less than one year ago, or inability or unwillingness to 
provide informed consent. Renal impairment, contrast allergy, atrial fibrillation, or other 
test specific contra-indications did not preclude study participation. The study was ap-
proved by the medical ethics committees at each participating site and all participants 
provided informed consent. The CRESCENT trial is registered at the US National Institutes 
of Health (ClinicalTrials.gov), number NCT01393028.
Randomization and study procedures
Patients were randomized in a 1:2 ratio between standard functional testing as dictated 
by local caregivers and the investigational CT algorithm. For the CT algorithm, all pa-
tients first underwent a calcium scan. Absence of calcium excluded CAD and obviated 
the need for further testing, except for patients with a high pre-test probability of CAD 
(>70% by Diamond and Forrester criteria 15). Patients with a calcium score between 1 
and 400, as well as patients without calcium but a >70% pre-test probability, underwent 
contrast-enhanced coronary CT angiography to detect obstructive CAD. Those with 
CT contra-indications, a calcium score >400, or non-conclusive CT angiogram (non-
interpretable or intermediate obstructive disease), underwent stress testing or invasive 
angiography at the discretion of the treating physician. All participating sites had prior 
experience in performing cardiac CT before initiation of the trial. Image acquisition 
was performed on a 64-slice or more advanced CT system with radiation minimizing 
measures depending on local practices and patients characteristics. For the standard 
arm the functional test was chosen and interpreted by the local physician, based on 
clinical guidelines 16, 17. Observed disease by CTA and XECG test results were recorded 
and compared between both sexes. A heart rate below 85% of the predicted heart rate, 
and a maximum workload below 100% of the predicted exercise capacity were clas-
sified as insufficient. A positive XECG was defined as >1-mm ST deviation. A negative 
XECG was defined as without >1-mm ST deviation, provided that the target heart rate 
and workload were achieved. CT scans were classified as negative calcium scan, <50% 
stenosis on CTA, not high-risk >50% CAD, and high-risk >50% CAD (left main stenosis, 
three-vessel disease or >50% proximal LAD stenosis).
All patients were contacted after 12 months for ascertainment of trial endpoints and 
health status measurements. The occurrence and results of downstream procedures 
(exercise ECG, cardiac CT, stress echocardiography, perfusion imaging, catheter angiog-
raphy and revascularization) were collected during follow-up. All diagnostic procedures 
were confirmed through review of the patients’ medical records. This pre-specified 
secondary analysis focused on differences between women and men with regard to the 
effectiveness and safety of a cardiac CT strategy versus standard functional testing in 
patients with suspected CAD.
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Endpoints
The primary outcome was the clinical effectiveness, defined as the absence of chest pain 
complaints after one year. Additionally, Seattle Angina Questionnaire (SAQ), EuroQol-
5D-5L (EQ-5D) and Short-Form-36 (SF-36) for quality-of-life responses were compared 
between baseline and one-year follow-up. Pre-specified secondary outcomes included 
the diagnostic yield, defined as the proportion of patients undergoing revasculariza-
tion (PCI or CABG) after invasive angiography. Efficiency outcomes included the time 
to diagnosis, defined as the period from presentation until the first test that led to the 
final diagnosis, or the final test that ruled out obstructive CAD. Downstream testing 
included all non-invasive testing and invasive angiography to detect CAD after the 
initial test. The diagnostic costs included all tests performed during one year follow up. 
Average costs per test were based on a previously published cost analysis 18. The safety 
outcomes included the event-free survival using the composite endpoint of all-cause 
mortality, non-fatal myocardial infarction or major stroke, unstable angina pectoris with 
objective ischemia and/or requiring revascularization, unplanned cardiac evaluations 
and late coronary revascularization procedures, defined as more than 90 days after the 
first presentation in the outpatient clinic. The cumulative radiation dose was defined as 
radiation exposure from all tests and interventions from the first outpatient clinic visit 
until 1 year of follow up, including CT, perfusion imaging and catheter angiography, 
calculated in millisieverts (mSv) using standard methods 19, 20, applying a conversion 
factor kappa (κ) of 0.017 for cardiac CT scans.
Statistical analysis
Continuous data are presented as means±SD or medians with interquartile ranges. 
Groups were compared using an independent-sample t-test or Mann-Whitney U-test for 
continuous variables, and chi-square or Fisher’s exact-test for categorical variables. We 
used logistic regression to test the interaction between sex and randomization strategy 
for binary outcomes and linear regression for continuous outcome, as appropriate. 
Logistic regression variables with more than two outcomes, were transformed into 
dichotomous variables. For adjusted analysis of sex interaction and randomization strat-
egy on the angina improvement we used multivariable models and controlled for age, 
cardiac risk factors (hypertension, dyslipidemia, smoking, diabetes and family history of 
premature CAD), as well as for other covariates that were found to be different between 
men and women (diastolic blood pressure, type of angina and pre-test probability). 
While the cumulative diagnostic costs are not normally distributed, costs are presented 
as means, as it better reflects the overall financial burden of each approach. The prob-
ability of event-free survival was calculated by the Kaplan-Meier method for each of the 
end points, and impact of randomization strategy in man and women was analyzed with 
the log-rank test. A Cox-proportional hazards model with treatment assignment, sex, as 
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well as their interaction were used to test the hypothesis that sex interacts with clinical 
adverse events. A two-sided p-value <0.05 was considered statistically significant. Sta-
tistical analysis were made using SPSS (version 21, IBM Corp, Armonk NY, United States 
of America), according to the intention-to-treat principle.
RESULTS
Study population
There were 192 (55%) women and 158 (45%) men. Women more often presented with 
atypical chest pain compared to men (58% vs. 46%, p=0.029), and had a lower pre-test 
probability of CAD, as determined using the Diamond and Forrester criteria (p<0.001). 
While cardiovascular risk factors were similar between sexes, except for a lower diastolic 
blood pressure, the Systematic Coronary Risk Evaluation 21 was lower in women (p<0.001)
(table 1). Neither for women nor men were there differences in baseline characteristics 
between the two diagnostic strategies (all p>0.05).
Test results
Women had a median calcium score of 1.0(0-43.5), compared to 17.0(0-143.5) in men 
(p=0.159). CAD was excluded based on the absence of calcium in 48% of women and 
35% of men (p=0.036). In women CT angiography demonstrated obstructive CAD in 7% 
and 13% of men (p=0.279) The technical test results are summarized in figure 1. There 
were no significant differences between women and men for the exercise test result, 
which showed comparable rates of insufficient heart rate or exercise capacity (figure 1). 
Overall, 41 patients (12%) underwent invasive angiography. In women that underwent 
CT the revascularization rate was 62% (8/13), compared to 50% (4/8) in the functional 
test group (p=0.604). For men 81% (13/16) were revascularized after CT, compared to 
75% (3/4) after revascularization (p=0.780).
Clinical effectiveness
After one year 40% of women randomized to CT reported no anginal symptoms in 
comparison to 22% of women in the functional testing group (p=0.026). For men 36% 
reported no symptoms after CT compared to 30% after functional testing (p=0.466). 
However, significant interactions by sex on the outcome of resolved angina could not 
be demonstrated (p-interaction=0.286) (Figure 2). For the Seattle angina questionnaire 
(SAQ) and the quality of life questionnaires (EQ-5D and SF-36), however, there were no 
significant differences in improvement between CT and functional testing, neither for 
women and men (table 2).
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Diagnostic efficiency
In women additional diagnostic testing over the subsequent year was less often needed 
after cardiac CT compared to standard care (16% vs. 57%, p<0.001). The reduced need 
for further testing after CT was significantly better in women compared to men (p-
interaction=0.009), in whom the secondary diagnostic testing rate just failed to reach 
statistical significance (27% vs. 41%, p=0.057)(figure 3). Women had lower downstream 
diagnostic costs after CT compared to functional testing (one-year mean cumulative 
costs for women in CT group: €326 ± 470 vs. functional testing: €478 ± 493, p<0.001; 
men: €421 ± 534 for CT vs. €394 ± 451, p=0.329). However, a sex-specific difference could 
Table 1. Baseline characteristics of patients by sex
Women Men
All
women
Cardiac
CT
Functional
testing
All
men
Cardiac
CT
Functional
testing
n 192 (55) 133 (55) 59 (55) 158 (45) 109 (45) 49 (45)
Demographics        
Age, years† 56 ± 10 56 ± 10 55 ± 10 54 ± 10 53 ± 10 55 ± 10
Systolic blood pressure (mmHg)† 139 ± 22 139 ± 23 136 ± 20 138 ± 20 137 ± 20 139 ± 21
Diastolic blood pressure (mmHg)† 82 ± 12* 82 ± 11 81 ± 13 87 ± 11* 86 ± 11 88 ± 10
Mean body mass index (kg/m2)† 28 ± 6 28 ± 6 28 ± 6 28 ± 5 28 ± 5 28 ± 5
Cardiovascular risk factors        
Former or current smoker 65 (34) 43 (32) 22 (37) 55 (35) 39 (36) 16 (33)
Hypertension 95 (49) 68 (51) 27 (46) 85 (54) 56 (51) 29 (59)
Dyslipidemia 104 (54) 70 (53) 34 (58) 91 (58) 59 (54) 32 (65)
Diabetes mellitus 32 (17) 22 (17) 10 (17) 26 (16) 19 (17) 7 (14)
Family history of ischemic heart disease 79 (41) 54 (41) 25 (42) 53 (34) 38 (35) 15 (31)
History of stroke 6 (4) 6 (5) 4 (7) 10 (5) 2 (2) 4 (8)
History of peripheral artery disease 7 (4) 4 (3) 3 (5) 9 (6) 5 (5) 4 (8)
Presenting chest pain symptoms        
Typical angina 40 (21) 29 (22) 11 (19) 41 (26) 28 (26) 13 (27)
Atypical angina 110 (58)* 77 (58) 33 (56) 72 (46)* 49 (45) 23 (47)
non-anginal complaints 40 (21) 26 (20) 14 (24) 42 (27) 30 (28) 12 (25)
None 1 (1) 1 (1) 0 2 (1) 1 (1) 1 (2)
Pre-test probability† 38 ± 28* 39 36 54 ± 28* 53 55
10 years Cardiovascular risk ‡ (SCORE) 7 ± 9* 3 [1-10] 4 [1-10] 12 ± 13* 6 [3-17] 8 [4-18]
Unless otherwise specified, data are numbers of patients, with percentages in parentheses. †Data are means 
± standard deviations. ‡ Data are medians, with interquartile ranges in parentheses. *Significant difference 
between men and women. Diabetes mellitus is defined as plasma glucose >11.0mmol/L or treated with ei-
ther diet regulation or medication. Dyslipidemia defined as a total cholesterol level >5mmol/L, low-density 
lipoprotein level >3mmol/L, or on lipid-lowering medication. Hypertension defines as >150mmHg systolic 
or >90mmHg diastolic or treated. Pretest probability based on Diamond and Forrester criteria 15. Estimated 
10-year risk of cardiovascular death was done using SCORE21 . SCORE = Systematic Coronary Risk Evaluation.
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not be statistically confirmed (p-interaction=0.120). For women the final diagnosis could 
be made on the same day in 86% after CT, compared to 44% of women after functional 
testing (median time to final diagnosis 0(0;0) vs. 10(0;57) days, p<0.001). While the di-
agnosis was also reached faster in men after cardiac CT (0(0;0) vs. 0(0;29), p=0.011), the 
improvement was more in women (p-interaction=0.012).
Safety
During an average of 1.2 years of follow-up (median follow up time: 1.2 IQR [1.0;1.7] 
years) a total of 19 clinical events were recorded, 8 (4%) in women and 11 (7%) in men 
(p=0.344) (table 3). The event-free survival was 97.7% for women randomized to CT and 
91.5% for functional testing (log rank p=0.061). For men randomized to CT the event-
Figure 1. Cardiac CT and exercise test results stratified by sex
CT results based on calcium scan or CTA, classified as absent calcium, calcium score >400, <50% CAD on 
CTA, and CTA>50% subdivided in high-risk or not (left main stenosis, three-vessel disease or proximal LAD 
stenosis). A negative calcium scan was more frequent in women (*p=0.036). XECG test results were classi-
fied as ischemic (>1 mm ST-deviation in ≥2 leads), non-significant (0.5-1 mm), normal, insufficient heart rate 
response, or insufficient exercise capacity. No significant XECG result differences were observed between 
women and men. These technical classifications did not necessarily correspond with clinical interpreta-
tions.
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free survival was 95.4% and for functional testing 87.8% (log rank p=0.083) (figure 4). 
Sex was not a significant predictor of clinical adverse events (p-interaction=0.759).
Radiation exposure
The median radiation dose for the complete cardiac CT examination was 1.7 mSv [0.8;4.7] 
in women, and 2.6 mSv [1.0;6.8] in men (p=0.179), while the mean doses were 3.7±4.2 mSv 
in women and 4.6±4.8 mSv in men. Because of the skewed cumulative dose distribution 
for women in the functional testing group, of whom a minority received relatively high 
radiation exposure from nuclear imaging and angiography, the median effective dose 
was 0 mSv [0;12.5], compared to 4.7 mSv [0.9;7.9] in the CT group (p=0.005). Similarly, 
Figure 2. Anginal symptoms
Anginal status at one year, stratified by randomized diagnostic strategy and sex. P-values between the blue 
stack bars signify differences between the cardiac CT and functional group with regard to the absence of 
angina symptoms after one year, left part of the graph for women and right for men. P-values above the 
stacked bars signify differences in the total distribution of anginal complaints between CT and functional 
testing. Above is the p-interaction signifying the interaction between sex and randomization strategy on 
anginal symptoms, which was not significant (0.286).
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in men the median cumulative dose was 4.7 mSv [1.1;11.5] in the CT group, compared 
to 0 mSv [0;14.0] in the functional testing group (p<0.001; p-interaction=0.097)(table 
4). If calcium scans had not been included in the decision making, and all patients had 
Table 2. Questionnaire derived changes in angina and quality of life
Women Men
Cardiac
CT
Functional
testing
p-value Cardiac
CT
Functional
testing
p-value p-inter-
action
Responders (n) 81 (108) 66 (39) 85 (93) 69 (34)
SAQ 10.3 ± 15.5* 9.9 ± 14.6* 0.874 10.3 ± 12.8* 9.0 ± 12.8* 0.628 0.896
EQ-5D total 0.005 ± 0.331 -0.020 ± 0.384 0.670 -0.017 ± 0.305 -0.016 ± 0.371 0.982 0.743
EQ-5D VAS score 3.4 ± 15.8* 3.9 ± 15.2 0.868 5.9 ± 15.2* -0.24 ± 16.4 0.063 0.118
SF-36 272 ± 619* 207 ± 672 0.668 369 ± 618* 305 ± 662* 0.685 0.997
Change in questionnaire score after one year. Responders are percentages, with numbers in parentheses. 
*Significant improvement in score from first outpatient clinic visit to one year follow up. A higher score 
indicates a better health status. Mean (±SD). P value signifies differences in improvement between CT and 
functional testing. P-interaction for sex-dependent differences. SAQ; Seattle Angina Questionnaire. EQ-5D 
total; EuroQol-5D-5L total quality of life score. EQ-5D VAS score; EuroQol-5D-5L quality of life respondent’s 
self-rated health on a vertical, visual analog scale from 0-100 scale; SF-36; Short-Form-36 quality of life 
questionnaire.
Table 4. Cumulative radiation dose
Cardiac CT Functional testing p-value
Women Median: 4.7[0.9;7.9] Mean: 5.3 ± 5.5 Median: 0[0;12.5]
Mean: 6.3 ± 10.3
0.005
Men Median: 4.7 [1.1;11.5] Mean: 8.2 ± 11.2 Median: 0[0;14.0]
Mean: 5.8 ± 8.1
<0.001
p-value 0.014 0.791 0.097*
Cumulative radiation dose in mSv. *p-interaction value
Table 3. Adverse events
Women Men
All Cardiac 
CT
Functional 
testing
All Cardiac 
CT
Functional 
testing
All-cause death 0 (0) 0 (0) 0 (0) 2.5 (4) 1.8 (2) 4.1 (2)
Non-fatal myocardial infarction 0.5 (1) 0 (0) 1.7 (1) 0.6 (1) 0.9 (1) 0 (0)
Unstable angina 0.5 (1) 0 (0) 1.7 (1) 0.6 (1) 0.9 (1) 0 (0)
Non-fatal stroke 0.5 (1) 0 (0) 1.7 (1) 0 (0) 0 (0) 0 (0)
Late revascularizations 1 (2) 0.8 (1) 1.7 (1) 1.3 (2) 0.9 (1) 2.0 (1)
Unplanned cardiac evaluations 1.6 (3) 1.5 (2) 1.7 (1) 1.9 (3) 0 (0) 6.1 (3)
All events 4.2 (8) 2.3 (3) 8.5 (5) 7.0 (11) 4.6 (5) 12.2 (6)
Data are percentages, with numbers in parentheses. No significant differences as stratified for sex
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undergone CTA instead, the estimated median radiation exposure from the CT exam 
might have increased to 4.7 mSv [3.7;10.7] (mean 7.5±8.6 mSv). In women below 60 
years (59%), in whom CAD was ruled out based on a negative calcium scan in 71%, the 
median cumulative radiation dose was 1.1 mSv [0.8;1.5] (mean 1.4±1.3mSv).
DISCUSSION
In this pre-specified sub-analysis of the CRESCENT trial we compared the performance 
of cardiac CT and functional testing between women and men. Apart from previously 
described differences in disease prevalence the main findings of our study are that car-
diac CT performs well in women with stable chest pain complaints. In women cardiac CT 
Figure 3. Downstream diagnostic testing stratified by sex
Proportion of patients requiring further non-invasive and/or invasive testing. P-values signify differences in 
total number of downstream diagnostic testing in the CT arm versus the functional testing arm. P-interac-
tion (0.009) indicates no significant interaction by sex and randomization strategy.
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resulted in more resolution of chest pain, a lower need for further testing and diagnostic 
expenses, however with a higher median radiation exposure. In terms of the need for 
further testing and time to reach the final diagnosis, women had significantly more 
benefit from cardiac CT compared to men.
Symptoms and disease prevalence
In concordance with prior observations, women in the CRESCENT trial more often had 
atypical symptoms (57% vs. 46%, p=0.032) and lower rates of focal, epicardial CAD than 
men4. All trials, including this cohort, had a low CAD prevalence with overestimation of 
the individual probability of disease by conventional prediction rules for both men and 
women 13, 14, 22. In CRESCENT the CAD prevalence was 9% in women, while the predicted 
probability by the Diamond and Forrester method was 38%. For men the prevalence 
was 12%, while the predicted probability was 54%. In PROMISE the pre-test probability 
of CAD was 53% by Diamond & Forrester criteria, while the observed disease prevalence 
was approximately 9%.
Figure 4. Event-free survival
Kaplan-Meier curves of event-free survival stratified by randomized diagnostic strategy and by sex. There 
was a difference in event rate between randomization strategy (p=0.011), but not between sexes.
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Sex differences in the performance of diagnostic testing
In many centers the routine diagnostic work-up of patients with suspected CAD in-
cludes stress testing. The recommended test modality depends on the patient’s pre-test 
probability of CAD, clinical characteristics, technical availability and local expertise. In 
women, exercise testing is thought to be less helpful due to a lower diagnostic accuracy 
and high rate of indeterminate test results 7. In the previously published subanalysis of 
the PROMISE trial women were less likely to have a positive CTA than a positive exercise 
ECG or nuclear stress test result, even after adjusting for clinical factors, which may 
be the result of false-positive stress test results 23. Interestingly, in the CRESCENT trial 
no differences were observed between sexes with regard to the exercise tolerance or 
achieved heart rate during exercise testing, possibly caused by the small population 
size. Both in women and men cardiac CT reached a final diagnosis faster, requiring fewer 
additional tests. In 47% of women randomized to functional testing additional testing 
was ordered by the treating physician, compared to only 8% after cardiac CT. Contrary to 
PROMISE and SCOT-HEART, in this study cardiac CT was not associated with an increase 
in the number of cardiac catheterizations in women 13, 14. The reduced catheterization 
referral rate after CT may theoretically be explained by the use of the calcium scan, or a 
higher accuracy by newer CT equipment, but may as well be the result of differences in 
management following the CT scan, compared to previous studies. Conservative man-
agement of low-risk CAD and functional confirmation before revascularization may have 
avoided premature catheterization referral in CRESCENT, although it is unknown if these 
treatment practices were different in other pragmatic trials. Alternatively, equivalent 
catheterization rates may also be explained by a higher referral rate in the control group 
resulting from different stress test decisions. While in PROMISE more revascularizations 
and catheterizations were performed after CTA, costs were comparable after 90 days 
and 3 years24. In CRESCENT, women had lower downstream diagnostic costs after CT 
compared to functional testing.
In women, as well as the cohort as a whole12, cardiac CT more often resulted in re-
solved anginal symptoms after one year in comparison to functional testing. This can be 
explained by a higher diagnostic performance of CT, followed by more appropriate man-
agement of cardiac as well as non-cardiac conditions. Perceived symptoms and further 
need for diagnostic tests may also be affected by differences in reassurance of patients 
and physicians by the test results. However, for the SAQ and quality of life questionnaires 
there were no significant differences between CT and functional testing for either sex. 
Similar equivalidity was found in the PROMISE trial25, while the PLATFORM trial observed 
more improvement in QoL scores after CT (including FFRCT), in comparison to a strategy 
with usual noninvasive testing26.
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Safety
Cardiac CT is in both women and men associated with a higher median cumulative 
radiation dose, compared to functional testing, however significant interaction by sex 
could not be demonstrated (p-interaction=0.097). In the functional testing group the 
cumulative radiation exposure increased because of more nuclear imaging tests (mean 
14±2mSv) and invasive angiography (mean 14±14mSv) after the initial functional test. 
We incorporated the calcium scan into the CT algorithm because of its excellent nega-
tive predictive value. By not performing CTA in patients with a negative calcium scan, 
contrast medium and additional radiation could be avoided in 48% of women. Young 
women are relatively more vulnerable to radiation exposure, but we observed that with 
the incorporation of the calcium scan the cumulative radiation dose in this group was 
very low. While it is possible that severe but non-calcified lesions may be missed if CT 
angiography is not performed, the clinical course of patients who did not undergo CTA 
was uneventful over the first 6 months.
Similar to other CT studies in populations with stable CAD the overall event rate was 
low. While for the entire population cardiac CT was associated with lower event rates 
12-14, no significant differences were found between sexes.
Diagnostic management of suspected CAD in women and men
While exercise-ECG has a modest diagnostic performance, especially in women, both 
American and European guidelines recommend it as the first choice test in patients 
with a low to intermediate pre-test probability, interpretable resting ECG and ability 
to exercise27, 28. PROMISE and SCOT-HEART, as well as CRESCENT, have demonstrated 
that cardiac CT is equally or more effective and safe as standard diagnostic testing for 
patients with suspected CAD 12-14. This sub analysis underlines the notion that cardiac CT 
is more efficient in women in terms of less downstream testing and a speedier diagnosis, 
compared to functional testing.
Limitations
This subgroup analysis was hampered by the small sizes of subgroups, which was par-
ticularly relevant for the comparison of the diagnostic yield of ICA as well as some other 
secondary endpoints. Observed differences in diagnostic performance may reflect in 
part differences in disease prevalence between men and women. While we performed 
adjusted analysis to correct for potential confounders, other relevant confounders may 
have remained unidentified. Although it was not possible to blind caregivers and pa-
tients to the test results, participants were treated by multiple physicians without direct 
involvement in the study. We compared cardiac CT to a functional strategy starting with 
exercise ECG in the majority of patients. Performance of the functional approach might 
have been different if stress imaging techniques had been applied more frequently. 
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Although the study was performed at several sites, appropriateness of extrapolation 
of our results to other centers will depend on comparability of the clinical setting in 
terms of current diagnostic care, available technology, cost-accounting systems and 
therapeutic management practices.
CONCLUSION
Cardiac CT is more efficient in women than men in terms of time to reach the final diag-
nosis and downstream testing. However, overall clinical outcome showed no significant 
difference between women and men after one year.
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ABSTRACT
Purpose: Demonstrate that using contemporary cardiac CT protocols equal coronary 
lumen opacification can be achieved with iso-osmolar and low-osmolar contrast media, 
when injected at the same iodine delivery rate. In addition, we investigate the cardiovas-
cular effect of iso-osmolar contrast media, and achieved image quality.
Materials and Methods: Institutional review board approval was obtained. Written 
informed consent was obtained from all subjects. Between November 2015 and August 
2016 306 patients (167 (55%) women) at least 18 years old and weight between 50-
125kg, were prospectively randomized between iso-osmolar iodixanol-270 (Visipaque) 
and low-osmolar iopromide-300 (Ultravist). All coronary segments were assessed for 
intraluminal opacification and image quality and compared using a student T-test. Heart 
rate, arrhythmia, patients discomfort and adverse events were also monitored.
Results: Measured coronary attenuation values were comparable between both con-
trast media (469 ± 167 HU vs 447 ± 166 HU, p=0.241, 95% CI: -15.1 -60.0), including sub-
analyses. Adjusted for the lower iodine concentration, the mean iodixanol-270 bolus 
was higher compared to iopromide-300 (76.8 ± 11.6 ml vs. 69.7 ± 10.8 ml, p<0.001). 
The higher injection rate was associated with a higher pressure (111 ± 44 PSI vs 90 ± 
36 PSI, p<0.001). Although in the iodixanol-270 group patients experiences less heat 
discomfort (72% vs. 86% p<0.001), no differences in heart rate or rhythm were observed.
Conclusion: If injected at comparable iodine delivery rates, the iso-osmolar contrast 
medium iodixanol-270 is not inferior to low-osmolar contrast medium iopromide-300 
in terms of coronary opacification (body weight 50-125 kg). Iodixanol-270 was associ-
ated with less heat discomfort, but did not affect heart rate differently compared to 
iopromide-300.
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INTRODUCTION
Coronary computed tomography angiography (CTA) is an established test in the diag-
nostic work up of patients with stable angina pectoris and allows for reliable exclusion of 
coronary artery disease (1). As a result of continued scanner development and iterative 
reconstruction algorithms contemporary CT systems allow for coronary imaging at lower 
tube voltages (kV). Nowadays many patients can be scanned using 80kV, lowering over-
all radiation exposure. Because of greater photoelectric effect and decreased Compton 
scattering, imaging at a lower kV also increases the attenuation differences between 
iodine and soft tissue (2). Because current technology allows comparable opacification 
at lower intra-coronary iodine concentrations, the iodine delivery rate can be reduced, 
permitting application of contrast media with lower iodine concentrations. When osmo-
lality increases, the viscosity as well as opacification of the contrast agent increases but 
the tolerance power of the patients decreases. Sensations of heat, discomfort or even 
pain are directly related to the osmolality of the contrast medium(3).
Most roentgen contrast media have an osmolarity higher than blood plasma, which is 
responsible for various clinical effects, such as sensations of heat, discomfort and even 
pain(4). Invasive coronary angiography studies suggest that arrhythmia occur more 
frequently with low-osmolar contrast media. Iso-osmolar contrast agents, with an osmo-
larity equal to plasma, cause less heart rate acceleration and arrhythmia, which should 
be of potential benefit for CT image quality (3, 5-8). In terms of opacification and image 
quality comparisons between iso-osmolar and low-osmolar contrast media have dem-
onstrated mixed results (6, 9, 10). Because many studies compared protocols of identical 
injection rates of contrast media, but unequal iodine concentrations, observations may 
be affected by differences in the net iodine delivery rates(3, 5-12). It remains unclear 
how an iso-osmolar contrast medium affects the opacification of the coronary arteries 
when identical iodine fluxes are applied. Also the effect on heart rate, arrhythmia, and 
subsequent image quality in case of identical iodine fluxes has not yet been evaluated 
in a randomized trial.
The aim of the Isocor randomized-controlled trial was to demonstrate that using 
contemporary cardiac CT protocols equal coronary lumen opacification can be achieved 
with iso-osmolar and low-osmolar contrast media, when injected at the same iodine de-
livery rate. In addition, we investigate the cardiovascular effect of iso-osmolar contrast 
media, and achieved image quality.
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MATERIALS AND METHODS
Study Design
The Isocor trial is a non-inferiority, multicentre, double-blinded randomized-diagnostic 
validation trial comparing the opacification between an iso-osmolar (iodixanol) and 
a low-osmolar (iopromide) contrast medium. Patients referred for coronary CTA were 
prospectively enrolled at three hospitals in Rotterdam. The study was conducted in ac-
cordance with the Declaration of Helsinki and international standards of Good Clinical 
Practice and was approved by the medical ethics committees of the central coordinating 
centre and both participating sites. Written informed consent was obtained from each 
participating patient. The Isocor trial is registered at the EU Clinical trials register (www.
clinicaltrialsregister.eu), EUdract-number 2014-000681-22. GE Healthcare, the manu-
facturer of iodixanol, provided unrestricted financial and material support (iodixanol 
contrast medium). The authors had full control of the data and information submitted 
for publication.
Study participants
Patients aged 18 years or older, body weight between 50-125kg, and referred for 
coronary CT-angiography in the context of suspected coronary artery disease (CAD) 
were study eligible. Exclusion criteria were pregnancy, renal dysfunction (eGFR<45ml/
min/1.73m2), allergies to iodine contrast media, manifest thyrotoxicosis, arrhythmia in-
cluding atrial fibrillation/flutter, 2nd or 3rd degree atrioventricular block, frequent ectopic 
beats prior to the exam (discretion of referrer), prior coronary artery bypass graft surgery 
or percutaneous coronary intervention with stents.
Randomization and blinding
From an electronically created randomization list, allocation results were placed in 
numbered envelopes, which were opened just prior to the CT scan when an eligible 
patient consented to the study. The allocation was unknown to the patient and to the 
reader of the images. For practical reasons (different injection rates) the CT technicians 
performing the examination were not blinded with regard to allocation.
Contrast material and injection
Iodixanol-270 mg iodine per ml (Visipaque, GE Healthcare, Amersham, UK) and iopro-
mide-300 mg iodine per ml (Ultravist, Bayer Healthcare, Berlin, Germany) were stored and 
administered in a similar, clinically standard manner, in accordance with the summary 
of product characteristics (SPC). Bottles of contrast media were stored at the CT suite at 
37° Celsius. Using a disposable system, contrast medium was transferred to a dual-head 
power injector, with external heating element. The power injector was then connected 
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to an 18-gauge IV canula in the antecubital vein. All participating hospitals used the 
same contrast injector type (Medrad® Stellant® CT Injection System, Bayer Medical Care 
Inc., Indianola, PA, USA). Contrast media were injected to achieve a net iodine deliv-
ery rate of 1.5gI/s (bodyweight 50-100kg), or 1.75gI/s for larger patients (bodyweight 
100-125kg) to maintain sufficient concentrations of iodine in the bloodstream and the 
coronary arteries at higher anticipated cardiac output. Iodixanol-270 was injected at 
5.6ml/s (body weight 50-100kg) or 6.5ml/s (100-125kg), iopromide-300 was injected 
at 5.0ml/s (50-100kg) or 5.8ml/s (100-125kg). The total contrast volume was calculated 
by [estimated scan duration + 8 seconds] * [flow rate], followed by a 40cc saline bolus 
chaser at same flow rate. The pressure limit of the power injector was 325 PSI.
CT examination
All CT angiograms were performed by standard contemporary protocols using 2nd or 
3rd generation dual-source CT systems (Somatom Definition Flash and SOMATOM Force, 
Siemens Healthineers, Forchheim, Germany). If indicated (heart rate >65 bpm) and 
clinically tolerable, beta-blockers were administrated. All patients received sublingual 
nitroglycerin just before scanning. First a non-enhanced calcium scan was performed 
to measure the Agatston score. The median total Agatston calcium score was 4 [0;89]. 
The scan parameters are summarized in table 2. In both groups the majority was im-
aged using the prospectively ECG-triggered axial scan mode (92% vs 94%, p=0.473), 
with an exposure window during diastole and/or systole depending on the heart rate. 
. Automatic tube current modulation and tube voltage selection based on the scout 
images were employed. The tube settings were optimized to achieve sufficient signal 
to noise. The system automatically selected the lowest possible tube voltage that still 
be supported by the tube current in a given patient and application, in order to achieve 
sufficient image quality at the lowest possible dose. The tube current was 70 or 80kV in 
51% of patients in the iodixanol-270 group and 53% in the iopromide-300 group (table 
2). The dose-length-product (DLP) and effective dose (k=0.017) was 160±119Gycm and 
2.7±2.0mSv in the iodixanol group, and 174±160mGycm and 3.0±2.7msV (p=0.387) in 
the iopromide group. Iterative reconstruction (Strength-3) was used. The reconstructed 
slice thickness was 0.6mm, reconstruction increment 0.4mm, reconstructed area dimen-
sions 180x180mm.
Image evaluation
All CTA images were assessed by an independent, experienced reader (ML, 4 years of 
cardiac CT experience), blinded to the patients’ clinical characteristics and the contrast 
medium used. The mean attenuation (Hounsfield units,HU) and standard deviation were 
measured in the proximal, mid and distal part of the right coronary artery (RCA), left 
anterior descending artery (LAD) (13), and left circumflex artery (LCX). The attenuation 
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measurements were performed on the axial images in vessel segments with a minimal 
diameter of 2mm and good or diagnostic image quality, by placing a circular region-
of-interest (ROI) with a minimum number of 10 image elements (pixels) in the center 
of the vessel at a location of sufficient image quality. Attenuation was also measured 
in the middle of the atrial and ventricular cavities, the middle of the ventricular septum 
(myocardium) and the ascending and descending aorta. For each coronary segment 
subjective image quality was classified on a 3-point scale as good, diagnostic, or poor. 
Image noise, signal-to-noise ratio, and contrast-to-noise ratio were determined for all 
scans (see formulas). The image noise was derived from the averaged SDs of the CT at-
tenuation values sampled using two large regions of interest in the proximal segments 
of both the left and right coronary arteries. The signal intensity was defined as the mean 
attenuation values derived from the same 2 regions of interest. The signal-to-noise ratio 
was calculated as mean CT attenuation values of the left and right coronary arteries di-
vided by image noise. The contrast-to-noise ratio was defined as the difference between 
the mean CT attenuation values of the proximal coronary arteries and the mean density 
of the left ventricular wall, which was divided by image noise.
Contrast − to − noise ratio =
([attenuation]LCA + [attenuation]RCA /2) − [attenuation]LV wall
[attenuation_SD]LCA + [attenuation_SD]RCA /2
Clinical effects and safety
The cardiovascular response to the contrast injection was monitored by measuring the 
mean heart rate. The heart rate was measured over 15 seconds before scanning (free 
breathing), at the time of the calcium scan (without contrast injection, but breath hold-
ing), and during CTA (after contrast injection and with breath holding), calculated from 
the ECG traces during data acquisition. Also the number of ectopic beats on the ECG 
recordings during CT-angiography were recorded, as well as the occurrence of atrial 
fibrillation. All adverse events, such as contrast extravasation, severe arrhythmia with 
hemodynamically significance, allergic reactions and renal failure were reported. The 
physical complaints during contrast injection were evaluated using a 5-point scale rang-
ing from 0(no complaints) to 4(worst thinkable).
Outcomes
The primary outcome was the coronary lumen opacification, defined as the averaged 
attenuation values (Hounsfield Units, HU) sampled in the middle segment of the LAD, 
the middle segment of the RCA, and proximal segment of the LCX, demonstrating non-
inferiority. Secondary outcome measures of image quality were the contrast attenuation 
values in the proximal, middle and distal coronary arteries, respectively, the signal-to-
noise ratio (SNR), the contrast-to-noise ratio (CNR), and the scaled subjective image 
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quality per coronary segment. Clinical outcome measures included adverse events, 
heart rate, arrhythmia, and patient reported sensations.
Statistical analyses
For 80%-power at a one-sided p-value of 0.025 we needed to recruit at least 272 patients 
to detect a difference of 30HU in coronary opacification, which was pre-specified and 
considered relevant for image interpretation. Anticipating a drop-out of up to 10%, we 
aimed to recruit 300 patients.
The primary endpoint to assess coronary opacification, the sampled and averaged 
attenuation values in the mid-segment of the RCA and LAD and proximal Cx, is a 
continuous variable with normal distribution reported as means ±SD. The hypothesis 
would be rejected if coronary opacification by iodixanol-270 were >30HU lower than 
by iopromide-300. Non-inferiority can be concluded when the lower bound of the 
confidence interval of the difference in attenuation does not exceed the non-inferiority 
margin(-Δ) of -30HU. Unavailable or technically failed scans were excluded. To meet the 
intention-to-treat principle, we corrected for missing data due to poor image quality. 
Missing values were replaced by the lowest measured mean coronary opacification 
(142HU). Results between the groups were compared using a student t-test. To correct 
for potential confounders influencing the opacification we also performed an analysis 
of covariance (ANCOVA).
Secondary, continuous measures (attenuation measures, SNR, CNR, contrast injection 
parameters) and categorical parameters (subjective quality, artifacts, adverse events) 
were compared using the student-t and Chi-square tests. The heart rate and change in 
heart rate in patients were compared using Wilcoxon signed-ranks test. Data distribu-
tion was tested with the Shapiro-Wilk test. Multi-variable linear regression analysis was 
performed to assess potentially confounding parameters towards the vessel opacifica-
tion, which were pre-specified and included age, gender, height, weight, BMI, heart 
rate, left ventricular function (determined by cardiac echocardiography, registered from 
patient records if available), IV gauge location, as well as other covariates found to be 
different between the randomization groups (gender and systolic blood pressure). To 
test whether injection rate was an effect modifier of contrast agent on opacification 
an ANCOVA model was performed with the interaction term contrast injection rate x 
randomization. A two-sided p-value of <0.05 was considered statistically significant. 
Statistical analyses were performed using SPSS (version 21, IBM Corp, Armonk NY, USA), 
according to the intention-to-treat principle.
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RESULTS
Study population
Between November 2015 and August 2016 329 eligible patients were approached, of 
whom 9(3%) declined participation, 4(1%) had atrial fibrillation, 3(1%) had a known 
contrast allergy, 2(1%) were unable to consent, 2(1%) had a body weight >125kg, 2(1%) 
were excluded because of technical reasons, and 1(0.3%) was excluded because of renal 
dysfunction (figure 1). Of the 306 enrolled patients, 154(50%) were randomly assigned 
to iodixanol-270 and 152(50%) to iopromide-300. No scans were excluded because of 
overall non-diagnostic image quality. All patients were included in the intention-to-treat 
analysis (figure 1). The mean age was 56±12 years. There were more women randomized 
to iopromide-300 (61% vs 48%, p=0.022), and also the mean systolic blood pressure was 
higher in this group (143±21 mmHg vs 136±20 mmHg, p=0.008). Otherwise there were 
no significant differences in clinical symptoms and cardiovascular risk factors (table 1). 
Most patients presented with chest pain complaints (90% vs 89%, p=0.896).
Table 1. Patient characteristics
Iodixanol-270
(n=154)
Iopromide-300
(n=152)
Mean age (years) 56±12 56±11
Female sex 74 (48%)* 93 (61%)*
Systolic blood pressure (mmHg) 136±20* 143±21*
Diastolic blood pressure (mmHg) 82±11 82±12
Length (cm) 172±11 172±10
Weight (kg) 82±15 81±16
Body-mass index (kg/m2) 27±4 27±5
eGFR (ml/min/1.73m2) 76±16 75±16
Cardiovascular risk factors
Current/past smoker 34 (22%) 22 (14%)
Hypertension 49 (32%) 49 (32%)
Dyslipidaemia 39 (25%) 36 (24%)
Diabetes mellitus 16 (10%) 14 (9%)
Family history of ischemic heart disease 33 (21%) 39 (26%)
History of obesity (BMI ≥30kg/m2) 45 (30%) 37 (25%)
Patient characteristics presented as mean ± standard deviation or n (%), or median and interquartile range. 
Hypertension: >150 systolic or >90 diastolic mmHg or using tension-lowering medication. Dyslipidaemia: 
total cholesterol >5mmol/L, low-density lipoprotein >3mmol/L, or on lipid-lowering medication. Diabetes 
Mellitus: plasma glucose >11.0mmol/L, or treated with diet regulation or medication. * Significant differ-
ence (p<0.05).
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Quantitative and qualitative image quality
The primary endpoint coronary lumen opacification, averaged in the middle segment 
of the RCA, LAD and proximal LCx, was 469 ± 167 using iodixanol-270 and 447±_166 
using iopromide-300 (p=0.241)(95% CI: -15.1 – 60.0) (appendix 1). Corrected for po-
tential confounders (age, gender, BMI and injection rate) the mean coronary lumen 
opacification in the iodixanol-270 group was 471 ± 450, compared to 439 ± 417 in the 
iopromide-300 group (p=0.037, 95% CI: 1.9 – 62.7). Comparisons on a segmental level, 
summarized for proximal, middle and distal coronary segments, and averaged per pa-
tient showed no differences (iodixanol-270 462±155 HU vs iopromide-300 440±150 HU, 
p=0.220). Interestingly, attenuation values in the interventricular septum were higher 
in the iopromide-300 group (110±29 vs 117±33, p=0.034). Coronary opacification was 
positively influenced by female gender (55.9 HU higher in women; 95% CI 12.0,100.0; 
p=0.013). Opacification was positively affected by age (4.0 HU increase per year of age; 
95% CI 2.0,5.9; p<0.001). Opacification was negatively influenced by BMI (-20.6 HU per 
1kg/m2; 95% CI -24.8,-16.5, p<0.001), weight (-6.3 HU per kg; 95% CI -7.2,-5.5, p<0.001) 
and length (B -4.6 lower per cm; 95% CI -6.2,-2.9, p<0.001). LV function, systolic blood 
pressure, heart rate before and during contrast administration and the location of the IV 
canula did not affect mean attenuation values. In a multivariate analysis the remaining 
predictor of coronary opacification was age (+3.1 HU per year; 95% CI 0.05,6.19, p=0.046). 
There were no differences in attenuation between both contrast media through the 
Figure 1. Enrolment and randomization of patients. There were no patients with a poor image quality of all 
the coronary arteries, so no scans were excluded based on poor image quality.
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sequential vasculature from right atrium to the distal aorta (appendix 2). The effect of 
contrast agent on opacification was not depended on the injection rate (p=0.652). A 
case example of the coronary opacification with both contrast agents is shown in fig-
ure 2. The signal-to-noise ratio and contrast-to-noise ratio did not differ between the 
groups (SNR: iodixanol-270: 22.3±9.3 HU vs 23.5±10.9 HU, p=0.290)(CNR: iodixanol-270: 
17.2±7.7 HU vs 17.5±8.4 HU, p=0.729) (appendix 1). The subjectively assessed image 
quality was good in 86% and 85% of all coronary segments and did not differ between 
iodixanol-270 and iopromide-300 (p=0.283, appendix 3).
Concordant with the different iodine concentrations the contrast volume was higher 
in the iodixanol-270 group to achieve similar iodine delivery rates (mgI/sec) to the 
iopromide-300 group (76.8±11.6 ml vs 69.7±10.8 ml, p<0.001), and at higher injection 
pressures (111±44 PSI vs 90±36 PSI, p<0.001)(table 2).
Effect on heart rhythm
Beta-blockers were administrated in nearly half of the patients. For both groups com-
bined, the heart rate decreased during the breath-held calcium scan from 64.8±9.9 
bpm to 63.4±10.5 bpm (p<0.001). During contrast-enhanced CT-angiography the heart 
rate remained virtually unchanged in the iodixanol-270 (+0.01±4.56, p=0.986) and the 
iopromide-300 group (+0.32±5.37; p=0.473), without a difference between both groups 
Figure 2. Coronary lumen opacification per-
formed with both contrast agents. Both patients 
were men of 54 years old and a BMI of 25. Patient 
A was scanned with iodixanol-270, at a heartrate 
of 63bpm and had a calciumscore of 0. Patient 
B was scanned with iopromide-300 at heartrate 
56bpm and had a calciumscore of 68. From left 
to right the right coronary artery (RCA), left ante-
rior descending artery (LAD) and left circumflex 
artery (LCx) are shown.
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(p=0.588) (figure 3). Ectopic beats occurred in 3(2%) of iodixanol-270 patients, compared 
to 6(4%) of iopromide-300 patients (p=0.334). No atrial fibrillation occurred in either 
group before or after contrast injection.
Table 2. Scan characteristics
Iodixanol-270
(n=154)
Iopromide-300
(n=152)
p-value
Heart rate
Before scanning (bpm) (mean±SD) [range] 65 ± 9 [45-98] 65 ± 11 [44-115] 0.638
During calcium scan (bpm) (mean±SD) [range] 63 ± 10 [45;98] 63 ± 11 [46-118] 0.887
During CTA(bpm) (mean±SD) [range] 63 ± 11 [43-98] 64 ± 11 [42-114] 0.590
Heart rate change* (bpm) (mean±SD) 0.01 ± 4.56 0.32 ± 5.37 0.588
Ectopic beats during and after contrast injection 3 (2%) 6 (4%) 0.334
Occurrence of atrial fibrillation 0 0 1.000
Pre medication
B-blockers 70 (46%) 65 (43%) 0.646
Contrast injection
Contrast bolus (cc) (mean±SD) [range] 76.8 ± 11.6
[48-100]
69.7 ± 10.8
[45-95]
<0.001
Iodine delivery rate, patients 50-100kg (gl/s) 1.5 1.5
Iodine delivery rate, patients 100-125kg (gl/s) 1.75 1.75
Maximal injection pressure (PSI) 111 ± 44 90 ± 36 <0.001
Scanning technique 0.473
Retrospectively gated spiral scan mode 13 (8%) 9 (6%)
Prospectively triggered axial scan mode 117 (76%) 124 (82%)
Prospectively triggered high-pitch spiral scan 
mode
24 (16%) 19 (13%)
Tube current (mAs) (mean±SD) [range] 341 ± 103
[88-600]
345 ± 103
[108-568]
0.716
Tube voltage (kV) (median, IQR) 80 (80;100) 80 (80;100) 0.796
Scan time (seconds) (mean±SD) 4.6 ± 2.4 4.9±2.3 0.264
Radiation dose
Dose-length product (mGycm) (mean±SD) [range] 160 ± 119 [19;561] 174 ± 160 [25;1038] 0.387
Total calcium score (mean±SD) [range] 118 ± 348 [0;3429] 123 ± 308 [0;2765] 0.897
Patient characteristics presented as mean ± standard deviation and range, or n (%), or median and in-
terquartile range. The heart rate before scanning was a mean over 15 seconds. *Difference in heart rate 
recorded during the calcium scan and the contrast-enhanced CTA. Number of patients with ectopic beats 
throughout the ECG recording during and after contrast injection. B-blockers are oral and intravenous. The 
maximum contrast injection pressure measured in pound-force per square inch (PSI). Dose-length product 
(DLP) in mGycm for CT-angiography.
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Clinical effect and safety
In the iodixanol-270 group fewer patients experienced heat discomfort during the scan 
compared to iopromide-300 group (72% vs 86%, p<0.001)(figure 4). Other symptoms 
and sensations were observed in similarly low rates between both groups. One patient 
in the iodixanol-270 group experienced contrast extravasation. In the iopromide-300 
group two patients experienced mild allergic reactions (sneezing and urticaria, respec-
tively), and one experienced blurred vision <2hours after the scan, all of which resolved 
shortly without treatment. No arrhythmias or renal failure occurred.
DISCUSSION
This multicentre, randomized trial was designed to assess whether iso-osmolar contrast 
medium with a low iodine concentration provides comparable coronary opacification 
to low-osmolar contrast media, if injected at a similar iodine delivery rate. We found 
that 1) coronary lumen opacification by iso-osmolar contrast (iodixanol) is not inferior 
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Figure 3. Change in heart rate. The mean heartrate (beats per minute), before the CT exam, calcium scan, 
and CT-angiography. Compared to measurements before the CT scan, heart rates decreased during both 
the calcium scan (iodixanol-270: p=0.004, iopromide-300: p=0.002) and CT-angiography (iodixanol-270: 
p=0.009, iopromide-300: p=0.050). The heart rate during CT angiography was not significantly different 
between the iodixanol-270 and iopromide-300 group (p=0.590).
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to a low-osmolar contrast (iopromide), 2) while iopromide-300 was associated with 
more frequent heat sensations, heart rate was not affected differently between the two 
groups, 3) objective and subjective measures of image quality were similar between 
iodixanol-270 and iopromide-300.
In this study we found that if contrast media are injected at comparable iodine delivery 
rates, by injecting the iso-osmolar contrast medium at a higher injection rate, coronary 
opacification by iodixanol-270 is not inferior to iopromide-300. In terms of coronary arte-
rial opacification and image quality comparisons between iso-osmolar and low-osmolar 
contrast media have demonstrated mixed results. While some studies demonstrated 
comparable coronary opacification between iso-osmolar and low-osmolar contrast (6, 
9), there is also data showing significantly lower opacification of low-osmolar contrast 
compared to high iodine-osmolality (5, 10). However, in these trials contrast media were 
injected with unequal iodine delivery rates.
Using an iodine delivery rate of 1.5 gI/s in both arms (body weight <100kg), we mea-
sured average attenuation values well above 400HU, with acceptable noise and image 
Figure 4. Clinical effect. All symptoms were classified as no symptoms, mild, moderate or severe. The io-
dixanol-270 group experienced less heat discomfort during contrast administration compared to the io-
promide-300 group (72% vs 86%, p<0.001). There were no significant differences in other symptoms and 
sensations between both groups.
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quality. The injection rate of iodixanol-270 was 5.6 - 6.5 ml/s. Until recently achieving 
sufficient coronary opacification at reasonable contrast injection rates required contrast 
media with a high iodine concentration of up to 400mgI/ml. High attenuation values 
partially compensated for some of the limitations of cardiac CT related to residual motion 
and calcifications. Technological innovation, in particular improved temporal resolution 
and iterative image reconstruction techniques, allow for reliable coronary assessment at 
a lower coronary opacification. In addition, desired attenuation values can be achieved 
with lower intra-coronary iodine concentration by using more powerful roentgen tubes 
operated at lower tube voltages. Iterative reconstruction algorithms reduce image noise 
and improve SNR and CNR while keeping intravascular attenuation values homogenous 
(2, 14).
The osmolarity of contrast media is associated with several clinical effects, such as sen-
sations of heat, discomfort and pain. Low-osmolar contrast media may increase heart 
rate, and thereby reduce image quality in coronary CT angiography. In the Isocor trial 
we found that the mean heart rate did not increase in either group. Multiple studies in 
stable patients evaluating suspected coronary artery disease, suggest that iso-osmolar 
contrast media cause less heart rate acceleration and arrhythmia (5, 7, 11, 15). Low 
heart rate and absent arrhythmia positively affect image quality in ECG-synchronized 
CT-angiography. However, other studies that compared iso-osmolar and low-osmolar 
contrast media in abdominal CT reported no difference in heart rate (12, 16). It should 
be noted that nearly half of the patients in this study received additional beta-blockers 
prior to scanning, but at comparable proportion in both groups.
In the Isocor study we found no significant differences in terms of coronary opacifica-
tion, nor for several other objective parameters of image quality. Previously, some inves-
tigators demonstrated similar diagnostic accuracy, coronary attenuation and subjective 
image quality of CTA using either iso-osmolar or low-osmolar contrast (6, 9), while other 
studies demonstrated better coronary enhancement and fewer inadequately visualized 
segments using high-iodine concentration low-osmolar contrast protocols (5).
There were a few occurrences of contrast extravasation and mild allergy, and a single 
incidence of blurred vision, which is a known side-effect of both contrast agents. Maxi-
mal injection pressure was higher for iodixanol (PSI 111 ± 44) compared to iopromide 
(PSI 90 ± 36, <0.001) as a result of higher injection rates and higher viscosity (6.3cP vs 
4.9cP at 37°C) for iodixanol, but never exceeded the safety threshold (PSI 325).
There are limitations to the study that require consideration. Because of the different 
injection rates the CT technicians could not be blinded towards the study allocation. 
However, this should not have affected the independent, blinded reading and establish-
ment of the primary outcome. Although unlikely given the comparable image quality 
parameters, we cannot exclude differences in diagnostic accuracy related to the contrast 
media. Except for heart rate no other hemodynamic parameters were monitored. A sys-
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tematic assessment of renal function after contrast exposure was not performed, how-
ever, no differences in CIN risk between iodixanol-270 and iopromide-300 have been 
reported in the past (19, 20). Comparison between the iso-osmolar contrast medium 
iodixanol was compared to only a single low-osmolar contrast medium, which may not 
be representative for the entire class.
In conclusion, if injected at comparable iodine delivery rates, the iso-osmolar contrast 
medium iodixanol-270 is not inferior to low-osmolar contrast medium iopromide-300 in 
terms of coronary opacification (body weight 50-125 kg). Iodixanol-270 was associated 
with less warmth discomfort during contrast injection, but did not affect heart rate or 
image quality compared to iopromide-300.
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ABSTRACT
Aims: To investigate the additional value of transmural perfusion ratio (TPR) in dynamic 
CT myocardial perfusion imaging for detection of hemodynamically significant coronary 
artery disease, compared with fractional flow reserve (FFR).
Methods: Subjects with suspected or known coronary artery disease were prospec-
tively included and underwent a CT-MPI examination. From the CT-MPI time-point data 
absolute myocardial blood flow values (MBF) were temporally resolved using a hybrid 
deconvolution model. An absolute MBF value was measured in the suspected perfusion 
defect. TPR was defined as the ratio between subendocardial and subepicardial MBF. 
TPR and MBF results were compared with invasive FFR using a threshold of 0.80.
Results: Forty-three patients and 94 territories were analyzed. The area under the 
receiver operator curve was larger for MBF (0.78) compared with TPR (0.65, P=0.026). 
No significant differences were found in diagnostic classification between MBF and TPR 
with a territory based accuracy of 77% (67-86%) for MBF, compared with 70% (60-81%) 
for TPR. Combined MBF and TPR classification did not improve diagnostic classification.
Conclusion: Dynamic CT-MPI based transmural perfusion ratio predicts hemodynami-
cally significant coronary artery disease. However, diagnostic performance of dynamic 
CT-MPI derived TPR is inferior to quantified MBF and has limited incremental value.
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INTRODUCTION
Dynamic computed tomography myocardial perfusion imaging (CT-MPI) is based on 
sequential scanning of the myocardium during the first pass of a contrast bolus. The 
dynamic imaging of the contrast medium allows for a non-invasive quantification of 
myocardial blood flow (MBF), until now mainly performed with either magnetic reso-
nance imaging or positron emission tomography [2; 3]. With recent developments in 
CT scanners this technique also became available for CT imaging [4; 5]. The diagnostic 
performance of CT-MPI compared with fractional flow reserve is good [6-8]. However, 
possible underestimation of absolute MBF values by CT-MPI is a potential concern [5; 9].
Reduced myocardial perfusion due to coronary artery disease (CAD) tends to be more 
pronounced in the subendocardium [10]. The high spatial resolution of CT allows for 
distinguishing of the subendocardium and subepicardium. A method to utilize the sus-
ceptibility of the subendocardium for ischemia is the transmural perfusion ratio (TPR) 
[11]. TPR is the ratio between subendocardium and subepicardium perfusion. As TPR is a 
relative index we hypothesized it would be less influenced by lower absolute MBF values 
and improve diagnostic performance of CT-MPI.
In this study TPR and MBF based on dynamic CT-MPI are investigated individually and 
in combination, and compared with invasive fractional flow reserve [1].
METHODS
Study Design
The local institutional review board approved this prospective study. Written informed 
consent was obtained from all patients. This study included cases from a previous study 
investigating the diagnostic performance of CT-MPI [8]. Patients with suspected or 
known CAD referred for invasive angiography were prospectively recruited. Included 
patients underwent a dynamic CT-MPI examination 1-14 days before invasive angiog-
raphy.
This study was designed to investigate the ability of CT-MPI to detect ischemia, there-
fore only territories with an FFR measurement in the associated coronary artery were 
included. Territories associated with a (sub)total occluded coronary artery were no FFR 
measurement could be performed were not included in the analysis.
Recruitment and Population
Patients with suspected or known coronary artery dished referred for invasive angiog-
raphy were recruited in the time period December 2010 till December 2014.. Exclusion 
criteria: younger than 40 years old, impaired renal function (serum creatinine >120 
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µmol/L), possible pregnancy or breast feeding, body weight over 120 kg, use of clopido-
grel, contra-indications for iodine contrast medium, or contra-indications for adenosine.
CT-MPI Acquisition
All patients were requested to withhold from caffeine intake 24-hours prior to the 
examination. In both arms 18-gauge cannulas were inserted in the antecubital veins. 
Blood pressure and ECG were monitored during the examination. Forty patients were 
scanned with a second-generation dual-source CT scanner, and three patients with a 
third-generation dual-source CT scanner (SOMATOM Definition Flash and SOMATOM 
Force, Siemens Medical Solutions, Forchheim, Germany). Adenosine was infused at a 
rate of 140µgram/kg/min. CT-MPI acquisition was started three minutes after start of 
adenosine infusion.
The acquisition protocol consisted of coronary CT angiography, a non-contrast scan 
and the dynamic CT-MPI scan. The non-contrast scan was acquired during end-systole, 
and served for planning of the CT-MPI. Before the CT-MPI acquisition all patients re-
ceived sublingual nitroglycerine. Intravenous beta blockers were used in patients with 
high heart rates prior to the coronary CT angiography, but very infrequently (N=3) as 
these potentially affect the CT-MPI performance. After 3 minutes of adenosine infusion, 
50 ml of contrast medium (Ultravist, 370 mgI/ml; Bayer, Berlin, Germany) was injected 
at 6 ml/s, followed by a saline bolus of 40 ml. All CT-MPI studies were made with an 
axial scan mode at 250 ms after the R wave (end-systolic). To sufficiently cover the left 
ventricle the myocardial acquisition was performed in alternating cranial and caudal 
table positions (shuttle-mode), acquiring two slightly overlapping data-sets [4]. CT-MPI 
acquisition was started 5 seconds after start of the contrast medium injection. Patients 
were asked to hold their breath during the entire dynamic CT-MPI acquisition (30-35 
seconds). The number of time points acquired varied per patient depending on the 
heart rate: 1 patient had 9 cranial and caudal time points, 11 patients had 10, 6 patients 
had 11, 12 patients had 12, 9 patients had 13, and 4 patients had 14 time points.
The second-generation dual-source CT scanned used the following scan parameters: 
collimation 2×64×0.6mm detector collimation with flying z-spot technique [12], gantry 
rotation time 280ms, temporal resolution 75ms, tube voltage/current 100kVp/ 300mAs, 
shuttle-mode coverage 73mm.
The third-generation dual-source CT scanner used the following scan parameters: 
collimation 2×96×0.6mm detector collimation with flying z-spot technique. Gantry 
rotation time 250ms, temporal resolution 66ms, Care-Kv [13] was used with reference 
settings for tube voltage/current: 80kVp/300mAs, shuttle-mode coverage 102mm.
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Post Processing
The CT-MPI images were reconstructed using a dedicated kernel for reduction of iodine 
beam hardening artifacts (b23f, Qr36), and transferred to a CT-MPI analysis software 
package (Volume Perfusion CT body, Syngo Somaris/7; Siemens, Germany). Motion 
correction was applied if necessary to correct for breathing displacement. The motion 
correction algorithm uses a time point selected by the user (with contrast in the left and 
right ventricle and smooth connection between the cranial and caudal section), and 
then registers the other time points to the selected time point using non-rigid registra-
tion. The left ventricle is segmented by combining thresholding and peak enhancement 
[14]. The change of attenuation in the myocardium over time was computed by creating 
time-attenuation curves (TAC). For quantification of the MBF the influx of contrast bolus 
was measured with an arterial input function [15]. The AIF was measured by placement 
of a ROI in the descending aorta in the CT-MPI images. Precision of the AIF was increased 
by including both the cranial and caudal sections (double sampling). For quantification 
of the MBF the myocardial TACs were coupled with the AIF using a hybrid deconvolution 
model. The model generates perfusion model curve based on the change in attenuation 
using a simplified impulse residue function for modeling the interaction between intra- 
and extracellular compartments. The MBF was computed on a per voxel basis by dividing 
the maximal slope of the model curve for the myocardial tissue by the maximum AIF [4; 
5; 16]. MBF data-sets were reconstructed with a 512 × 512 matrix resulting in a pixel size 
of 0.35 × 0.35 mm and were reconstructed as a stack of color-coded maps with a slice 
thickness of 3mm and an increment of 1.5 mm.
Image Analysis
MBF and TPR were individually evaluated by readers with previous experience in dy-
namic CT-MPI examinations. Both readers were provided with the color-coded CT-MPI 
datasets. For each patient a list of vessels investigated by FFR was provided. To ensure 
correct territory-vessel correspondence left or right coronary dominance was provided 
for each patient. All readers were asked to measure MBF or TPR value corresponding to 
the vessel where the FFR measurements were performed. Each independent reader was 
blinded to all other medical information.
Within the MBF short axis slice interpreted as representing the myocardium depen-
dent on the vessel in which the FFR was made, a freehand ROI was placed surrounding 
the suspected perfusion defect (Syngo Via 2.0, Siemens AG, Germany). The freehand ROI 
had a minimal area of 50 mm2. Careful considerations were made to prevent inclusion 
of artifacts in the ROI.
For TPR the CT-MPI color-coded maps were visually assessed to identify the slice most 
representative for a subendocardial/subepicardial ratio. The section of interest was 
loaded onto a dedicated image analysis application (ImageJ 1.48, National Institutes of 
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Health, USA).[17] To measure the transmural differences in MBF a series of linear samples 
perpendicular to the myocardial surface were taken at 0.4mm equal intervals (Figure 
2). The mean MBF values from the pixels under the line are projected in the transmural 
MBF profile curve. Care was take not to sample too close to the LV lumen and epicardial 
border as the MBF absolute values are unreliable due to displacement artifacts. From 
the short-axis MBF image and the MBF profile curve the user selected the endocardial 
and epicardial position. The TPR was calculated by dividing the subendocardial by the 
subepicardial MBF.
Invasive Angiography and Fractional Flow Reserve
Invasive coronary angiography was performed according to local clinical standards. 
Prior to the invasive angiography intracoronary nitroglycerine was given, as is the 
standard in our center. Invasive FFR was performed in all vessels with a visual stenosis 
grade between 30-90% by invasive angiography. By protocol, an FFR pressure wire (Pres-
sureWire Aeris/Certus, St. Jude Medical, St. Paul, USA or Prime/Combo Wire, Volcano, San 
Diego, USA) was placed distal to the stenosis of interest, after which hyperemia was 
induced by intravenous infusion of adenosine at 140 µg/kg/min. An invasive FFR ≤0.80 
was considered hemodynamically significant.
Statistics
Absolute variables are represented as total and percentage, continuous variables as 
mean and standard deviation (±). The mean values for MBF and TPR for normal and isch-
emic territories were compared with an unpaired two-sided independent t-test. Pearson 
coefficient correlation was calculated for respectively MBF and TPR against invasive FFR. 
The receiver-operator characteristic (ROC) curves including area under the curve (AUC) 
were presented for MBF and TPR. To investigate the combine diagnostic performance 
for MBF and TPR an ROC curve was also plotted for a new combined variable MBF mul-
tiplied by TPR (MBF×TPR). The optimal threshold for MBF and TPR diagnostic accuracy 
was calculated using the Youden index[18]. A sub-analysis was made for territories with 
an intermediate MBF between 50-100 ml/100ml/min, as these represent territories with 
MBF values close to the diagnostic threshold [6; 8]. Diagnostic performance was evalu-
ated as sensitivity, specificity, positive predictive value, negative predictive value and 
accuracy, with their corresponding 95% confidence intervals (CI). The 95% confidence 
intervals were corrected for within subject clustering of data using variance adjust-
ment[1]. MBF and TPR were displayed against each other with territories classified as 
normal or ischemic. Inter-observer variability was determined for 72 (75%) randomly 
selected territories by intra-class correlation coefficient for absolute MBF and TPR, di-
agnostic classification was compared using Kappa statistics. Results were reported on a 
per-territory and per patient basis and in accordance with the STARD initiative (Standard 
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for Reporting Diagnostic accuracy) [19]. Most statistical analysis were made using SPSS 
(version 21, IBM Corp, Armonk NY, United States of America), while MedCalc (version 
13.0; MedCalc Software, Ostend, Belgium) was used to compare the AUCs by using the 
method of DeLong et al [20].
RESULTS
53 patients were recruited, 10 patients were excluded of whom 8 due to a lack of in-
vasive FFR measurements (Figure 1). Resulting in a study population consisting of 43 
patients, in whom 94 vessels were analyzed by invasive FFR (Table 1). The mean FFR was 
0.79±0.17, of which 48 vessels were considered hemodynamically significant with an 
FFR ≤0.80. The mean dose-length product for the CT-MPI acquisition was 640±135 mGy-
cm, resulting in an effective dose of 9.0±1.9 mSv applying a conversion factor of 0.014.
The mean MBF for FFR confirmed ischemic territories was 71.3±24.3 ml/100ml/min, 
and for normal territories 92.2±21.6 ml/100ml/min (Figure 3). Pearson correlation 
coefficient was 0.55 for MBF directly compared with invasive FFR. The area under the 
curve (AUC) was 0.78 (Figure 4). Optimal threshold for diagnostic classification was ≤76 
ml/100ml/min. The territory based accuracy for MBF was 77% (67-86%) (Table 2).
The mean TPR for ischemic territories was 0.85±0.31 (Figure 3). Pearson correlation be-
tween TPR and invasive FFR was 0.37. The AUC for TPR was 0.65 and significantly smaller 
than MBF (P=0.026). The optimal threshold for diagnostic classification was ≤0.82 (Figure 
4). The territory based accuracy of TPR was 70% (60-81%) (Table 2).
The AUC for the MBF and TRP combined was 0.71 significantly higher than TPR alone 
(P=0.032), the difference with MBF just failed to reach statistical significance (P= 0.070). 
To further investigate the incremental value of TPR a combined interpretation is shown 
in Figure 5. Concordance between MBF and TPR diagnostic classification was present in 
the majority of the territories (74%). For territories with concordant abnormal MBF and 
Figure 1. Inclusion flow chart
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TPR a trend towards an increase positive predictive value was observed. A combined 
classification did not yield significant improvement in diagnostic accuracy, not for all 
territories, and neither for the territories with an intermediate MBF between 50-100 
ml/100ml/min (Table 2).
The inter-observer variability for TPR was moderate to good with an intra-class cor-
relation coefficient of 0.77 and a Kappa of 0.66. For MBF reproducibility was better with 
an intra-class correlation of 0.84 and a Kappa of 0.77.
Only three patients were scanned with a 3rd generation DSCT. Reanalysis after exclu-
sion of these cases did not affect the results (data not shown).
DISCUSSION
The main findings of this study are 1) Transmural perfusion ratio from dynamic CT-MPI 
predicts functionally flow limiting CAD. 2) Transmural perfusion ratio based on dynamic 
CT-MPI myocardial blood flow maps is inferior to quantified myocardial blood flow.
Table 1. Patient Characteristics
Number of patients, n 43
Age (years) 62.6±8.7
Male gender, n (%) 36 (84)
Body mass index (kg/m2)* 20.1±2.3
Body surface area (m2)* 2.0±0.14
Cardiovascular risk factors, n (%)
Hypertension 27 (63)
Dyslipidaemia 20 (47)
Diabetes 7 (16)
Family history of CAD 17 (40)
Smoking within the last year 10 (22)
Prior myocardial infarction, n (%)† 8 (19)
Prior PCI, n (%)† 5 (12)
Agatston coronary calcium score‡ 628 (265-1450)
Heart rate during rest 63.4±12.9
Heart rate during hyperemic CT-MPI. 83.0±13.7
Values are reported as mean and ± standard deviation or absolute number n and percentage (%). CAD, 
coronary artery disease; PCI, percutaneous coronary intervention.
* In four patients length and weight data were not available.
† Not in the vessel territories interrogated by invasive FFR.
‡ Represented in median and (quartiles).
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Figure 2. TPR case example: 65-years-old man presenting after exertional collapse. a) Short-axis CT-MPI 
image with the transmural perfusion line placed in the anterior-lateral segment. (white arrow). b) The trans-
mural MBF profile. The subendocardial MBF was 58ml/100ml/min (purple marker), and 91ml/100ml/min in 
the subepicardium (orange marker). The TPR was 0.64 (58/91), and thus considered positive for ischemia. c) 
Invasive angiography showing a stenosis in the proximal LAD with an FFR of 0.69. A subtotal stenosis was 
directly stented in the LCX (arrow head), as such no FFR measurement was performed. In panel a however a 
perfusion defect with a transmural perfusion ratio can be seen in the territory associated with the LCX. The 
RCA was normal with an FFR of 0.91. RCA: right coronary artery, LAD: left anterior descending artery, LCX: left 
circumflex artery, TPR transmural perfusion ratio, MBF: myocardial blood flow, FFR: fractional flow reserve.
Figure 3. MBF and TPR: Median and mean myocardial blood flow and transmural perfusion ratio in 94 ter-
ritories for normal (n=46) and ischemic (n=48) territories. Normal territory defined as invasive FFR >0.80, 
and ischemic territories as FFR ≤0.80. FFR: fractional flow reserve.
Figure 4. ROC: Receiver operator curves for MBF 
and TPR validated against FFR using a threshold of 
0.80 for hemodynamically significance. Area under 
the curve for MBF was 0.78 (95% CI:0.67-0.87), for 
TPR 0.65 (95% CI:0.53-0.77), and for MBF×TPR 0.71 
(95% CI:0.60-0.82) . The optimal diagnostic thresh-
old was calculated at 76 ml/100ml/min for MBF and 
0.82 for TPR. MBF: myocardial blood flow, TPR: trans-
mural perfusion ratio, FFR fractional flow reserve, 
CI: confidence interval.
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The subendocardial layer is more susceptible for ischemia, which is thought to be due 
to a reduction in the diastolic perfusion time-interval, higher contractile intra-myocardial 
tissue pressures, and differences in coronary microvasculature [10; 21]. By comparing 
the subendocardial and subepicardial perfusion the susceptibility of the endocardium 
for ischemia can be used as a diagnostic criteria.
Barmeyer et al. found that subendocardial/subepicardial ratio using stress MRI per-
fusion was associated with functional CAD in comparison with coronary flow reserve, 
however measurements taken only in the subendocardial layer showed superior 
diagnostic performance [22]. Using oxygen positron emission tomography MPI a similar 
association between TPR and functional stenosis measurement was found, however 
similar to our study TPR was inferior to quantified myocardial perfusion measurements 
[23]. The high spatial resolution of CT is well suited for differentiating the myocardial lay-
ers, and identification of subendocardial perfusion differences. George et al. showed the 
potential of transmural perfusion ratio using static CT-MPI to detect ischemia, validated 
by a combination of quantitative angiography analysis and SPECT [11]. In another static 
CT-MPI study validated by SPECT a good diagnostic performance of a transmural perfu-
sion gradient was found [24]. Ko et al. found static rest and stress CT-MPI assets visually 
was of incremental value to coronary CT angiography [25]. More recently Yang et al. 
published visual static CT-MPI assessment performed better than transmural perfusion 
Figure 5. Classification by MBF and TPR: Scatterplot showing the combined classification by MBF and 
TPR. The solid lines represent the diagnostic threshold for MBF (76) and TPR (0.82). A larger proportion of 
ischemic territories was observed in the bottom left quarter, representing territories with a concordant 
abnormal MBF and TPR. The area between the two vertical dashed lines represent the territories with an 
intermediate MBF between 50 and 100 ml/100ml/min. TPR: transmural perfusion ratio, MBF: myocardial 
blood flow, FFR: fractional flow reserve.
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ratio, validated by FFR [26]. In these studies a segmental based TPR was calculated while 
for the epicardial layer the entire circumferential attenuation was averaged. In our study 
we used the epicardial myocardial blood flow at the location of the suspected perfu-
sion defect. Because calculated MBF values vary between different regions of the heart, 
even in the absence of CAD, we compared the subendocardial MBF values against the 
adjutant subepicardial layer.
Several studies showed good diagnostic performance of dynamic CT-MPI to identify 
hemodynamically significant coronary artery disease compared with fractional flow 
reserve [6-8; 27]. A potential concern are the relative low absolute myocardial blood 
flow values computed with dynamic CT-MPI [5; 28; 29]. We hypothesized that a relative 
endocardial/epicardial perfusion ratio would be less vulnerable to individual variations 
in global MBF values and would be more sensitive in the identification of subtle perfu-
sion defects.
This study shows that the transmural perfusion ratio identifies hemodynamically rel-
evant coronary artery disease. However, no significant incremental value of TPR on top 
of MBF was found. In patients with an abnormal MBF, addition of TPR could reclassify a 
number of false positive results, however a statistical significant improvement could not 
be demonstrated in this modestly sized cohort. There are several possible explanations 
for the negative outcome in this study: The TPR methodology in this study is different 
from methods previously used in static CT-MPI. In dynamic CT-MPI the endocardial zone 
directly adjacent to the left ventricle cavity is prone to artifacts related to myocardial 
displacement, beam hardening and partial voluming potentially obscuring subtle perfu-
sion defects. Future research related to improving MBF reconstruction in the endocardial 
layer adjacent to the ventricle cavity, is of importance as the endocardial layer is more 
susceptible to myocardial ischemia and perfusion imaging defects.[30]
Limitations
These results are based on a limited number of patients recruited over a relatively long 
period of time (4 years) from a single-center study. As a result of the study complexity, 
as well as logistic factors such as availability of researchers and competing competitive 
research, only a fraction of the potentially eligible patients were recruited in this study. 
While the non-consecutive enrolment was mostly based on these logistic factors, some 
degree of selection bias cannot be excluded. In a clinical setting CT-MPI will most likely 
be performed in conjunction with coronary CTA. However, this study focused on the di-
agnostic performance of CT-MPI specifically. As the diagnostic performance of dynamic 
CT-MPI using manual sampling of absolute MBF values is already good, a larger sample 
size might be needed to demonstrate an incremental value of other parameters. Motion 
correction algorithms were used if indicated, however especially around the edge of 
the MBF color-coded images myocardium displacement artifacts can still be present. In 
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several cases these artifacts result in high MBF values directly next to the left ventricle 
lumen. Even though care was taken to avoid these artifacts they may have negatively 
affected the performance of TPR. In this study preference was given to a robust, rela-
tively user-independent transmural MBF profile curve as base for TPR. However, a more 
flexible freehand ROI in the endocardial and epicardial layer might affect TPR.
CONCLUSION
Transmural perfusion ratio measurements are feasible from dynamic CT-MPI and can 
identify functional obstructive CAD. Transmural perfusion ratio, as investigated in this 
study, from dynamic CT-MPI is inferior to and has limited incremental value on top of 
absolute myocardial blood flow measurements. In the future other myocardial flow 
parameters may be investigated to enhance the diagnostic performance of dynamic 
CT-MPI to identify myocardial ischemia.
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ABSTRACT
Objectives: To assess the effectiveness, efficiency and safety of a tiered, comprehensive 
cardiac CT protocol in comparison to functional-testing.
Background: While CT angiography accurately rules out coronary artery disease (CAD), 
incorporation of CT myocardial perfusion imaging as part of a tiered diagnostic ap-
proach could improve the clinical value and efficiency of cardiac CT in the diagnostic 
workup of patients with angina pectoris.
Methods: Between July 2013 and November 2015 268 patients (mean age 58 years; 
49% female) with stable angina (mean pretest-probability 54%) were prospectively ran-
domized between cardiac CT and standard guideline-directed functional-testing (95% 
exercise-ECG). The tiered cardiac CT protocol included a calcium scan, followed by CT-
angiography if calcium was detected. Patients with ≥50% stenosis on CT-angiography 
underwent CT-myocardial perfusion imaging.
Results: By six months, the primary endpoint, the rate of invasive coronary angiograms 
without an ESC class-I indication for revascularization, was lower in the CT group than 
the functional-testing group (2/130 (1.5%) vs. 10/138 (7.2%), p=0.035), while the propor-
tion of invasive angiograms with a revascularization indication was higher (88% vs 50%, 
p=0.017). The median duration until the final diagnosis was 0(0;0) days in the CT group 
and 0(0;17) in the functional-testing group (p<0.001). Overall, 13% of patients random-
ized to CT required further testing, compared to 37% in the functional-testing group 
(p<0.001). The adverse event rate was similar (3% vs 3%, p=1.000), though the median 
cumulative radiation dose was higher for the CT group (3.1mSv [IQR: 1.6;7.8] vs 0mSv 
[0;7.1], p<0.001).
Conclusions: In patients with suspected stable CAD, a tiered cardiac CT protocol with 
dynamic perfusion imaging offers a fast and efficient alternative to functional-testing.
Clinical Trial: US National Institutes of Health (ClinicalTrials.gov): NCT02291484
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INTRODUCTION
Coronary computed tomography angiography (1) has become an established, reliable 
diagnostic test in the management of coronary artery disease (CAD). Two large random-
ized studies demonstrated that coronary CTA performs at least equally well as functional 
tests for the evaluation of stable angina(2,3). In the CRESCENT-I trial we found that in-
corporation of a calcium scan in a tiered CT strategy is safe and effective(4). Although 
coronary CTA effectively rules out coronary disease, it is limited in its ability to assess the 
hemodynamic importance of angiographic lesions. Because anatomical lesion severity 
is a poor predictor of hemodynamic significance, functional evaluation of intermedi-
ate stenoses is recommended for therapeutic decision-making(5,6). The performance 
of myocardial perfusion imaging (MPI) by CT has been validated in a large number of 
studies(6-11). A comprehensive cardiac CT examination, combining CTA and CT-MPI, 
could provide all essential information for clinical decision-making in CAD, and avoid 
invasive coronary angiography (ICA) in patients without hemodynamically significant 
CAD(7-9,12).
In the Comprehensive Cardiac CT versus Exercise Testing in Suspected Coronary 
Artery Disease (CRESCENT-II) randomized-controlled trial we assessed the effectiveness, 
efficiency and safety of a tiered cardiac CT protocol, consisting of a calcium scan with 
selective performance of CTA and CT-MPI, in comparison to functional-testing.
METHODS
Study design
The CRESCENT-II trial is a pragmatic randomized-controlled trial comparing the effec-
tiveness, efficiency and safety of a comprehensive, tiered cardiac CT approach with a 
standard diagnostic workup using functional-testing. At four hospitals in the Nether-
lands, 268 patients referred with stable chest pain and suspected CAD were prospec-
tively enrolled. Medical ethics committees at each of the sites approved the study. The 
CRESCENT-II trial is registered at the US National Institutes of Health (ClinicalTrials.gov): 
NCT02291484.
Study participants
Patients ≥18 years with chest pain symptoms suspicious of obstructive CAD, and CAD 
probability >10% were study eligible(13). Exclusion criteria were prior myocardial in-
farction or revascularization procedure, renal failure (eGFR<60ml/min/1.73m2), iodine 
allergy, contra-indications to adenosine or known pregnancy.
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Study procedures
After an outpatient clinic assessment, participants provided written informed consent 
and were randomly assigned to either the CT group or the functional-testing group. 
All participants filled out the Seattle Angina Questionnaire(SAQ), EuroQol-5D-5L(EQ-5D) 
and Short-Form-36(SF-36) for quality-of-life assessment, and a cost questionnaire. All 
testing was performed at the recruiting center. For ascertainment of trial endpoints at 
six months, results of downstream diagnostic and therapeutic procedures were col-
lected from the medical records, and patients completed again the questionnaires for 
ascertainment of angina complaints, quality of life and health status.
Cardiac CT strategy
In the CT group all patients first underwent a non-contrast-enhanced calcium scan 
(Somatom Definition Flash and Force, Siemens Healthineers, Forchheim, Germany). In 
patients with a low-intermediate probability of CAD (10-80% by Diamond and Forrester)
(13), the absence of calcium excluded obstructive CAD and obviated the need for further 
testing. Patients with a zero calcium score but >80% pre-test probability, and all patients 
with a positive calcium score (>0) underwent contrast-enhanced coronary CTA.
All patients received sublingual nitroglycerin before CTA studies. If indicated (HR>65/
min) and clinically acceptable, beta-blockers were administrated. The prospective elec-
trocardiographically triggered axial scan mode was used, with an exposure window dur-
ing diastole and/or systole depending on the heart rate. Tube current and tube voltage 
were selected semi-automatically on the basis of body size. A test bolus acquisition was 
performed using 15-ml of contrast medium followed by a 40-ml saline chaser. For the 
CT angiogram, a contrast bolus of 50-60 ml (depending on iodine concentration) was 
injected to achieve an iodine delivery rate of 2.2-g/s, followed by a 40-ml saline bolus 
chaser. Images were reconstructed with a medium-smooth kernel (B26, Bv40), slice 
thickness of 0.5-mm, and an increment of 0.3-mm. The CTA was immediately assessed, 
and all patients with >50% stenosis underwent an adenosine-stress dynamic myocardial 
perfusion CT scan (CT-MPI) during the same session. All recruiting sites had previous 
cardiac CT experience.
Dynamic CT myocardial perfusion imaging
Detailed descriptions of the dynamic myocardial perfusion imaging protocol were 
published previously (8,11). In brief, CT perfusion started 10 minutes after CTA for wash-
out of contrast media. Myocardial hyperemia was achieved by adenosine infusion (≥3 
minutes, 140µg/kg/min) over a second venflon. To avoid interference with adenosine 
patients abstained from caffeine-containing beverages 24-hours prior to their appoint-
ment. A 50-ml contrast bolus (Ultravist, 370mgI/ml; Bayer, Germany) and 40 ml saline 
were injected at 6ml/s. Using an alternating table positions (shuttle mode) for complete 
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myocardial coverage, systolic images were acquired every second heart cycle while the 
patient maintained a 35-s inspiratory breath hold.
The following scan parameters were used for the second-generation dual-source scan-
ner: 2×64×0.6-mm collimation, 280-ms gantry rotation time, 75-ms temporal resolution, 
100-kV and 300-mA or 80-kV and 370-mA tube voltage and current per rotation, and 
shuttle-mode with 73-mm total z-axis coverage; for the third-generation dual-source 
scanner: 2×96×0.6-mm collimation, 250-ms gantry rotation time, 66-ms temporal reso-
lution, 80-kV tube voltage and 300-mA current (Care-kV as a reference), and 102-mm 
shuttle-mode z-axis coverage.
From a series of 12-15 consecutive datasets, myocardial attenuation was plotted 
against time. A parametric deconvolution technique based on a 2-compartment model 
was used to fit the time-attenuation curves (Volume Perfusion CT body, Siemens). 
Myocardial blood flow (MBF, ml/100ml/min) was computed by dividing the convoluted 
maximal slope of the myocardial time-attenuation curve by the maximum arterial input 
function (aorta). By calculating MBF on a per-voxel basis, 3D-MBF maps were recon-
structed with a slice thickness of 3.0-mm and an increment of 1.5-mm, which were used 
for interpretation of hypoperfusion in relation to angiographic obstructions (figure 1). 
Patients without (substantial) myocardial ischemia were treated medically. Patients with 
substantial myocardial ischemia (visually ≥10% LV) were referred for invasive angiogra-
phy, in accordance with international guidelines(5).
Functional test strategy
The functional-testing strategy was selected by the treating physicians in accordance 
with international guidelines(5). Most underwent a symptom-limited exercise-ECG, with 
a target heart rate defined as 85% of the age-defined maximum-predicted heart rate. 
The main diagnostic ECG criterion for ischemia consists of a horizontal or down-sloping 
ST-segment depression ≥0.1mV, persisting for at least 0.06–0.08s after the J-point, in 
one or more ECG leads. SPECT MPI or stress echocardiography were performed in case 
of contraindications to exercise-ECG, or non-interpretable or equivocal results. Criteria 
for the presence of ischemia were reversible perfusion defects on SPECT MPI (≥10% 
ischemia, based on a segment difference score of 7 or higher) or the presence of new 
wall motion abnormalities on echocardiography. All functional imaging tests were in-
terpreted for the presence of inducible ischemia and risk of adverse outcome, applying 
established criteria for each respective test (14,15).
Interpretation of CT and functional test results, using all available clinical data, as 
well as subsequent clinical management decisions, were performed by local physicians. 
Patients considered to be at high risk based on test results and clinical interpretation, 
or those with refractory symptoms despite optimal medical treatment, were generally 
referred to invasive coronary angiography.
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Outcomes
The primary outcome was the negative invasive angiography rate, defined as the 
number of angiograms without a class I indication for revascularization based on ESC 
guidelines(16), as a proportion of the total number of patients. Class I indication for re-
vascularization were: left main >50% with objective ischemia, proximal LAD >50% with 
ischemia, two or three-vessel disease with impaired LV function and ischemia, proven 
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Figure 1. Case example of the comprehensive cardiac CT protocol. 52-years-old man with atypical angina, 
randomized to cardiac CT. Agatston score: 338.6 (A). CT-angiography: diffuse narrowing (50-70%) in the 
proximal, small RCA (arrow)(B), normal LAD (C), two 50-70% stenoses in the Cx(D). CT-MPI: low myocardial 
blood flow (0.55-0.73ml/min/g) in inferior wall (green-blue, arrows)(E,F). Invasive angiography: confirmed 
Cx lesions (H-I) were percutaneously treated(H-I), RCA regarded too small for revascularization(G).
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large area of ischemia (>10% LV), >50% stenosis with limiting angina unresponsive to 
optimal medical treatment(16). An external, independent reviewer reassessed revascu-
larization criteria, irrespective of clinical decisions by the treating physician.
Pre-specified secondary outcomes included the positive yield of invasive coronary 
angiography: proportion of invasive angiograms leading to a class I revascularization 
indication. Clinical effectiveness was defined by persistent or recurrent anginal symp-
toms and quality of life at 6 months. Efficiency outcomes included time to diagnosis from 
first outpatient visit until the first test that led to the final diagnosis, or the final test 
that ruled out obstructive CAD. Downstream testing included all non-invasive tests and 
invasive angiography to diagnose CAD after the initial test. Diagnostic costs included all 
tests to diagnose CAD over the first six months. Costs per test were based on previously 
published cost analyses(17).
Major adverse events included death, non-fatal myocardial infarction, unstable angina, 
urgent revascularization and stroke. For the survival analysis, events were counted once 
for each patient in the hierarchical order listed above. The cumulative effective radia-
tion dose (mSv) included all tests and interventions applying radiation. For cardiac CT 
a conversion factor of 0.017 was used. For SPECT and invasive angiography conversion 
factors of 0.0085mSv/millibecquerel and 0.24mSv/Gy*cm2 were used(18,19).
Statistical analyses
Based on registry data, an angiography without class I indication for revascularization 
rate of 1.2% in the CT group and 10.9% in the control group were predicted(20). For 80% 
power at a two-sided p-value of 0.05 at least 250 patients were required to detect a simi-
lar difference in invasive angiograms without a class I revascularization indication. Con-
tinuous data are presented as means±SD or medians with interquartile ranges. Groups 
were compared by independent-sample t-test or Mann-Whitney U-test for continuous 
variables, and chi-square or Fisher’s exact-test for categorical variables. The invasive 
angiography without class I indication for revascularization rate was compared using 
a Fisher exact test. The event-free survival probability was estimated by Kaplan-Meier 
survival analysis and log-rank statistic. A Cox-proportional hazards model was employed 
to estimate the relative hazard of events by randomized test strategy, deriving hazard 
ratios and 95% confidence intervals (CIs). A two-sided p-value of <0.05 was considered 
statistically significant. Statistical analyses were performed using SPSS (version 21, IBM 
Corp, Armonk NY, USA), according to the intention-to-treat principle.
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RESULTS
Study population
Between July 2013 and November 2015, out of 352 potential candidates 268 pa-
tients (age 58±11years, 49% women) could be enrolled and randomized between 
cardiac CT (138) and functional-testing (138) (table 1; figure 2). All patients were in-
cluded in the intention-to-treat analysis. Pre-test CAD probability was 54±30% based on 
Diamond&Forrester(13). Invasive angiography demonstrated >50% CAD in 28 patients 
(8%). At 6-months follow-up original records of hospital visits and events were available 
in 266 of 268 (99%) patients.
Test results
In the functional-testing group the first test was exercise-ECG in 131 (95%) and nuclear 
imaging in 7 patients (5%), with a result interpreted as positive in 12 (9%), negative in 77 
(56%), inconclusive in 47/138 (34%), while 2 patients did not undergo their scheduled 
Table 1. Patient characteristics
Cardiac CT
(n=130)
Functional testing
(n=138)
Mean age (years) 58±11 58±11
Female sex (%) 49 56
Systolic/diastolic blood pressure (mmHg) 136±19/84±11 137±18/83±9
Median body-mass index 28±5 28±5
History (%)
Transient ischemic attack or stroke 6 7
Peripheral artery disease 2 4
Cardiac risk factors (%)
Current or past smoker 33 42
Hypertension 52 52
Dyslipidemia 38 40
Diabetes mellitus 18 18
Family history of ischemic heart disease 36 38
Presenting chest pain symptoms (%)
Typical angina 38 36
Atypical angina 45 51
Non-anginal complaints 18 14
Pre-test probability – Diamond&Forrester (%)(13) 56±30 53±30
Patient characteristics as mean±SD, percentage, or median and interquartile range. No significant differ-
ences between both groups. Hypertension: systolic >150mmHg, diastolic >90mmHg, or medication. Dys-
lipidemia: total cholesterol>5mmol/L, low-density lipoprotein>3mmol/L, or medication. Diabetes mellitus: 
plasma glucose>11.0mmol/L, or medication.
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examination. Additional testing, and multiple tests in some patients, included: SPECT-
MPI (n=24), stress echocardiography (n=4), cardiac CT (n=11), exercise-ECG (n=1) and 
invasive angiography (n=20)(figure 3). Of 20 patients undergoing invasive angiograms, 
10 required revascularization.
In the CT group, the median calcium score was 5 (0-146), and 50 (39%) patients had no 
detectable calcium. CT-angiography was performed in 79 (61%) patients with a positive 
calcium scan, and 5 patients with a zero calcium score but >80% pre-test probability. 
Out of 29 patients with >50% stenosis, 19 (66%) showed myocardial ischemia on per-
fusion imaging (figure 3). Concordant ischemia was demonstrated by CT-MPI in 7/12 
(58%) vessels of patients with three-vessel disease (n=4), 3/4 (75%) with left main or 
proximal left anterior descending coronary disease, and 13/25 (52%) vessels of patients 
with other one- or two-vessel disease (n=21) by CT-angiography. Concordant ischemia 
was demonstrated by CT-MPI in 11/12 (92%) patients with >70% maximum stenosis and 
8/17 (47%) patients with 50-70% maximum stenosis by CT angiography. Of 19 patients 
with myocardial ischemia, 14 underwent invasive angiography, and 13 were revascular-
ized. Two patients with a normal CT-MPI later underwent PCI because of insufficient 
symptomatic relief, one in the setting of unstable angina.
Assessed for eligibility
(n = 352)  Excluded (n=84):
 Pre-test probability ≤ 10% (n=20)
 Contra-indications to contrast
  - eGFR <60ml/min/1.73m2 (n=10)
  - iodine allergy (n=10)
 Contra-indications to adenosine (n=2)
 History of CAD (n=5)
 Declined participation (n=25)
 Unable to provide consent (n=12)
CT strategy 
(n=130) [49%]
Functional testing 
(n=138) [51%]
Lost to follow up 
(n=0)
Lost to follow up 
(n=2)
Complete clinical follow up 
(n=130) [100%]
(79% questionnaire response)
Complete clinical follow up 
(n=136) [99%]
(74% questionnaire response)
Randomized 
(n = 268)
Figure 2. Enrolment, randomization, follow-up. Patient flow diagram with disposition by randomized arm. 
Complete clinical follow-up: clinical events at 6-months. Questionnaire response at 6 months: SAQ, EQ-5D 
and SF-36 questionnaires.
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Calcium negative 
(n=50)
Cardiac CTFunctional testing
Pos
(n=19)
Neg
(n=10)
Negative
(n=77)
* Including 5 patients without calcium but high pretest probability  
   (>80 by Diamond & Forrester).
† SPECT-MPI (n=24), CTA (n=11), stress echocardiography (n=4), exercise-ECG (n=1).
‡ Inconclusive SPECT-MPI scan (n=1).
§ Positive SPECT-MPI (n=1). 
¶ Independent review of class I indication for revascularization, based on the 2010 
ESC guidelines. 
#  Invasive angiography without class I indication for revascularization (n=2).
Inconclusive
(n=47)
Calcium positive (> 0)
(n=79)
< 50% 
CAD
(n=55)
Negative
(n=30)
‡ 
Neg
(n=10)
> 50% 
CAD
(n=29)
Pos
(n=12)
Pos
(n=9)
Pos
(n=15)
Pos
(n=10)
Additional non-invasive tests 
Invasive angiography ¶ 
First diagnostic test
Exercise-ECG (n=131)/ SPECT scan (n=7) Calciumscan (n=129)
CTA (n=84) *
CTP (n=29)
† (n=40)  §
(n=20) (n=17)
‡
#
Figure 3. Flowchart of diagnostic testing. Flowchart showing the first and additional diagnostic tests and 
their outcome, per randomization arm.
* Including 5 patients without calcium but high pretest probability
(>80 by Diamond & Forrester).
† SPECT-MPI (n=24), CTA (n=11), stress echocardiography (n=4), ex rcise-ECG (n=1).
‡ Inconclusive SPECT-MPI scan (n=1).
§ Positive SPECT-MPI (n=1).
¶ Independent review of class I indication for revascularization, based on the 2010 ESC guidelines.
# Invasive angiography without class I indication for revascularization (n=2).
Table 2. Diagnostic yield of invasive angiography
Cardiac
CT
(n=130)
Functional 
testing
(n=138)
p-value
Invasive angiograms 17 (13.1%) 20 (14.5%) 0.860
Class I indication for revascularization1 15 (11.5%) 10 (7.2%) 0.294
Left main >50% with objective ischemia 1 1
Proximal LAD >50% with ischemia 4 0
2 or 3-vessel disease with impaired LV function and 
ischemia
1 2
Proven large area of ischemia (≥10% of LV) 6 2
Any stenosis >50% with limiting anginal symptoms 
unresponsive to OMT
3 5
Without class I indication 2 10 0.035
Positive diagnostic yield of invasive angiography 15/17 (88.2%) 10/20 (50.0%) 0.017
1. Cardiac catheterizations with class I indication for revascularization(16). OMT: optimal medical treatment
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Diagnostic effectiveness
Fewer invasive angiograms without class I indication for revascularization were ob-
served in the CT group (2/130, 1.5%), compared to the functional-testing group (10/138, 
7.2%, p=0.035)(table 2). At a comparable rate of invasive angiograms (p=0.860), the 
positive yield was higher after CT (15/17, 88%), compared to functional-testing (10/20, 
50%; p=0.017). The independently assigned class I revascularization indications were 
concordant with the clinically performed revascularization procedures.
Diagnostic efficiency
In both groups the majority of patients reached the final clinical diagnosis the same day 
at the outpatient clinic, though most frequently in the cardiac CT group (87% vs. 64% 
of functional-testing group, p<0.001)(figure 4). Further testing was needed in 13% of 
patients randomized to CT, compared to 37% after functional-testing (p<0.001)(figure 
5). Although index testing costs were higher for CT, the mean cumulative diagnostic 
expenses were comparable for CT €435 [range: €64- €2439] and functional-testing €450 
[range: €106- €2015] (p=0.827).
Anginal symptoms and quality of life
After six months 38% of patients in the CT group reported absent anginal symptoms, 
in comparison to 28% in the functional-testing group (p=0.118). In both groups com-
parable improvements in SAQ-subscales were observed (appendix 1). Quality-of-life 
improvement by EQ-5D-questionnaire did not differ (p=0.245)(appendix 2). The im-
provement in QoL-VAS scale for CT was from 66.8 to 73.7 (p<0.001) compared to 68.9 to 
72.4 (p=0.042) for functional testing, this numerical difference failed to reach statistical 
significance (p=0.168)(appendix 3).
Time (days)
200150100500
Pr
op
or
�o
n 
of
 p
a�
en
ts
 w
ith
 d
ia
gn
os
is
1.0
0.8
0.6
0.4
0.2
0.0
Func�onal tes�ng
Cardiac CT
Page 1
Figure 4. Time to diagnosis. Proportion of pa-
tients with a diagnosis plotted against time. 
P<0.001.
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Safety
After an average follow up of 250±95 days (8±3 months) three non-cardiac deaths, four 
nonfatal infarctions, and one case of unstable angina requiring revascularization, were 
observed in 266 patients (CT 4 vs. functional 4 events, p=1.000). Event-free survival was 
similar (CT 96.9% vs. functional 97.1%, p=0.929) with an adverse event hazard ratio of 
1.07 (95%CI 0.27-4.26) for CT compared to standard care (p=0.929).
No adverse events occurred in the 45 patients (35%) in whom CAD was ruled out 
based on a zero calcium score. One patient later presented with acute chest pain and 
ECG changes, though biomarkers were negative and invasive angiography revealed no 
abnormalities. Amongst the five patients without calcium, but >80% pre-test probabil-
ity, CT-angiography revealed single-vessel CAD with ischemia on CT-MPI in one case.
In the functional-test group only 51 patients (37%) were exposed to radiation, which 
resulted in a lower median cumulative dose (CT 3.1mSv [1.6;7.8] vs 0mSv [0;7.1], p<0.001). 
The mean dose of the cardiac CT exam was 5.6±6.3mSv. The mean dose was 1.3±0.7mSv 
for the calcium scan, 3.5±3.0mSv for CT-angiography, and 10.6±6.3mSv for CT-MPI.
1% 
12% 
0%
10%
Cardiac CT Func�onal
tes�ng
Addi�onal tes�ng
23% 
11.5% 
7.2% 
38% 
28% 
3% 3% 1% 
5% 
12% 
9% 
1.5% * 
7.2% * 
0%
10%
20%
30%
40%
Cardiac CT Func�onal
tes�ng
Cardiac CT Func�onal
tes�ng
Cardiac CT Func�onal
tes�ng
Cardiac CT Func�onal
tes�ng
Addi�onal tes�ng Invasive coronary
angiography
Relief of angina MACE
Primary and secondary endpoints 
invasive
tes�ng
both
non-invasive
tes�ng
p<0.001 
p=0.860 
p=0.118 
p=1.000 
Revasc. -
Revasc. +
Figure 5. Primary and secondary outcomes. Additional tests after the first diagnostic test, divided into non-
invasive, invasive or both. Invasive angiography: followed by revascularization (+), or no revascularization 
(-). Angiography without class I indication for revascularization rate was the primary endpoint and was 
significantly different (*) between CT and functional testing (1.5% vs 7.5%, p=0.035). Relief of angina at 6 
months. MACE: death, myocardial infarction and stroke.
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DISCUSSION
In this multicenter randomized clinical trial, a comprehensive cardiac CT examination 
that involved a stepwise performance of a calcium scan, CT-angiography and CT myo-
cardial perfusion imaging, was compared to the current standard of functional-testing 
for suspected CAD. The main findings are that a tiered cardiac CT protocol improves the 
efficiency of invasive angiography without increasing overall catheterization rates. The 
combined CT protocol achieved a diagnosis faster, and removed the need for additional 
noninvasive testing.
Diagnostic management of stable angina
While there are many noninvasive techniques for diagnosing CAD, the low diagnostic 
yield of invasive angiography suggests lack of effectiveness by current diagnostic prac-
tices(21). Although stress imaging is more sensitive to the detection of angiographic 
CAD, without evident clinical outcome benefit(22), the ACC/AHA guidelines maintain 
exercise ECG as the first-choice test in suitable patients with a low-intermediate CAD 
probability(23). CT-angiography is a relatively new diagnostic option with a high sen-
sitivity for the detection of CAD. In a very large cohort the PROMISE trial demonstrated 
equivalent clinical outcome for CT-angiography and stress testing(2). Meta-analyses, 
however, indicate that CT-angiography may increase catheterization and revasculariza-
tion rates, of which clinical benefit remains yet unproven(24,25). Functional tests can dif-
ferentiate patients more likely to benefit from revascularization, although the prospec-
tive evidence for this is stronger for fractional flow reserve than noninvasive functional 
tests. In SCOT-HEART, which demonstrated improved outcome from CT-angiography, 
cardiac CT was combined with an exercise ECG in the majority of patients(3,26). This 
supports the idea that both anatomical and functional information are required for 
therapeutic decisions that affect clinical outcome. Another observation from these trials 
is the low, but often overestimated CAD prevalence, as well as a low adverse event rate 
in real-world populations with stable chest pain(2-4), fueling a paradoxical debate on 
the value of extensive testing in low-risk populations(27).
Comprehensive cardiac CT protocol
The objective of the CRESCENT-II trial was to test a tiered comprehensive cardiac CT 
protocol that would allow safe rule-out of CAD by relatively simple means, while at the 
same time incorporating functional measures of CAD for well-informed decisions and 
avoidance of premature invasive procedures. Calcium imaging in symptomatic patients 
is controversial due to the possibility of non-calcified obstructions. Supported by CON-
FIRM and other registries in real-world populations(28-32), and the low CAD prevalence 
in recent trials (2-4), we concluded that triage by calcium imaging in lower-risk patients 
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would be a safe opportunity to reduce radiation exposure and save resources. Similar to 
CRESCENT the present study suggest an uneventful intermediate-term outcome when 
CAD is excluded based on a negative calcium scan(4). Restriction to patients with detect-
able calcium or a high CAD probability increased the positive yield of CT-angiography 
to more than a third.
While there are multiple more established stress imaging techniques, CT-MPI may 
have practical advantages, as it can be performed in conjunction with CT-angiography, 
and allows for a comprehensive assessment of anatomy and function. Contrary to CRES-
CENT(4), the addition of CT-MPI virtually removed the need for a separate functional test 
after CT (1% in CRESCENT-II vs 16% in CRESCENT).
Overall, cardiac CT increased the diagnostic yield of invasive angiography (88% vs 50%, 
p=0.017), but without affecting the overall catheterization rate. All except one patients 
referred for invasive angiography after a positive CT-angiogram and CT-MPI (19/29) 
required revascularization. CRESCENT-II was not large enough to assess differences in 
adverse events, or in a statistically significant manner reproduce the symptomatic relief 
after CT, as observed in the previous trial(4).
While anatomical imaging as the first step appears to be most efficient in our cohort 
with a low prevalence of CAD and no history of CAD, this may be different in population 
with a history or truly high prevalence of CAD.
Safety
The use of contemporary CT technology, and restricting CT-MPI to the highest-risk pa-
tients, resulted in a median overall effective dose of 3.1mSv (including diagnostic tests 
after cardiac CT), compared to a median cumulative dose of 10.0mSv in PROMISE, and a 
4.1mSv median dose for CT-angiography alone in SCOT-HEART.
In patients with a low CAD probability, often younger and female, calcium imaging 
and new CT technology lowered doses in those most vulnerable to radiation exposure. 
However, radiation exposure was lowest in the functional-testing group, of whom most 
underwent exercise testing without nuclear imaging.
Future outlook
As scanner and data processing technology further develop, the comfort of use and 
radiation exposure of dynamic CT-MPI will likely improve. Apart from dynamic CT-MPI, 
and well-known established functional modalities, several other CT-based functional 
assessment techniques have emerged. Static myocardial perfusion imaging (7,12,33), 
potentially with dual-energy protocols, or hybrid systems that combine CT with PET 
or SPECT, also offer functional interpretation in conjunction with CT-angiography. CTA 
based FFR (CT-FFR) computes coronary flow parameters from conventional CT angio-
grams(34,35). While CT-FFR is not a direct physiological measurement, and relies on 
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sufficient CT quality, the lack of additional testing and radiation exposure are obvious 
advantages. The PLATFORM study demonstrated how CTA combined with CT-FFR can 
improve the diagnostic yield of invasive angiography(36). The few direct comparisons 
published to date suggest a comparable and partially complementary performance of 
CT-MPI and CT-FFR (37-39).
Limitations
Although this study allowed several relevant observations, the cohort size does not 
permit conclusive results in terms of clinical outcome. Similar to other pragmatic di-
agnostic trials, the CRESCENT-II trial did not apply a predefined management protocol. 
While blinding of caregivers and patients was not possible, participants were treated 
by multiple physicians without direct involvement in the study. We designed a specific 
CT algorithm, and compared performance with a control group that mostly underwent 
exercise ECG. While the use of exercise ECG is supported by guidelines and part of 
standard practice in many parts of the world, extrapolation of the results may not be 
possible to settings with substantially different diagnostic as well as therapeutic prac-
tices. More stress imaging would be expected to improve diagnostic accuracy, but could 
also increase cost(22). Although dynamic CT-MPI was validated in multiple studies, the 
technique requires specific CT equipment and is not yet widely practices. Implementa-
tion of the tiered algorithm requires scheduling flexibility and immediate reading, which 
can pose practical challenges.
CONCLUSION
In patients with stable angina and a typically low CAD prevalence the challenge is to 
accurately rule out CAD in the majority by relative simple means, while comprehen-
sively assessing those who may benefit from revascularization. A tiered, comprehensive 
cardiac CT protocol, including dynamic perfusion imaging, appears to be a fast and 
efficient alternative to standard functional-testing in these patients.
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Appendix 1. Seattle Angina Questionnaire results
Cardiac CT
Baseline Follow-up p-value
Physical limitations 71.8 ± 23.2 81.4 ± 21.9 <0.001
Angina stability 49.2 ± 27.5 77.6 ± 23.9 <0.001
Anginal frequency 71.9 ± 13.9 90.5 ± 12.0 <0.001
Treatment satisfaction 81.9 ± 15.4 81.2 ± 16.2 0.720
Quality of life 55.8 ± 29.6 77.5 ± 28.2 <0.001
Total SAQ 324.8 ±403.7 403.7 ±78.1 <0.001
Functional testing
Baseline Follow-up p-value
Physical limitations 67.9 ± 26.3 78.4 ± 23.0 <0.001
Angina stability 47.2 ± 24.3 71.2 ± 23.9 <0.001
Anginal frequency 71.7 ± 17.4 87.4 ± 13.6 <0.001
Treatment satisfaction 78.4 ± 18.9 75.9 ± 17.1 0.245
Quality of life 55.4 ± 26.9 73.3 ± 26.4 <0.001
Total SAQ 317.1 ± 78.0 378.0 ±83.3 <0.001
Improvement from baseline
to follow-up
Cardiac
CT
Functional
testing
p-value
Physical limitations 9.6 ± 23.2 10.5 ±24.3 0.782
Angina stability 28.4 ± 32.0 24.0 ±30.2 0.325
Anginal frequency 18.6 ± 15.4 15.7 ±18.8 0.225
Treatment satisfaction -0.7 ± 19.6 -2.4 ±21.5 0.538
Quality of life 21.7 ± 31.9 17.9 ±28.7 0.373
Total SAQ 78.9 ± 81.5 60.9 ±87.0 0.121
SAQ results and subgroups at baseline and six months follow-up. The Seattle angina questionnaire consists 
of 17 questions. For every question points can be scored on an incremental scale from 0-100. Every ques-
tion contributes to one of the five SAQ-subscales. Scores are shown as means ±SD. A higher score indicates 
better angina health state.
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Appendix 2. EQ-5D results
Cardiac CT
BL FU p-value
Total EQ-5D score 0.711±0.243 0.818± 0.134 <0.001
VAS scale 66.8±16.9 73.7±13.6 <0.001
Functional testing
BL FU p-value
Total EQ-5D score 0.736±0.213 0.805±0.165 0.003
VAS scale 68.9±17.7 72.4±15.5 0.042
Improvement
CT FT p-value
Total EQ-5D score 0.107±0.240 0.069±0.223 0.245
VAS scale 6.8±16.6 3.5±16.9 0.168
Total EQ-5D quality of life score at baseline (BL) and 6-months follow up (FU). The EQ-5D questionnaire 
consists of 5 questions, questioning problems with mobility, self-care, usual activities, pain and anxiety. 
Combined this creates the total EQ-5D score between 0 (worst QoL) and 1 (best QoL). The last question is 
the VAS scale, it is the respondent’s self-rated health on a vertical, visual analog scale where the endpoints 
are labelled best and worst imaginable health state, ranging from 0-100. A higher score indicates a better 
health state. Scores are shown as means ± SD.
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Appendix 3. Short Form 36 results
Cardiac CT
BL FU p-value
Physical functioning 653 ± 238 756 ± 229 <0.001
Role limitations due to physical health 211 ± 178 275 ± 169 0.001
Role limitations due to emotional problems 214 ± 122 223 ± 115 0.499
Energy/fatigue 203 ± 78 237 ± 77 <0.001
Emotional well being 351 ± 90 369 ± 90 0.038
Social functioning 111 ± 23 105 ± 20 0.046
Pain 122 ± 41 151 ± 45 <0.001
General health 197 ± 60 211 ± 70 0.079
Functional testing
BL FU p-value
Physical functioning 634 ± 242 708 ± 242 0.001
Role limitations due to physical health 221 ± 173 266 ± 168 0.002
Role limitations due to emotional problems 191 ± 128 215 ± 127 0.070
Energy/fatigue 210 ± 77 223 ± 75 0.090
Emotional well being 352 ± 84 356 ± 95 0.665
Social functioning 108 ± 24 110 ± 24 0.659
Pain 125 ± 42 149 ± 45 <0.001
General health 208 ± 67 221 ± 73 0.154
Improvement
CT FT p-value
Physical functioning 103 ± 211 75 ± 222 0.365
Role limitations due to physical health 64 ± 180 45 ± 138 0.426
Role limitations due to emotional problems 9 ± 133 25 ± 133 0.412
Energy/fatigue 34 ± 81 12 ± 70 0.052
Emotional well being 18 ± 86 4 ± 81 0.227
Social functioning - 6 ± 29 2 ± 35 0.108
Pain 29 ± 48 23 ± 51 0.449
General health 14 ± 77 13 ± 86 0.225
SF-36 quality of life scores at baseline (BL) and 6-months follow up (FU). SF-36 quality-of-life questionnaire 
subdivided into eight subscales. A higher score indicates a better health state. Scores are shown as means 
± SD.
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ABSTRACT
Aims - This study assessed whether a diagnostic strategy supplemented by early CCTA 
improves clinical effectiveness compared with contemporary SOC.
Methods - In a prospective, open-label, multicenter, randomized trial, we enrolled 
patients presenting with symptoms suggestive of an ACS at the ED of 5 community and 
2 university hospitals in the Netherlands. Exclusion criteria included the need for urgent 
cardiac catheterization and history of ACS or coronary revascularization. The primary 
endpoint was the number of patients identified with significant coronary artery disease 
requiring revascularization within 30 days.
Results - The study population consisted of 500 patients, of whom 236 (47%) were 
women (mean age 5410 years). There was no difference in the primary endpoint (22 
[9%] patients underwent coronary revascularization within 30 days in the CCTA group 
and 17 [7%] in the SOC group [p = 0.40]). Discharge from the ED was not more frequent 
after CCTA (65% vs. 59%, p = 0.16), and length of stay was similar (6.3 h in both groups; p 
= 0.80). The CCTA group had lower direct medical costs (€337 vs. €511, p < 0.01) and less 
outpatient testing after the index ED visit (10 [4%] vs. 26 [10%], p < 0.01). There was no 
difference in incidence of undetected ACS.
Conclusion - CCTA, applied early in the work-up of suspected ACS, is safe and associated 
with less outpatient testing and lower costs. However, in the era of hs-troponins, CCTA 
does not identify more patients with significant CAD requiring coronary revascular-
ization, shorten hospital stay, or allow for more direct discharge from the ED. (Better 
Evaluation of Acute Chest Pain with Computed Tomography Angiography [BEACON]; 
NCT01413282)
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INTRODUCTION
Acute chest pain can herald severe cardiovascular conditions, such as an acute coronary 
syndrome (ACS) (1). However, the differential diagnosis of acute chest pain is broad, and 
the consequences of misdiagnosis can be detrimental (2–4). Physicians confront this 
diagnostic dilemma daily. Coronary computed tomography angiography (CCTA) allows 
noninvasive visualization of the coronary arteries (5). Because of its high accuracy in rul-
ing out coronary artery disease (CAD), CCTA has been proposed for better decision mak-
ing in the emergency department (ED), allowing for rapid discharge of patients without 
important CAD and, possibly, more appropriate referral for coronary revascularization 
(6,7). Early CCTA as a diagnostic strategy in low- to intermediate-risk patients suspected 
of ACS is considered safe and may provide logistic and economic benefits (8–10). Mean-
while, high-sensitivity troponin assays (hs-troponins) have become standard practice in 
many institutions, allowing for more accurate and faster rule-out of ACS (11,12). Whether 
hs-troponins will erode the potential clinical, logistic, and economic benefits of CCTA 
has not yet been investigated. The BEACON (Better Evaluation of Acute Chest Pain with 
Coronary Computed Tomography Angiography) trial is a European randomized trial 
comparing a diagnostic strategy supplemented by early CCTA with standard optimal 
care (SOC) for patients suspected of ACS in the era of hs-troponins.
METHODS
STUDy DESIGN
The BEACON study is a prospective, open-label, multicenter, randomized trial. Patients 
were enrolled at 2 university and 5 community hospitals in the Netherlands. Enrollment 
was performed during working hours, except at the Erasmus Medical Center University 
Medical Centre, where patients were included around the clock. The study complied 
with the CONSORT 2010 Statement and Declaration of Helsinki, and was approved by 
the institutional ethics committees of each participating center. All patients provided 
written informed consent.
PARTICIPANTS
Patients with acute chest pain or symptoms suggestive of ACS warranting further diag-
nostic evaluation, as determined by the treating physician, were eligible for inclusion. 
We included patients 30 years of age and older, with a maximum age of 75 years for men 
and 80 years for women. Patients were excluded if symptoms were clearly of noncardiac 
origin or a coexisting condition already necessitated hospital admission. Exclusion cri-
teria also included a history of known CAD, clinical need for urgent invasive coronary 
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angiography (ICA), clinical instability, serum troponin levels above 3 times the upper 
limit of the 99th percentile of the local assay, impaired renal function (estimated glo-
merular filtration rate <60% of age-corrected normal values), pregnancy, known allergy 
to an iodinated contrast agent, severe arrhythmias, and body mass index >40 kg/m2.
RANDOMIZATION
Trial participants were randomly assigned to a CCTA-based diagnostic strategy or SOC (1:1). 
For allocation, a computer-generated block randomization sequence was used, stratified 
by participating center. An independent physician at the coordinating center extracted 
the randomization schedule from an electronic randomization tool and codes were sent 
in sealed, sequentially numbered, opaque envelopes to the participating centers.
PROCEDURES
The initial standard clinical work-up at the ED included a 12-lead electrocardiogram 
(ECG) and blood analysis. If the initial clinical work-up did not reveal either an evident 
ACS or an evident noncardiac cause, eligible and consenting patients were random-
ized between a CCTA-guided strategy and SOC. In the intervention group, CCTA was 
performed after the initial clinical work-up at the ED. In both groups, hs-troponins were 
available (supplemental table 1). Image acquisition was performed on 64-slice or a more 
advanced computed tomography (CT) system, using ECG-synchronized axial or spiral 
scan protocols combined with radiation minimizing measures, depending on local prac-
tices, available technology, and patient characteristics. Results of CCTA were reported 
by certified radiologists with a minimum of 2 years of experience reading CCTA. Treating 
physicians were informed directly at the point of care regarding the result of CCTA and 
imaging-based recommendations were issued. Final medical management decisions 
were, however, left to the treating physicians (Figure 1). In the SOC group, the attending 
physicians made clinical decisions regarding further testing, including repeated cardiac 
marker assessment, hospital admission, noninvasive tests, and referral to ICA, according 
to current guidelines (13,14). Participants from both groups who were discharged from 
the ED, without prolonged observation (<8 h) were asked to return to the outpatient 
clinic after 48 to 72 hours for repeated measurement of cardiac biomarkers and a 12-
lead ECG. All participants were followed-up at the outpatient clinic or contacted by 
telephone after 30 days.
OUTCOME MEASURES
The pre-defined primary endpoint of the study was the number of patients identified 
with significant CAD requiring coronary revascularization, as interpreted by the clinical 
operators, within the follow-up period of 30 days. This outcome parameter was cho-
sen on the basis of the hypothesis that a CCTA-driven strategy would identify more 
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clinically important CAD, as suggested by the results of our single-center pilot study, 
which could effectuate a prognostic benefit (15). The use of fractional flow reserve for 
ischemia-proven coronary revascularization was encouraged, but not mandatory. This 
study was set up as a pragmatic clinical trial focusing on initial ED management without 
protocol-mandated medical management during the remaining clinical course. Second-
ary endpoints included expedited discharge rate from the ED, length of hospital stay, 
undetected ACS, cumulative radiation exposure, direct medical costs, and repeat visits 
to the ED or re-hospitalization for recurrent chest pain within 30 days of follow-up. We 
defined expedited discharge as discharge within 8 h from the ED, and length of stay as 
the time from presentation in the ED until hospital discharge. The treating physician 
made the decision to discharge. ACS was defined as either unstable angina pectoris or 
myocardial infarction, according to current guidelines (16). The diagnosis of ACS was not 
on the basis of the CCTA results. The occurrence of undetected ACS was assessed at both 
the safety follow-up within 72 hours and the general follow-up at 30 days. Cumulative 
radiation exposure was expressed in millisieverts (mSv) and defined as radiation expo-
sure from all tests and interventions undergone within the first 30 days, including CCTA, 
single-photon emission computed tomography (SPECT) myocardial perfusion imaging, 
and ICA. Effective radiation dose was derived by multiplying the dose-length product by 
a conversion factor of 0.014 for CCTA, 0.0085 mSv/mBq for SPECT and 0.22 mSv/Gycm2 
for ICA. To estimate the radiation dose of procedures without reported exposure data, 
the median radiation dose per procedure was used. Direct medical costs during the 
index visit and within the follow-up period of 30 days were assessed using reports from 
the Erasmus MC University Medical Centre cost-accounting system in 2013 in Euros. Fi-
nally, we compared the occurrence of total major adverse cardiac events within 30 days, 
defined as death, ACS, and coronary revascularization. Information on clinical events, 
repeat visits to the ED, re-hospitalization for recurrent chest pain, diagnostic testing, 
or interventions was verified by medical records. An adjudication committee consist-
ing of 2 certified, independent cardiologists reviewed medical records of patients with 
clinically relevant events and a random 10% sample of patients without a diagnosis of 
cardiac disease.
STATISTICAL ANALySIS
Statistical analyses were performed on the basis of an intention-to-treat analysis. 
Continuous data are presented as mean SD or medians with interquartile ranges. Inde-
pendent samples Student t test or Mann-Whitney U test were used for between-group 
comparisons for continuous variables, and chi-square or Fisher exact test was used 
for categorical variables. A 2-sided p value <0.05 was considered to indicate statistical 
significance. For statistical analyses, we used SPSS version 20.0.
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Table 1. Baseline Characteristics
CCTA
(n = 250)
SOC
(n = 250)
p-value
Age, yrs* 55 ± 10 53 ± 9 0.07
Sex, female 123 (49) 113 (45) 0.37
Medication
Statin 65 (26) 51 (20) 0.14
Aspirin 48 (19) 35 (14) 0.12
Beta-blocker 41 (16) 40 (16) 0.90
ACE inhibitor 29 (12) 29 (12) 1.00
Angiotensin-receptor blocker 18 (7) 17 (7) 0.86
Calcium-channel blocker 18 (7) 19 (8) 0.86
Diuretic agent 36 (14) 23 (9) 0.07
Oral antidiabetic agent 22 (9) 24 (10) 0.76
Insulin 6 (2) 3 (1) 0.31
Cardiovascular risk factors
Diabetes mellitus 31 (12) 33 (13) 0.79
Hypertension 0.95
>150 mm Hg systolic or >90 mm Hg diastolic 43 (17) 43 (17)
Treated 66 (26) 69 (28)
Hypercholesterolemia 0.31
Total cholesterol >5 mmol/l 25 (10) 35 (14)
Treated 65 (26) 52 (21)
Smoking 0.26
Current 93 (37) 78 (31)
Stopped >1 yr 25 (10) 22 (9)
History of cardiovascular disease 0.95
Peripheral artery disease 8 (3) 7 (3)
TIA/CVA 16 (7) 17 (7)
Family history 112 (45) 98 (39) 0.21
Blood pressure (mm Hg)
Systolic* 140 ± 19 141 ± 20 0.67
Diastolic* 82 ± 12 82 ± 11 0.63
Heart rate* (beats/min) 72 ± 14 72 ± 13 0.86
TIMI risk score (39)† 1 (0-2) 1 (0-2) 0.31
0 74 83 
1 84 91 
≥2 92 76 
Grace risk score (40)† 85 (70–100) 81 (67–98) 0.28
Low 211 (84) 208 (83) 0.20
Intermediate 31 (12) 39 (16)
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On the basis of our previous observational data, we anticipated an absolute 9% 
increase in the number of coronary revascularizations if the results of CCTA were to 
be incorporated (15). Considering an α = 0.05 and β = 0.8 with an intervention versus 
control group enrollment ratio of 1:1, and allowing a loss to follow-up of approximately 
10%, we would require 500 participants to detect a difference in the number of patients 
requiring revascularization of relevant CAD.
Table 1. Baseline Characteristics (continued)
CCTA
(n = 250)
SOC
(n = 250)
p-value
High 8 (3) 3 (1)
Ischemic ECG abnormalities 60 (24) 44 (18) 0.08
Baseline troponins
Elevated‡ 11 (4) 13 (5) 0.67
Unless otherwise specified, data are numbers of patients, with percentages in parentheses. *Data are 
means ± SD. †Data are medians, with interquartile ranges in parentheses. Diabetes mellitus is defined as 
plasma glucose >11.0 mmol/l or treated with either diet regulation or medication. Ischemic ECG abnor-
malities defined as Q-wave or ST-T-segment alterations suggestive of ischemia. ‡Elevated within 3 times 
the upper limit of the 99th percentile. CCTA = coronary computed tomography angiography; CVA = cere-
brovascular accident; SOC = standard optimal care; TIA = transient ischemic attack; TIMI = Thrombosis in 
Myocardial Infarction.
Table 2. Primary Outcome and Clinical Endpoints Within 30 Days After Index Visit
CCTA SOC p-value
Invasive coronary angiography* 41 (17) 31 (13) 0.20
Invasive coronary angiography at index visit 34 (14) 25 (10) 0.21
Coronary revascularization* 22 (9) 17 (7) 0.40
Percutaneous coronary intervention 22 (9) 13 (5)
Coronary artery bypass graft surgery 0 4 (2)
Acute coronary syndrome at discharge 22 (9) 17 (7) 0.40
Unstable angina 8 (3) 3 (1) 0.64 
Myocardial infarction 14 (6) 14 (6)  
Repeat emergency department visit 13 (5) 19 (8) 0.27
Repeat hospital admission 7 (3) 14 (6) 0.12
Undetected acute coronary syndrome 1 (0) 3 (1) 0.62
Major adverse cardiac event 25 (10) 21 (9) 0.54
All-cause mortality 1 (0) 0 1.0
Unless otherwise specified, data are numbers, with percentages in parentheses. Major cardiac adverse 
event includes all-cause mortality, myocardial infarction and coronary revascularization. Abbreviations as 
in Table 1. *Includes procedures at index visit.
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RESULTS
Between July 11, 2011, and January 30, 2014, 573 eligible patients were approached 
for the study; 73 (13%) declined to participate (Figure 2). In total, 7 patients in the CCTA 
group did not have a CT scan, and 6 patients in the SOC group eventually under-went 
a CT examination to exclude either CAD or other vascular conditions. At 30 days, 5 pa-
tients in each group had withdrawn from the study, resulting in complete follow-up in 
490 (98%) patients.
STUDy POPULATION
Table 1 shows patient demographics, clinical characteristics, and medical treatment at 
baseline. The mean age of the study population was 54 ± 10 years and 236 (47%) partici-
pants were women. Baseline characteristics and clinical status were similar between the 
2 groups. In the intervention group, CCTA identified 106 (42%) patients with no detect-
able CAD. Among the patients with CAD on CCTA, 71 (28%) had atherosclerotic plaque 
with <50% luminal narrowing, 35 (14%) had 50% to 70% luminal narrowing in 1 or more 
coronary arteries, and 13 (5%) had >70% luminal narrowing in 1 or more coronary arter-
ies. The scan was considered non-diagnostic in 18 patients (7%). The mean radiation 
dose in the CCTA group was 7.3 ± 6.6 mSv versus 2.6 ± 6.5 mSv in the SOC group.
PRIMARy OUTCOME AND CLINICAL ENDPOINTS
For the primary outcome, the number of patients requiring revascularization within 30 
days, no difference was observed between the CCTA group and SOC, that is, 22 (9%) 
versus 17 (7%) (p = 0.40) (Table 2). Also, the total number of ICAs performed within 30 
days was similar. At hospital discharge, 22 (9%) patients in the CCTA group and 17 (7%) 
in the SOC group were diagnosed with ACS(p = 0.40). Repeat visits to the ED occurred in 
13 (5%) patients in the CCTA group, compared with 19 (8%) in the SOC group (p = 0.27). 
At 30 days, a similar incidence of total major adverse cardiac events, that is, 25 (10%) in 
the CCTA group and 21 (9%) in the SOC group was observed (p = 0.54).
SAFETy ENDPOINTS
Undetected ACS occurred once (0.5%) in the CCTA group and 3 times (1%) in the SOC 
group within the 30-day follow-up period (p = 0.62). In the CCTA group, 1 patient had 
recurrent chest pain with ECG changes suggestive of myocardial ischemia at his safety 
visit. In the SOC group, 1 patient returned with recurrent complaints, and underwent 
coronary revascularization following an abnormal exercise electrocardiography (ExECG) 
result. Another patient reported intermittent chest pain at his safety visit within 72 hours 
and his laboratory tests showed elevated cardiac biomarkers. The third patient returned 
after 5 days with recurrent complaints and elevated cardiac biomarkers. One patient in 
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the CCTA group died of a hemorrhagic stroke following emergency thrombolysis for 
occlusive peripheral artery disease 11 days after the index ED visit. Nine CCTA examina-
tions (4%) had minor com-plications: 3 patients had self-limiting, transient increases in 
their creatinine levels, 4 patients experienced contrast medium extravasation without 
clinical consequences, and 2 had mild, medically treated allergic skin reactions. In the 
SOC group, 1 patient who was discharged early had a transient increase in the creatinine 
level at his safety visit.
DIAGNOSTIC TESTING AND RESOURCE UTILIZATION
More patients were discharged immediately from the ED after CCTA (159 [65%] vs. 144 
[59%]), although this difference did not reach statistical significance (p = 0.16) (Table 3). 
The median length of stay was similar in both groups. ExECG was the most commonly 
performed alternative noninvasive diagnostic test. In the CCTA group, 32 (13%) patients 
underwent ExECG within 30 days: 3 (9%) were suspected of ischemia and 10 (31%) were 
non-diagnostic. In the SOC group, 143 (58%) patients underwent ExECG within 30 days: 
9 (6%) were suspected of ischemia and 39 (27%) were non-diagnostic (supplemental 
table 2). Outpatient testing was less frequently performed in the CCTA group (10 [4%] 
vs. 26 [11%]; p < 0.01), and direct medical costs after 30 days were lower (€337 [€337 to 
€932] vs. €511 [€309 to €916]; p < 0.01).
Table 3. Diagnostic Testing and Resource Utilization
CCTA SOC p-value
Length of stay (h)* 6.3 (4.8–11.1) 6.3 (4.5–25.5) 0.80
Discharge status 0.16
Discharge from emergency department 159 (65) 144 (59)
Admitted to hospital 86 (35) 101 (41)
ExECG at index visit 23 (9) 130 (53) <0.01
ExECG<30 days 32 (13) 143 (58) <0.01
SPECT at index visit 2 (1) 7 (3) 0.18
SPECT <30 days 2 (1) 16 (7) <0.01
CMR at index 1 (0) 1 (0) 1.0
CMR <30 days 1 (0) 3 (1) 0.62
CCTA after index visit 1 (0) 2 (1) 1.0
Outpatient diagnostic testing <30 days† 10 (4) 26 (11) <0.01
Cost (€)* 337 (337–932) 511 (309–916) <0.01
Unless otherwise specified, data are numbers of patients, with percentages in parentheses. *Data are me-
dians, with interquartile ranges in parentheses. †Total of ExECG, SPECT, CMR, and CCTA in an outpatient 
setting after index ED visit. CMR = cardiac magnetic resonance imaging; ExECG = exercise electrocardiogra-
phy; SPECT = single-photon emission computed tomography myocardial perfusion imaging. Other abbrevia-
tions as in Table 1.
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DISCUSSION
In this prospective, open-label, multicenter, randomized trial, we compared a diagnostic 
strategy supplemented by early CCTA with contemporary SOC encompassing hs-tropo-
nins. In a European setting, early CCTA was safe, less expensive, with less sub-sequent 
outpatient testing than SOC alone. However, a diagnostic strategy supplemented 
Figure 3. Central illustration
A. Primary and secondary outcomes in the early CCTA group and SOC group.
B. Length of stay and proportion of patients discharged.
ACS = acute coronary syndrome; CCTA = coronary computed tomography angiography; ED = emergency 
department; ICA = invasive coronary angiography; SOC = standard optimal care.
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by early CCTA did not identify more patients with significant CAD requiring coronary 
revascularization, reduce the length of stay, or allow more expedited discharge from the 
ED (Figure 3).
CCTA IN THE EMERGENCy DEPARTMENT
Initial observational studies showed that CCTA was feasible and could safely be per-
formed in the ED (19,20). The ROMICAT (Rule Out Myocardial Infarction using Computer 
Assisted Tomography) study, where 50% of patients with acute chest pain were free 
from any CAD, demonstrated high negative predictive value and underlined the poten-
tial of CCTA in this setting (6). Because CCTA identifies the presence of nonobstructive 
coronary atherosclerotic plaque, it also may provide the basis for preventive therapeutic 
medical measures, as opposed to SPECT or ExECG, which detect the presence of existing 
myocardial ischemia (21). In the current study, non-obstructive coronary atherosclerosis 
was found in 28% of patients, warranting preventive management, which would be 
overlooked with SOC.
Figure 4. Length of Stay and Discharge Rate From 
the Emergency Department in the ACRIN-PA, ROMI-
CAT-2, and BEACON trials
Reported data are medians. Abbreviations as in Fig-
ure 1.
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Shortly after these initial studies, randomized controlled trials were initiated to ex-
amine whether a CCTA-based strategy would be more clinically effective than current 
practice. The CT-STAT trial compared CCTA with nuclear myocardial perfusion imaging 
as initial tests in the management of patients with acute chest pain (10). Investigators 
reported a 54% reduction in time to diagnosis and 38% lower costs of ED care with 
CCTA. In the ACRIN-PA (American College of Radiology Imaging Network-Pennsylvania) 
trial, investigators left decisions to perform diagnostic tests in the SOC group to the 
discretion of the treating physicians (9). The study demonstrated that low-risk patients 
could be safely discharged with early CCTA twice as often, and CAD was more likely to be 
diagnosed with CCTA. The ROMICAT-2 trial also included a cost analysis, demonstrating 
a reduction of the median length of hospital stay from 26.7 to 8.6 hours with early CCTA 
and a 4-fold higher discharge rate from the ED (47% vs. 12%) without increasing medical 
expenditure (8).
Since these trials were completed, the introduction of hs-troponin has changed SOC 
considerably. These new assays are more sensitive and reach negative predictive values 
of >97% for myocardial infarction within 3 h (11,12). Early observations indicated that 
hs-troponins would allow fast and accurate exclusion of ACS in a substantial proportion 
of low- to intermediate-risk patients, obviating the need for prolonged observation 
and in-hospital diagnostic testing in the absence of elevated high-sensitivity cardiac 
biomarkers or precarious ECG abnormalities (22–24).
CURRENT RESULTS IN PERSPECTIVE
The BEACON trial was designed to compare the clinical effectiveness of a diagnostic 
strategy supplemented by early CCTA with contemporary SOC encompassing hs-tropo-
nins. The current study included a population with a higher prevalence of obstructive 
CAD on CCTA (19%) compared with previous randomized trials. The majority of patients 
were referred by a general practitioner, deferring very low-risk patients or those with 
non-cardiac conditions from the ED. Furthermore, as mandated by the study protocol, 
only patients with acute chest pain or symptoms suggestive of an ACS warranting fur-
ther diagnostic evaluation, as determined by the treating physician, were eligible for 
inclusion. Finally, the inclusion of patients with mildly elevated troponins probably led 
to an increased prevalence of CAD.
A diagnostic strategy supplemented by early CCTA was inclined to detect more pa-
tients with significant CAD requiring coronary revascularization in our study; however, 
this was not of statistical significance. The results of our logistic endpoints differ from 
previous trials, as early performance of CCTA did not shorten the length of stay, nor re-
duce the number of hospital admissions in our study. The length of stay with early CCTA 
in this study is com-parable or even lower than previously reported (Figure 4). However, 
the length of stay in our SOC group was substantially lower (median 6.3 hours), underlin-
Coronary CT angiography for suspected ACS 165
8
ing the vigorous improvement of SOC after the introduction of hs-troponins, and also 
making it harder to achieve an improvement with early CCTA.
Similarly, as many as 59% of patients in the SOC group could be discharged from the 
ED, a proportion 2 to 4 times higher than reported in previous randomized trials with 
physician-directed standard care as a comparator. Differences in the Netherlands and 
U.S. health care systems may be responsible, to some extent, for the contrast between 
our observations and those from previously published studies from the United States. 
In the Netherlands, primary care physicians, who are easily accessible and fully covered 
by medical insurance, have an important gatekeeper role and can defer patients at very 
low risk or with probable non-cardiac etiology from the ED, which avoids overcrowding 
and likely increased the overall coronary disease prevalence in our population (25,26). 
Furthermore, coverage by Dutch insurance companies is comparable for elective and 
emergency care, and financial incentives that stimulate outpatient work-up and testing 
are in place (27,28). In the United States, delays in access to care, social differences, and 
insurance coverage problems in-crease the number of patients seeking care in the ED 
(29,30). In addition, although guidelines allow for outpatient testing in 48 to 72 hours 
after discharge from the ED, U.S. physicians are more inclined to achieve a conclusive 
work-up for the presence of CAD before discharge because of the availability of the 
testing, poor follow-up, and vulnerability to litigation (31–34). Testing is typically avail-
able only during working hours, leading to prolonged hospital stays. Nonetheless, we 
believe that the contrasting findings are largely explained by the profound effect of the 
introduction of hs-troponins in the work-up of suspected ACS (11,12,35).
An attractive consequence of early CCTA in our study was the reduced number of 
subsequent outpatient testing and lower medical costs at 30 days. Outpatient testing 
was mostly driven by the preference of the treating physician to assess the presence 
of CAD as the cause of symptoms, which was no longer necessary if CCTA had been 
performed at first presentation. Although direct comparison of absolute costs between 
studies is difficult, the shorter length of stay, more frequent use of exercise testing 
instead of nuclear imaging, and relatively lower cost of CCTA likely reduced general 
medical expenditure in this study (36). When comparing costs between the 2 groups 
in our study, some important aspects should be taken into account. According to the 
applied hospital cost-accounting system, CCTA was only slightly more expensive than 
ExECG. Nuclear myocardial imaging, which is substantially more costly than either CCTA 
or ExECG in the Netherlands, was more frequently performed in the SOC group. Finally, 
the higher costs in the SOC group can likely be attributed to the higher proportion of 
admitted patients. The median cost per patient in the SOC group was not affected by the 
unbalanced coronary artery bypass graft distribution.
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CLINICAL IMPLICATIONS
There is growing evidence that patients with hs-troponin values below the 99th percen-
tile of the upper reference limit have a very low likelihood of ACS. These patients have 
a very good prognosis and very often have a normal functional or CCTA test (37–39). 
However, those with levels above the 99th percentile might benefit from additional 
testing (i.e., CCTA or a functional test) where (especially in those with low clinical risk 
profile) a negative test would make the occurrence of cardiovascular events in the short 
term very unlikely and the need for immediate further testing unnecessary. In this light, 
it would be of interest for future studies to assess the value of a tiered approach, where 
application and timing of CCTA or test of choice is directly guided by risk profiles and 
biomarker results.
STUDy LIMITATIONS
The majority of patients were enrolled during office hours, and round-the-clock imple-
mentation of CCTA in the ED poses practical challenges. In real-world clinical practice, 
SOC might prove more efficient than CCTA for 24-hours use. Extrapolation of our results 
may be affected by differences in CT technology, imaging expertise, local practices, 
and cost-accounting systems. The overall observed incidence of the primary endpoint 
was lower than anticipated on the basis of experiences from our observational study. 
Although speculative, we believe that the exceptional sensitivity of hs-troponins, allow-
ing early and precise detection of ACS, reduced the incidence of the primary endpoint 
in both groups, resulting in an underpowered sample size. Earlier troponin elevations 
and expedited catheterization procedures rendered a proportion of high-risk patients 
ineligible for study inclusion. In addition, a substantial proportion of patients (50%) 
with obstructive CAD on CCTA were ultimately not referred for catheterization. Without 
elevated troponins, these lesions were probably considered stable, which would justify 
optimal medical treatment on the basis of large coronary revascularization outcome 
trials (40). Given the low incidence of undetected ACS, this strategy does not appear 
to have affected safety. Inherent to the nature of diagnostic trials, blinding of patients 
and treating physicians was not possible, although study participants were treated by 
physicians who aimed for optimal clinical care, and had no direct involvement in the 
design and realization of this study. The effect of an early CCTA strategy on long-term 
downstream testing, resource utilization, and clinical outcome has yet to be determined. 
Although the majority of patients were evaluated with hs-troponins, 21% entered the 
study when these assays were not yet available at a number of centers. Finally, an im-
portant and noteworthy disadvantage of CCTA is the exposure of patients to radiation. 
However, use of more innovative CT technology and dose-saving protocols resulted in 
lower radiation exposure compared with earlier trials (7.3 vs. 14.3 mSv).
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CONCLUSION
CCTA, applied early in the work-up of suspected ACS, is safe and associated with less 
outpatient testing and lower costs. However, in the era of hs-troponins, CCTA does not 
identify more patients with significant CAD requiring coronary revascularization, nor 
does CCTA shorten hospital stay or allow for more immediate discharge from the ED.
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SUPPLEMENTAL MATERIAL
Direct medical costs
Based on the costs of the initial ED evaluation (including fee of physician, costs of laboratory tests and 
ECG), proportions of diagnostic tests, costs of hospital admission, and costs of repeat ED evaluation and 
readmission, an estimation of costs for the two arms can be compared for other settings and prices using 
the following formula:
Average cost per patient in the CCTA group = [cost of initial ED evaluation] + [cost CCTA] + 0.13 * [cost 
XECG] + 0.01 * [cost SPECT] + 0.004 * [cost CMR] + 0.17 * [cost ICA] + 0.09 [cost PCI] + 0 * [cost CABG] + 0.05 
[cost repeat ED evaluation] + 0.03 [repeat hospital admission]
Average cost per patient in the SOC group = [cost of initial ED evaluation] + 0.58 * [cost XECG] + 0.07 * [cost 
SPECT] + 0.01 * [cost CMR] + 0.13 * [cost ICA] + 0.05 [cost PCI] + 0.02 * [cost CABG] + 0.08 [cost repeat ED 
evaluation] + 0.06 [repeat hospital admission]
Supplemental Table 1. Detailed information on the troponin assays used.
Assay
N
(%)
Infarction
threshold
(ng/L)
Management
Interm. 
range
(ng/L)
Level of
detection
(ng/L)
99th
percentile 
(ng/L)
10%
Coeff. of
variation
(ng/L)
hs-cTnT
Roche 
Elecsys
39
 (78)
50
Serial measurement (3h 
interval).
Value above the pre-defined 
threshold or a significant rise is 
regarded as infarction
14-50 5 14 13
TnT Gen 4
Roche 
Elecsys
87
(17)
30
Serial measurement (6h 
interval).
Value above the pre-defined 
threshold is regarded as 
infarction
10-30 10 10 30
cTnI
Abbott 
ARCHITECT
13
(3)
50
Serial measurement (6h 
interval).
Value above the pre-defined 
threshold is regarded as 
infarction
28-50 10 28 32
hs-cTnI
Abbott 
ARCHITECT
4
(1)
34
Serial measurement (3h 
interval)
Value above the pre-defined 
threshold or a significant rise is 
regarded as infarction
16-34 1.2 16 3
AccuTnI
Gen 3 
enhanced 
Beckman 
Coulter
4
(1)
60
Serial measurement (6h 
interval)
Value above the pre-defined 
threshold is regarded as 
infarction
40-60 10 40 60
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Supplemental Table 2. Clinical care in the SOC and CCTA group.
Standard optimal care Coronary CT angiography
TIMI 0 
(83)
TIMI 1
(91)
TIMI ≥2 
(76)
No CAD
(106)
<50%
(71)
50-70%
(35)
>70%
(13)
Non-
diagnostic
(18)
Exercise ECG 51 (61) 47 (52) 32 (42) 4 (4) 1 (1) 11 (31) 2 (15) 5 (28)
SPECT MPI 1 (1) 5 (5) 1 (1) 0 0 0 0 2 (7)
Invasive angiography 4 (5) 4 (4) 17 (22) 0 4 (6) 13 (37) 11 (85) 6 (33)
Revascularization 1 (1) 1 (1) 10 (13) 0 0 6 (17) 11 (85) 2 (7)
Numbers of patients are shown with percentages between parentheses. Tests performed within 30 days 
from initial presentation. Standard optimal care (SOC) arm sub-classified by Thrombolysis In Myocardial In-
farction score (TIMI) (1). Coronary CT angiography (CCTA) arm, sub-classified by most severe obstructive le-
sion per patient. SPECT MPI = single-photon emission computed tomography myocardial perfusion imaging.
1. Antman EM, Cohen M, Bernink PJ et al. The TIMI risk score for unstable angina/non-ST elevation MI: A 
method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
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ABSTRACT
Background: The optimal diagnostic test in the work-up of suspected acute coronary 
syndrome (ACS) might differ between men and women. The aim of this study was to 
compare the clinical effectiveness of early coronary CT angiography (CCTA) in women 
and men.
Methods: 500 patients presenting with symptoms suggestive of an ACS at the emergen-
cy department (ED) were randomized between a diagnostic strategy supplemented by 
early CCTA or standard optimal care (SOC) with high-sensitivity troponins (hs-troponins) 
available in both groups. Interactions between sex and diagnostic group were assessed 
using regression analysis.
Results: ACS was diagnosed less often in women (5% versus 10%, p=0.03). No signifi-
cant interaction was found for the number of hospital admissions, length of stay, repeat 
ED visits or outpatient testing between sexes and diagnostic groups (all p-interactions 
>0.05).
Conclusions: Women had a lower prevalence of CAD, were less often admitted and 
had a shorter length of stay. The results of our study suggest that CCTA provides no 
additional benefit for women compared to men who have normal hs-troponin levels.
Clinical Trial Registration - www.clinicaltrials.gov NCT01413282
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SHORT REPORT
INTRODUCTION
The burden of coronary artery disease (CAD) in women may still be under-recognized 
[1]. This might be the result of distinct pathophysiological differences or disease percep-
tion by patients and physicians [2]. The optimal diagnostic test in the work-up of sus-
pected acute coronary syndrome (ACS) might therefor differ between men and women 
[3]. In this pre-specified sub-analysis of the Better Evaluation of Acute Chest Pain with 
Coronary Computed Tomography Angiography (BEACON) trial, we compare the clinical 
effectiveness of early coronary CT angiography (CCTA) in women and men.
METHODS
The study design, criteria for enrolment, and primary results have been reported previ-
ously [4]. Briefly, in the BEACON-trial, we randomized 500 patients suspected of ACS 
(47% women) at the emergency departments (ED) of 7 hospitals to either a diagnostic 
strategy supplemented by early CCTA or standard optimal care (SOC) with high-
sensitivity troponins (hs-troponins) available in both groups. Patients with the need for 
urgent cardiac catheterization were excluded. The results of the main study showed that 
CCTA, applied early in the work-up of suspected ACS, is safe and associated with less 
outpatient testing and lower costs. To assess interactions between sex and diagnostic 
group we used logistic regression analysis for binary outcomes and linear regression 
analysis for continuous outcomes.
RESULTS
In the BEACON-trial, women were generally older, i.e. 56 ± 10 versus 53 ± 10 years (p<0.01) 
and less often active smokers, i.e. 28% versus 40% men (Table 1, p<0.01). Type of chest 
pain at presentation was not different between sexes, with atypical chest pain as the 
most frequent type in both groups (52% of women and 51% of men, p= 0.62 for trend). 
Obstructive coronary artery disease (CAD) on CCTA (>50% luminal narrowing) was less 
frequent in women than in men (14% versus 29%, p<0.01). No significant difference 
was observed for results of exercise electrocardiography (p=0.42), which was the most 
frequently used diagnostic test in the SOC group. Regardless of randomization, women 
were admitted less often (33% versus 43%, p=0.02) and had a shorter length of stay than 
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men (p=0.04). At discharge, ACS was diagnosed less often in women (5% versus 10%, 
p=0.03). The use of coronary angiography and the rate of coronary revascularization 
was not statistically different for women regardless of diagnostic strategy. Moreover, 
no significant interaction was found for the number of hospital admissions, length of 
stay, repeat ED visits or outpatient testing between sexes and diagnostic groups (all 
p-interactions >0.05).
Table 1. Baseline characteristics and study outcomes
Women
(n=236)
Men
(n=264)
p-value p interaction
Age, years ± SD† 56 ± 10 53 ± 10 <0.01
Diabetes mellitus 25 (11) 39 (15) 0.16
Hypertension 102 (43) 119 (45) 0.68
Dyslipidemia 76 (32) 101 (38) 0.15
Smoking 65 (28) 106 (40) <0.01
Family history 101 (43) 109 (41) 0.73
Chest Pain 0.62
 Non-anginal 40 (17) 44 (17)
 Atypical 120 (51) 134 (51)
 Typical 76 (32) 84 (32)
Diagnostic test
 Coronary CT angiography <0.01
 <50% CAD 95 (86) 82 (71)
 ≥50% CAD 15 (14) 33 (29)
 Exercise-ECG 0.42
 Normal 45 (40) 51 (38)
 Inconclusive 21 (19) 18 (13)
 Ischemic 5 (4) 4 (3)
 Coronary angiography 27 (11) 45 (17) 0.07 0.92
 Coronary revascularization 15 (6) 24 (9) 0.25 0.94
ACS diagnosis at discharge 12 (5) 27 (10) 0.03 0.93
Hospital admission 77 (33) 113 (43) 0.02 0.81
Length of stay‡ 6.1 (4.5-15) 7.0 (4.7-24.5) 0.04 0.80
Repeat ED visit 17 (7) 15 (6) 0.49 0.36
Outpatient testing 18 (8) 18 (7) 0.74 0.31
Table 1. Unless otherwise specified, data are numbers of patients, with percentages in parentheses. †Data 
are means ± standard deviations. ‡ Data are medians, with interquartile ranges in parentheses. Diabetes 
mellitus is defined as plasma glucose >11.0mmol/L or treated with either diet regulation or medication. 
Hypertension defines as >150mmHg systolic or >90mmHg diastolic or treated. Dyslipidemia defined as a 
total cholesterol level >5mmol/L, low-density lipoprotein level >3mmol/L, or on lipid-lowering medication. 
CAD, coronary artery disease; ACS, acute coronary syndrome; ED, emergency department
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DISCUSSION
Previously, it has been shown that early CCTA may be a more efficient work-up for 
suspected ACS, especially in women [5]. Women are thought to have a general lower 
risk of CAD and that they might benefit more than men from CCTA, which is known for 
its excellent negative predictive value. However, at the same time concerns exist about 
radiation associated cancer in young women resulting from increased exposure to radia-
tion from medical testing [6]. Our results show indeed a lower incidence of obstructive 
CAD and ACS in women, however no additional benefit of CCTA could be demonstrated. 
We believe that there are two important reasons that can explain current findings. Novel 
to prior reports was the availability of hs-troponins for clinical decision making in both 
groups. The majority of patients in the current study (>90%) had normal hs-troponin lev-
els (<99th percentile of the upper limit of normal). It has been shown that these patients 
have a very low risk of ACS [7]. Further advanced testing, in the form of CCTA, might 
therefor not be needed for them, and this is regardless of sex [8]. Secondly, it is believed 
that less classical causes of angina such as endothelial dysfunction and microvascular 
disease are more relevant in women, while epicardial CAD is more prevalent in men [9]. 
Consequently, it is likely that CCTA as a anatomic modality would provide less benefit in 
women following this pathophysiological hypothesis.
CONCLUSION
In conclusion, women had a lower prevalence of CAD, were less often admitted and had 
a shorter length of stay. Obstructive CAD on CCTA was more often found in men and 
they were more likely to undergo invasive angiography. The results of our study suggest 
that CCTA provides no additional benefit for women compared to men who have normal 
hs-troponin levels.
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ABSTRACT
Objective - To assess the image quality of coronary CT-angiography for suspected Acute 
Coronary Syndrome (ACS) outside office hours.
Methods - Patients with symptoms suggestive of an ACS underwent coronary CT-angi-
ography (CCTA) at the emergency department 24-hours, 7 days a week. A total of 118 
patients, of whom 89 (75%) presented during office hours (weekdays between 07:00 and 
17:00) and 29 (25%) outside office hours (weekdays between 17:00 and 07:00, weekends 
and holidays) underwent CCTA. Image quality was evaluated per coronary segment by 
two experienced readers and graded on an ordinal scale ranging from 1 to 3.
Results - There were no significant differences in acquisition parameters, beta-blocker 
administration or heartrate between patients presenting during office hours and out-
side office hours. The median quality score per patient was 30.5 [interquartile range 
26.0-33.5] for patients presenting during office hours in comparison to 27.5 [19.75-32.0] 
for patients presenting outside office hours (p=0.043). The number of non-evaluable 
segments was lower for patients presenting during office hours (0 [0-1.0] vs. 1.0 [0-4.0], 
p=0.009).
Conclusion – Image quality of CCTA outside office hours in the diagnosis of suspected 
ACS is diminished.
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INTRODUCTION
The optimal diagnostic work-up of suspected acute coronary syndrome (ACS) remains 
a topic of controversy (1). Recently, several trials have demonstrated that coronary CT 
angiography (CCTA) is a safe and potentially more efficient diagnostic option for the 
triage of patients with acute chest pain (2-7). While patients with acute chest pain may 
seek medical attention at any time during the day, most medical centers offer CCTA only 
during office hours. A round-the-clock CCTA service poses various challenges, in terms 
of the availability of scanners and experienced staff, as well as patient characteristics 
and severity of disease. (8, 9). It is currently unknown whether the time of the day affects 
the image quality of CCTA. In this pre-specified sub-analysis of the Better Evaluation of 
Acute Chest Pain with Computed Tomography Angiography (BEACON) trial, we investi-
gated the feasibility of CCTA outside office hours.
MATERIALS AND METHODS
Study design and participants
In the multicenter randomized BEACON trial, we compared a diagnostic strategy with 
early CCTA to standard optimal care in patients suspected of acute coronary syndrome. 
At one institution, patients were enrolled 24 hours, 7 days a week. The study design, 
inclusion and exclusion criteria, and primary results have been reported previously (5). 
Briefly, we enrolled patients with symptoms suggestive of an ACS at the emergency 
department (ED). Exclusion criteria included the need for urgent cardiac catheterization 
and history of ACS or coronary revascularization.
Study participants were divided into patients presenting during regular office hours 
(weekdays between 07:00 and 17:00) and outside office hours (weekdays between 17:00 
and 07:00, weekends and holidays). Information regarding clinical characteristics, time 
of presentation, time between presentation and CT angiography, image quality, pres-
ence of coronary artery disease and clinical outcome were collected prospectively.
Procedures
After initial workup at the ED, consisting of a clinical evaluation including an ECG and 
laboratory tests, patients underwent CCTA. Image acquisition was performed on either 
a 128-slice single source scanner, present at the ED or a dual-source system, situated at 
the radiology department depending on physician preference and availability. We used 
ECG-synchronized axial or spiral scan protocols combined with radiation minimizing 
measures. During the day CT scans were performed by a cardiac dedicated technician 
team. At night the examinations were performed by a broader group of technician, 
184 CHAPTER 10
although all were trained to perform cardiac CT. If indicated and clinically acceptable, 
beta-blockers were administrated. All patients received sublingual nitroglycerin one 
minute before scanning. First a coronary calcium scan was performed, and the Agatston 
calcium score calculated. Subsequent CCTA was evaluated according to SCCT criteria 
(10). For clinical decision making CCTAs were assessed at the point of care by cardiolo-
gists and radiologists with at least 5 years of experience in cardiac CT.
Image evaluation
Image quality was evaluated per segment in accordance with the American Heart As-
sociation (AHA) classification (10), by two independent observers (A.K. and A.D., each 
with more than 3 years’ experience), blinded to the time of acquisition. Data sets were 
transferred offline and evaluated for quality purposes at a later time. If necessary, 
multiple data sets were used for the quality assessment in sequential and retrospec-
tive spiral scans. Artefacts were defined as stack, motion, breathing, blooming, noise or 
streak. Small segments with a diameter of less than 1.5 mm were excluded from analysis. 
Image quality was graded on an ordinal scale ranging from 1 to 3. Segments scored 
as 1 representing poor image quality due to major artefacts and diagnostic evalu-
ation was deemed impossible. In segments scored as 2 there were artefacts present, 
but image quality was adequate for diagnostic evaluation, and segments scored as 3 
had no artefacts with good image quality. Image quality was assessed for all segments 
of each coronary artery (left main coronary artery, left anterior descending coronary 
artery, left circumflex coronary artery, and right coronary artery) and then averaged 
for every patient. Image quality comparison was performed using several approaches: 
1) the median quality score per patient; 2) the median quality score per patient of the 
proximal coronary segments (segments 1,2,5-7 and 11); 3) the number of non-evaluable 
segments per patient; and 4) the number of non-evaluable proximal coronary segments 
per patient.
Values for effective radiation dose (mSv) were calculated by multiplying the dose-
length product (DLP) with a conversion factor for cardiac CT of κ = 0.017 mSv/mGy x 
cm (11).
Statistical analysis
Continuous data are presented as means ± SD or medians with interquartile ranges 
as appropriate, and categorical variables as frequencies or percentages. Groups were 
compared using an independent-sample t-test or Mann-Whitney U-test for continuous 
variables, and chi-square or Fisher’s exact-test for categorical variables. A two-sided 
p-value of <0.05 was considered statistically significant. Statistical analyses were per-
formed using SPSS (version 21, IBM Corp, Armonk NY, USA).
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RESULTS
Study population
A total of 118 patients with suspected acute coronary syndrome underwent CCTA. 89 
(75%) presented during office hours and 29 (25%) outside office hours. Baseline char-
acteristics are shown in table 1. The mean age was 54 ± 10, 47% were women and the 
majority had a low GRACE risk score. Aside from ischemic ECG abnormalities (mostly 
T-wave abnormalities), which were seen more frequently in patients presenting during 
office-hours patients, no differences were found in other baseline characteristics.
Table 1. Baseline characteristics
Office hours (n=89) Outside office 
hours (n=29)
p-value
Age, years 54 ± 10 55± 11 0.749
Sex, female 42 (47) 15 (52) 0.671
Blood pressure, systolic, mm Hg 140 ± 16 143 ± 16 0.332
Blood pressure, diastolic, mm Hg 84 ± 12 86 ± 10 0.456
Cardiovascular risk factors
Diabetes mellitus 8 (9) 3 (10) 0.330
Hypercholesterolemia 25 (28) 10 (34) 0.612
Smoking 41 (46) 18 (62) 0.187
Family history 34 (38) 13 (45) 0.663
Hypertension 39 (44) 14 (48) 0.798
TIMI risk score 1 (0-2) 1 (1-2) 0.259
0 29 (33) 5 (17)
1 33 (37) 12 (41)
≥ 2 27 (30) 12(41)
Grace risk score 85 [70-98] 96 [72-121] 0.131
Low 76 (85) 21 (72)
Intermediate 12 (13) 6 (21)
High 1 (1) 2 (7)
Ischemic ECG abnormalities 26 (29) 15 (52) 0.042
Baseline hs troponins elevateda 36 (40) 13 (45) 0.829
Values are mean ± SD, n (%), or median [interquartile range]. Diabetes mellitus is defined as plasma glucose 
>11.0 mmol/l or treated with either diet regulation or medication. Hypertension is defined as >150 mmHg 
systolic or >90 mm Hg diastolic or treated with medication. Ischemic ECG abnormalities are defined as Q-
wave or ST-T segment alterations suggestive of ischemia. a Elevated within 3 times the upper limit of the 
99th percentile.
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The median Agatston calcium score was 1 [0-30] in patients presenting during office 
hours and 4 [0-48] in patients presenting outside office hours. CCTA identified 40 (45%) 
patients presenting during office hours with no detectable CAD, compared to 11 (38%) 
of patients presenting outside office hours. Obstructive CAD (>50% luminal narrowing) 
was found in 13 (15%) patients presenting during office-hours and 5 (17%) presenting 
outside office hours. The scan was considered non-diagnostic in 5 (6%) of patients 
presenting during office-hours and in 2 (7%) of patients presenting outside office-hours 
(all p>0.05) (figure 1). The mean radiation dose for CT-angiography was 4.2 ± 3.7 mSv 
for patients presenting during office-hours and 4.2 ± 2.8 mSv for patients presenting 
outside office-hours (p=0.957).
CT acquisition
Scan acquisition parameters are shown in table 2. There were no significant differences 
in acquisition parameters between patients presenting during office hours and outside 
office hours. The number of patients receiving intravenous beta-receptor antagonists 
prior to the scan was similar between the office- and outside office hours presenting 
patients, as well was the dose (table 2). The mean heart rate was higher in the group 
presenting outside office hours although not reaching statistical significance (64 ± 13 
vs. 69 ± 13, p=0.095).
45% 
34% 
9% 
6% 6% 
Office hours (n=89) 
No detectable CAD
CAD with <50%
luminal narrowing
CAD with 50-70%
luminal narrowing
CAD with ≥ 70% 
luminal narrowing 
Non-diagnostic scan
38% 
38% 
10% 
7% 7% 
Outside office hours (n=29) 
No detectable CAD
CAD with <50%
luminal narrowing
CAD with 50-70%
luminal narrowing
CAD with ≥ 70% 
luminal narrowing 
Non-diagnostic scan
Figure 1. CT results stratified 
for patients presenting during 
and outside office hours. All 
p>0.05. CAD, coronary artery 
disease.
Round-the-clock performance of coronary CT angiography 187
10
Image quality
The total quality score per patient was higher for patients presenting during office 
hours in comparison to patients presenting outside office hours (30.5 [26.0 - 33.5] vs. 
27.5 [19.75 - 32.0], p=0.043, table 3). The total per-patient quality score of the proximal 
coronary segments (segments 1,2,5-7 and 11) was higher for patients presenting during 
office hours (16.0[14.0 - 17.0] vs. 15.0[10.5 - 17.0], p=0.014). The number of non-evaluable 
segments was lower for patients presenting during office hours (0[0 – 1] vs. 1[0 – 4], p= 
0.009), as well as the number of non-evaluable proximal coronary segments (0[0 – 0] vs. 
0[0 – 2], p=0.021). An example of image quality is shown in figure 2.
Table 2. Scan acquisition parameters
Office hours 
(n=89)
Outside office hours 
(n=29)
p-value
Type CT scanner 0.340
Single Source 128-slice 67 (75) 19 (66)
Dual Source 128-slice 22 (25) 10 (34)
Heart rate /min. during scanning (range) 64 ± 13 (38-100) 69 ± 13 (50-98) 0.095
Scan protocol 0.183
Axial 76(85) 28 (97)
Spiral 13 (15) 1 (3)
Beta blocker administration 0.590
Yes 47 (53) 13 (45)
No 19 (21) 7 (24)
Missing 23 (26) 9 (31)
Beta blocker dose 5 [5-6.5] 5 [5-6.25] 0.371
Tube voltage, kV 100 [100-120] 120 [100-120] 0.361
Tube current-time product, mAs 194 [144-332] 322 [146-307] 0.562
Dose Length Product (DLP) 280 ± 245 271 ± 198 0.851
Values are n (%), median [interquartile range], or means ± standard deviation
Table 3. Median quality score
Office hours 
(n=89)
Outside office hours 
(n=29)
p-value
Total quality score of all segments 30.5 [26.0-33.5] 27.5 [19.75-32.0] 0.043
Quality of all proximal segmentsa 16.0 [14.0-17.0] 15.0 [10.5-17.0] 0.014
Total number of unevaluable segments 0 [0-1.0] 1.0 [0-4.0] 0.009
Number unevaluable proximal segmentsa 0 [0-0] 0 [0-2.0] 0.021
Image quality was graded on an ordinal scale ranging from 1 to 3, 1 representing poor image quality due to 
major artefacts, no diagnostic evaluation possible, 2 artefacts present, but image quality was adequate for 
diagnostic evaluation, and grade 3, no motion artefacts present, good image quality. a Proximal segments 
included segment 1,2,5-7 and 11.
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Clinical outcome and downstream testing
From the group of patients presenting during office hours, 22 (25%) patients were admit-
ted, in comparison to 12 (41%) patients that presented outside office hours (p=0.085). 
The overall number of major adverse cardiac events (including all-cause mortality, 
myocardial infarction, and coronary revascularization) within 30 days after the index 
visit was low, and comparable between groups (9(10%) vs 3(10%), p=0.320)). In addition, 
there was no difference in the rate of invasive coronary angiography and the rate of 
coronary revascularization between patients presenting during and outside office hours 
(table 4). The length of stay at the ED was significantly longer for patients presenting 
outside regular office hours (4.8 [4.0-7.5] vs 6.4 [5.5 - 22.9] hours, p=0.005).
A                                         B 
C                                         D 
Figure 2. Example of image quality in patient presenting during office hours (A and B), and outside office 
hours (C and D). Showing a good image quality, with a good coronary enhancement, no motion or other ar-
tefacts of the right coronary artery (A – during office hours), and a well-defined lumen with partly calcified 
and partly non-calcified plaque in the left main coronary artery and left anterior descending (C – outside 
office hours).
Poor image quality due to motion artefacts and low contrast enhancement of the right coronary artery are 
shown (B – during office hours). Poor image quality mainly due to major motion artefacts (D – outside office 
hours), made diagnostic evaluation deemed impossible.
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DISCUSSION
In this pre-specified sub-analysis of the BEACON trial, we assessed the feasibility of CCTA 
outside office hours. Our results show that image quality of CCTA outside office hours is 
slightly lower than during office hours. While no worse clinical outcome was observed 
after 30 days, patients presenting outside office hours had a longer length of stay and 
were more likely to be admitted to hospital.
CCTA performance
To the best of our knowledge, this is the first study to investigate round-the-clock 
utilization of CCTA for suspected ACS. We found image quality of CT scans made 
outside office hours to be sufficient in the majority of patients. There is a small, but 
statistically significant difference in image quality and non-assessable scans in favour 
of examinations performed during office hours. An explanation for this difference was 
not immediately evident from the clinical characteristics, type of scanner or acquisition 
parameters, which were largely comparable between the two groups. However, there 
was a trend towards higher heart rates in patients presenting outside office hours, which 
might partly explain the difference in heart rate. A relative small sample size may have 
obscured any existing difference in clinical characteristics or acquisition parameters. 
Also, other unidentified confounders or a combination of factors may explain the lower 
image quality of CT scans acquired outside office hours. While not investigated, experi-
ence of the technician and workflow pressure in the emergency ward during off-hours 
could have played a role as well.
Differences in clinical outcome
Patients presenting outside office hours had a longer length of stay with the tendency 
to be admitted more often, which is consistent with previous observations (8, 9). Logistic 
reasons, such as the accessibility to testing and staffing, next to unfavourable clinical 
Table 4. Clinical outcome and downstream testing within 30 days after index visit
Office hours
(n=89)
Outside office hours
(n=29)
p-value
Admitted to hospital a 22 (25) 12 (41) 0.085
Length of ED stay, hours 4.8 [4.0-7.5] 6.4 [5.5 – 22.9] 0.005
Major adverse cardiac events 9 (10) 3 (10) 0.320
Invasive coronary angiographyb 13 (15) 5 (17) 0.749
Coronary revascularizationb 8 (9) 2 (7) 0.714
Values are n (%) or median [interquartile range]. a Admission to hospital is defined as at least 8 hours in 
hospital. Major cardiac adverse events includes all-cause mortality, myocardial infarction, and coronary re-
vascularization. b Includes procedures at index visit. ED; emergency department.
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characteristics are suggested as possible reasons for this difference. In our study, the 
clinical profiles were unexpectedly comparable between patients presenting outside 
or within office hours. Their short-term prognosis, expressed in major adverse cardiac 
events, was also not different. While the difference was small, lower image quality and 
subsequent less reliability of CCTA outside office hours might have contributed to a 
longer hospital stay. Also, logistic reasons and the inclination of physicians to admit 
patients more easily during night hours, rather than clinical profiles, may also play a role.
24/7 implementation of CCTA at the emergency department
While CCTA is becoming an accepted diagnostic tool in the workup of low- to intermedi-
ate-risk patients presenting with suspected acute coronary syndrome, round-the-clock 
performance of CCTA at the emergency department has not yet been widely imple-
mented (12). CCTA is still one of the more demanding CT examination that requires 
state-of-the-art scanner technology, sufficiently trained staff and time for preparation 
and optimization of the procedure. Also, it is important that CT readers at the ED are 
well trained in assessing CCTA. These conditions are difficult to achieve 24 hours per day, 
seven days per week, which is why most centres opt to limit the cardiac CT service to 
regular office hours. Some of the current barriers towards full-time implementation may 
be overcome in the future with further improved technology, lowering the complexity 
and lessening need for premedication, as well as remote expert reading.
Limitations
There are some study limitations that need to be addressed. The current sub-analysis 
comprises a relatively small number of patients from a single centre. The proportion of 
patients enrolled outside office hours (25%) was lower than expected. Screening of all 
potential study candidates by the medical team may not have been concordant dur-
ing regular hours and shifts. Quality of CCTA depends on the available technology and 
personnel. Therefore extrapolation of our results to other centres may be limited. Larger 
studies with patients enrolled in different centres are needed to thoroughly address the 
performance of CCTA outside office hours.
CONCLUSION
Image quality of CCTA outside office hours in the diagnosis of suspected ACS is dimin-
ished.
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SUMMARy AND GENERAL DISCUSSION
Over the past decade non-invasive coronary angiography using cardiac CT has become 
a valuable technique for the diagnostic triage of patients with suspected coronary 
artery disease (CAD) in various settings. Multiple studies have shown that coronary CT 
angiography (coronary CTA) (1) has a high sensitivity and an excellent negative predic-
tive value for the detection of obstructive CAD, allowing confident exclusion of CAD 
(2-6). Despite the limited accuracy of exercise ECG for the detection of CAD, in many 
parts of the world this test remains the first choice for patients with stable chest pain 
and a low-intermediate probability of CAD (7, 8). In patients with a higher probability of 
disease stress imaging is often performed (7, 8). Large randomized trials demonstrated 
equivalence between coronary CTA and standard functional tests, but did not investi-
gate the role of calcium imaging or the value of new CT applications for interpretation 
of the hemodynamic severity of CAD. In case of acute chest pain, several studies have 
shown that coronary CTA has clinical, logistic and economic benefits to rule out an acute 
coronary syndrome (ACS). Since these studies were published, high-sensitivity troponin 
assays (hs-troponins) have become standard practice in Europe, which allow for accurate 
and fast rule-out of ACS, leaving uncertainty about the role of cardiac CT in the ED(9, 10).
In this thesis, we assessed the value of cardiac CT in patients with suspected CAD. We 
investigated the effectiveness, (cost-) efficiency and safety of cardiac CT in comparison 
to standard functional testing. In this discussion, we will address our research questions 
and discuss the outcomes against the background of published literature. We will end 
this chapter with a brief discussion on future perspectives.
In chapter 2 we provided an in-depth description of the technical background of 
cardiac CT imaging, to understand how images are acquired, post-processed and 
interpreted. In addition, an overview of the diagnostic accuracy and the current recom-
mendations for clinical use are presented.
CT Calcium imaging and CT angiography in stable angina
Chapter 3 focused on the clinical use of cardiac CT in stable ambulatory patients with a 
suspicion of obstructive CAD. At four centers in the Rijnmond region we randomized 350 
patients [CRESCENT Trial] with stable chest pain between a tiered cardiac CT protocol 
and standard functional testing. The protocol started with a calcium scan and ruled out 
CAD in low-intermediate probability patients with a negative calcium scan(11). Patients 
with a very high calcium score underwent functional testing. Coronary CTA was per-
formed in the remaining 49% of patients. Standard care started with an exercise ECG 
in the majority of patients. After one year fewer patients randomized to CT reported 
anginal symptoms in comparison to the functional testing group. This can be explained 
by a higher diagnostic performance of CT and subsequently more appropriate manage-
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ment of cardiac as well as non-cardiac conditions, although differences in experienced 
reassurance from cardiac CT by patients and physicians may have played a role as well. 
Although the study was not powered to demonstrate differences in mortality or myocar-
dial infarction, cardiac CT did result in a lower combined event rate that included death, 
myocardial infarction, stroke, late revascularizations and unplanned cardiac evaluations 
(3.3% vs.10.2%). The use of X-rays represents a drawback of CT, although by applying the 
calcium scan, contemporary CT equipment and dose reducing techniques, the cumula-
tive radiation dose exceeded the functional testing group by less than 10%. Cardiac CT 
achieved a conclusive diagnostic result faster, required fewer additional tests, did not 
significantly increase catheterization rates, and was less expensive, compared to func-
tional testing (€369 versus €440). In conclusion: a tiered cardiac CT protocol that includes 
a CT calcium scan, is safe, avoids contrast medium in 39% of patients, reduces exposure 
to radiation, and appears cost-effective compared to standard functional testing.
Two randomized controlled trials that compared the effectiveness of coronary CTA 
standard care to standard testing were published just before the CRESCENT trial. The 
pragmatic PROMISE trial randomized 10,003 US patients between coronary CT angiog-
raphy and functional testing (67% nuclear imaging) for evaluation of suspected CAD, 
and reported no difference in adverse cardiac events after two years(12). Cardiac CT 
lead to more invasive angiograms, but fewer (angiographically) negative invasive angio-
grams. Differences between CRESCENT and PROMISE include the use of calcium imaging 
and the less frequent use of functional imaging in the control group (27% in CRESCENT 
vs ~90% in PROMISE). The SCOT-HEART trial demonstrated in 4146 patients with stable 
angina that the addition of coronary CTA to standard care improved the certainty of the 
diagnosis, but not the frequency of the diagnosis of angina due to coronary heart disease 
(13). After 1.7 years there was a close to statistically significant 38% reduction in the 
composite endpoint of death related to coronary heart disease and myocardial infarc-
tion (p=0.0527). Contrary to CRESCENT and PROMISE, in the SCOT-HEART trial coronary 
CTA did not replace functional testing, but was added to a standard care protocol with 
exercise ECG in most cases. The low prevalence of CAD and the generally benign clinical 
outcome of patients with stable chest complaints in these studies, has raised questions 
concerning the need for advanced and expensive imaging tests in these patients. In 
this respect our randomized trial, albeit much smaller in population size, adds to the 
evidence from PROMISE and SCOT-HEART by demonstrating that a tiered approach 
including calcium imaging can mitigate the potential risks and costs of cardiac CT, while 
achieving comparable if not better performance to a functional test approach.
The diagnostic management of women with suspected CAD is challenged by under-
recognition due to differences in presentation, pathophysiology such as the higher 
prevalence of vasospasm and microvascular angina in women (14, 15), a lower per-
formance of standard noninvasive tests resulting in equivocal test results and missed 
Summary and General Discussion 201
11
diagnoses (16-19) and a paradoxically low diagnostic yield of invasive angiography for 
angiographic CAD, due to a relative overuse, perhaps fueled by the limited confidence 
in noninvasive tests (20, 21). Based on the hypothesis that direct visualization of CAD by 
cardiac CT may be particularly effective in women, in Chapter 4 we investigated gender 
differences in the performance of cardiac CT compared to functional testing in the evalu-
ation of stable chest pain, and found that cardiac CT was more efficient in women than 
men in terms of time needed to reach the final diagnosis and downstream testing. In the 
previously published sub-analysis of the PROMISE trial women were less likely to have a 
positive CTA than a positive exercise ECG or nuclear stress test result, even after adjust-
ing for clinical factors, which may be the result of false-positive stress test results(22). 
Interestingly, in the CRESCENT trial no evident differences were observed between the 
sexes with regard to the exercise tolerance or achieved heart rate during exercise testing. 
Contrary to PROMISE and SCOT-HEART, in the CRESCENT trial cardiac CT was not associ-
ated with an increase in the number of cardiac catheterizations in women(12, 13). The 
reduced catheterization referral rate after CT may be explained by the use of the calcium 
scan, or a higher accuracy by newer CT equipment, but may as well be the result of 
differences in management following the CT scan, compared to previous studies.
Enhancement of the coronary lumen is essential for the detection of CAD on CTA. Con-
trast media vary in terms of iodine concentration and osmolarity. Until recently the goal 
in coronary CTA was to achieve maximum lumen opacification, to overcome limitations 
related to residual motion and vessel calcifications, by injecting high-concentration 
contrast media (up to 400mg I/ml) or high injection rates. With more powerful roent-
gen tubes and iterative reconstruction techniques, many patients can be scanned at 
a lower tube potential (80kVp), which reduces overall radiation exposure. Because of a 
greater photoelectric effect and less Compton scattering, imaging at a lower kV also in-
creases attenuation differences between iodine and soft tissue(23). As a result, sufficient 
coronary contrast can be achieved with less iodine injected in to the body. Iso-osmolar 
contrast media with an osmolarity equal to plasma were demonstrated to cause less 
heart rate acceleration and arrhythmia, which should be of potential benefit for CT im-
age quality(24-28). In terms of opacification and image quality comparisons between 
iso-osmolar and low-osmolar contrast media have demonstrated mixed results, which 
may in part be related to the lower iodine concentration of iso-osmolar contrast media 
(26, 29, 30). In the IsoCOR trial, in Chapter 5, we randomized 306 patients scheduled 
for coronary CTA at 3 centers in the Rijnmond region, between iso-osmolar iodixanol-
270mg I/ml (Visipaque) and low-osmolar iopromide 300mg I/ml (Ultravist) injected at 
the same iodine delivery rate. When injected at a similar iodine delivery rate, we found 
that coronary lumen opacification by iodixanol-270 was not inferior to iopromide-300 
(476 ± 160 Hounsfield Units (HU) vs 454 ± 158 HU). Contrary to earlier studies that sug-
gested that iso-osmolar contrast media cause less heart rate acceleration and arrhyth-
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mia with potential benefits to cardiac imaging (24, 27, 31, 32), we found that although 
in the iodixanol-270 group patients experienced less heat discomfort (72% vs. 86%), no 
differences in heart rate, heart rhythm, or image quality were observed.
CT myocardial perfusion imaging in stable angina
Although coronary CT angiography effectively rules out coronary artery disease, it is 
limited in its ability to assess the hemodynamic importance of angiographic lesions. 
Because anatomical lesion severity is a poor predictor of hemodynamic significance, 
functional evaluation of stenosis with intermediate severity is recommended for thera-
peutic decision making(7, 33). Recent developments in CT technology have created the 
technical prerequisites for the application of stress CT myocardial perfusion imaging 
(CT-MPI) for the evaluation of CAD. Thereby CT provides not only anatomical informa-
tion, but it also allows to determine the functional relevance of coronary stenosis, 
rendering it a potential “one stop shop” procedure for the diagnosis and management of 
CAD(34). Pioneered by Kurata et al. in 2005 (35), static CT-MPI acquires a single CT data-
set during the first pass of contrast medium through the heart, to visualize differences in 
myocardial enhancement at a single time point. The assessment of perfusion defects is 
qualitative and hypo-enhanced regions are compared with normal remote myocardial 
segments -, comparable to nuclear imaging techniques- potentially disguising globally 
reduced myocardial perfusion. While advantages of the static perfusion technique are 
the relatively simple scan acquisition and a full heart coverage with any scanner, a draw-
back lies in the assessment of only one sample of data and potentially incorrect timing 
of the contrast bolus missing the peak attenuation resulting in poor contrast-to-tissue 
ratios (36) its susceptibility to artefacts.
While most experience exists with static CT-MPI(37-39), newer scanners with wider de-
tector coverage also allow for dynamic CT-MPI with total coverage of the left ventricular 
myocardium. Dynamic CT-MPI was performed in our studies with myocardial hyperemia 
achieved by infusion of adenosine (≥3 minutes, 140µg/kg/min). At alternating table 
positions (shuttle mode) systolic images were acquired every second heart cycle while 
the patient maintained an inspiratory breath-hold. From a series of 12-15 low-resolution 
datasets the changes in myocardial enhancement during contrast medium passage 
could be plotted over time, from which the myocardial blood flow could be calculated 
using a previously described methodology(40). In contrast to static CT-MPI, dynamic 
CT-MPI allows for calculation of absolute myocardial blood flow(33, 40, 41). Furthermore 
the differentiation between true perfusion abnormalities and various artefacts is easier 
by evaluating the time course of the myocardial enhancement. However, because of the 
acquisition of different data points over time, the scan technique is more challenging 
and more time consuming compared to static CT-MPI, and is associated with a higher 
radiation dose (40, 42).
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Reduced myocardial perfusion due to CAD tends to be more pronounced in the sub-
endocardium(43). This is thought to be due to a reduction in diastolic perfusion time-
interval, higher contractile intra-myocardial tissue pressures, and differences in coronary 
microvasculature(43, 44). The high spatial resolution of CT allows the distinction 
between sub-endocardium and sub-epicardium. A method to utilise the susceptibility 
of the sub-endocardium for ischaemia is the transmural perfusion ratio (TPR). TPR is the 
ratio between sub-endocardium and sub-epicardium perfusion. Since it is a relative 
index, we hypothesized that this ratio could improve the diagnostic performance of 
dynamic CT-MPI, because this relative index of perfusion could be less sensitive to the 
variation of absolute myocardial blood flow values between patients. In chapter 6 we 
evaluated the accuracy of TPR alone in comparison to regular myocardial blood flow 
(MBF) values by dynamic CT-MPI for the detection of haemodynamically significant CAD. 
We found an area under the receiver operator curve that was significantly larger for MBF 
(0.78) compared with TPR (0.65), concluding that dynamic CT-MPI derived TPR is inferior 
to quantified MBF and has limited incremental value. Also no significant incremental 
value of TPR on top of MBF was found. While some studies showed the potential of TPR 
to detect ischemia(45), recently other studies demonstrated that visual assessment 
performed better than TPR(46).
Anatomical and functional parameters are both essential for clinical decision-making 
in patients with CAD(47, 48). While CT angiography is reliable for ruling out CAD, angio-
graphic and hemodynamic severity may be overestimated with CT angiography alone. 
A comprehensive stepwise cardiac CT examination, combining calcium scoring, CT angi-
ography and CT-MPI, could provide all essential information for clinical decision making 
in CAD, and avoid invasive coronary angiography in patients without hemodynamically 
significant CAD(37, 38, 40). In chapter 7 we presented the CRESCENT-II randomized-
controlled trial performed at 4 centers in the Netherlands, in which 268 patients with 
stable angina were randomized between cardiac CT and standard guideline-directed 
functional testing between July 2013 and November 2015. The tiered cardiac CT pro-
tocol included a calcium scan, followed by CT angiography if calcium was detected. 
Patients with significant stenosis on CT angiography underwent CT-MPI. The functional 
testing strategy was selected by the treating physicians in accordance with international 
guidelines (initial test 95% exercise ECG)(7).
The purpose of noninvasive testing is to accurately rule out coronary disease and 
invasive angiograms without coronary artery disease are considered a failure of that 
gatekeeper function. In CRESCENT II the rate of negative invasive coronary angiograms 
(primary endpoint) was lower in the CT group than the functional test group (1.5% vs 
7.2%). Myocardial ischemia was excluded in 34% of patients with >50% CAD on CT 
angiography. Hereby, CT-MPI improved the performance of cardiac CT as a gatekeeper 
to invasive angiography and did not increase catheterization rates (13% vs. 14%).
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Presently, patients evaluated and treated for suspected CAD are characterized by a 
low but overestimated CAD prevalence and overall benign outcome. This was observed 
in the PROMISE and SCOT-HEART trials, as well as the CRESCENT trials(12, 13, 49). The 
objective of the CRESCENT-II trial was to test a diagnostic strategy that would allow safe 
rule-out of CAD by relatively simple means, while at the same time incorporating func-
tional measures of CAD for well-informed decisions and avoiding unnecessary invasive 
procedures. Incorporation of CT-MPI in CRESCENT-II resulted in a higher diagnostic yield 
for invasive angiography (88% vs 50%) (compared to 72% in CRESCENT-I), while only 13% 
of cardiac CT patients required further testing, compared to 37% in the functional testing 
group(12, 38, 50). In the CRESCENT-II trial the complete cardiac CT protocol, with an ex-
amination time of up to 30 minutes, provided a conclusive diagnosis on one day in 87% 
of patients, achieved a conclusive diagnostic result faster and required fewer additional 
tests. Although results should be confirmed in larger populations, these findings suggest 
a promising role for a tiered, comprehensive cardiac CT protocol. A drawback of CT and 
especially CT-MPI is the radiation dose. By using dynamic CT-MPI the radiation exposure 
is higher compared to static perfusion imaging protocols (42). The mean radiation dose 
for dynamic CT-MPI in our trial was 10.6±6.3mSv. But because CT-MPI was only necessary 
in 22% of CT patients the average cumulative dose in the CT group was 5.6±6.3mSv. X-ray 
exposure was higher compared to the functional test group, in whom exercise-ECG was 
the predominant initial test, and only 37% required (secondary) testing involving nuclear 
imaging and invasive angiography. We concluded that, In patients with suspected stable 
CAD, a tiered cardiac CT protocol that involved a stepwise use of a calcium scan, CTA and 
CT-MPI offers a fast, safe and efficient alternative to functional testing.
Coronary CT angiography in suspected acute coronary syndrome
Patients presenting to the emergency department (ED) with symptoms suggestive of an 
acute coronary syndrome remain a diagnostic challenge. While it is important to reliably 
rule out an acute coronary syndrome (ACS) or any other life-threatening condition, a 
clinical efficient work-up is needed as many of these patients are not suffering any seri-
ous illness.
Recently, several trials have demonstrated that coronary CT angiography is a safe and 
potentially more efficient diagnostic procedure for the triage of patients with acute 
chest pain(51-54).
The previously published CT-STAT trial compared coronary CT angiography with 
nuclear myocardial perfusion imaging as initial tests in the management of patients 
with acute chest pain(51). Investigators reported a reduction of 54% in time to diagnosis 
and 38% lower costs of ED care with CT. In the ACRIN-PA trial investigators left deci-
sions to perform a diagnostic test in the standard care group to the discretion of the 
treating physicians(53). The study demonstrated that low-risk patients could be safely 
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discharged with early coronary CT angiography twice as often and CAD was more likely 
to be diagnosed with CT. The ROMICAT-2 trial, also included a cost-analysis, demonstrat-
ing a reduction of the median length of hospital stay from 26.7 to 8.6 hours with early 
coronary CT angiography and a 4-fold higher discharge rate from the ED without in-
creasing medical expenditure(52). Since the completion of these trials standard optimal 
care has changed considerably with the introduction of high sensitive troponin assays. 
These new assays are more sensitive and reach negative predictive values of >97% for 
myocardial infarction within three hours (9, 10). Hs-troponin allows fast and accurate ex-
clusion of ACS in a substantial proportion of low to intermediate risk patients, obviating 
the need for prolonged observation and in-hospital diagnostic testing in the absence 
of elevated high sensitivity cardiac biomarkers or suggestive ECG abnormalities (55-58).
In chapter 8 the results of the prospective, multicenter randomized BEACON trial are 
described in which 500 patients presenting with symptoms suggestive of an ACS were 
enrolled at the emergency departments of five community and two university hospitals 
in the Netherlands. Patients in need of urgent revascularization were excluded. Patients 
were randomized to either a diagnostic strategy supplemented by early coronary CT 
angiography or standard optimal care. In both groups hs-troponins were available. We 
found that a diagnostic strategy supplemented by early coronary CT angiography was 
safe, less expensive and prevented downstream testing in the outpatient setting. How-
ever, in the era of hs-troponins, coronary CT angiography did not identify more patients 
requiring coronary revascularization, nor did it shorten hospital stay or allow for more 
direct discharge from the ED.
The results of the BEACON trial differ from previous trials as early coronary CT angiog-
raphy did not shorten the length of stay, nor reduce the number of hospital admissions. 
We found that the length of stay using an early CT exam was comparable or even lower 
than reported in previous trials. However, the length of stay in our standard care group 
was substantially shorter, underlining the substantial improvement of standard care 
after the introduction of hs-troponins. Similarly, the proportion of discharged patients 
in the standard care group was 2 to 4 times higher compared to previous trials, however 
compared to our CT group this was not significantly different. Other differences between 
healthcare systems in previously published trials from the United States and the Neth-
erlands, such as the important gatekeeper role of the general practitioner and delays in 
access to care, social differences and insurance coverage problems, may also influence 
the patient population, and could be responsible for the different results(59-61). The 
BEACON trial demonstrated that early coronary CT angiography reduced the need for 
subsequent outpatient testing if CT was performed at first presentation. Additionally, 
we found lower medical costs at 30 days. This was caused by a combination of shorter 
length of stay and the more frequent use of exercise ECG instead of nuclear imaging.
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The burden of CAD in women may still be under-recognized(62). This might be the 
result of distinct pathophysiological differences or disease perception by patients and 
physicians(15). The optimal diagnostic test in the work-up of suspected ACS might there-
for differ between men and women. In chapter 9 we compared the clinical effectiveness 
of an early coronary CT angiography strategy on the ED in women and men. Women 
were found to have a lower prevalence of CAD and were at discharge less frequently 
diagnosed with ACS compared to men. In terms of efficiency women were less often 
admitted and had a shorter length of stay after CT, however there was no significant 
interaction by sex. In conclusion, we found that the performance of coronary CT angi-
ography was comparable in women and men who have normal hs-troponin levels. In 
contrast, it has previously been shown that early CT may be a more efficient work-up 
for suspected ACS, especially in women(63). The different findings in the BEACON trial 
can be explained by the novel availability of hs-troponins for clinical decision making. 
The majority of patients (>90%) in our study had normal hs-troponin levels, and it has 
been shown that these patients have a very low ACS risk (64). The logistic benefit of 
early advanced diagnostic testing may therefore be of limited value in this context, 
regardless of sex(65). Secondly, it is believed that less classical causes of angina such as 
endothelial dysfunction and microvascular disease are more frequent in women, while 
epicardial CAD is more prevalent in men(66). Consequently, it is likely that coronary CT 
angiography as an anatomic modality would provide less benefit in women.
The presentation of patients with acute chest pain is not limited to office hours and if 
coronary CT angiography is considered for triage in the ED it is important to investigate 
its performance around the clock. A 24/7 availability of a cardiac CT service poses vari-
ous challenges, in terms of the availability of scanners and experienced staff, as well as 
patients characteristics and severity of disease(67, 68). As one of the participants in the 
BEACON trial, the Erasmus MC recruited patients 24-hours a day, 7 days a week. In this 
population, consisting of 118 patients, of whom 75% presented during office hours and 
25% outside office hours, we investigated the image quality of coronary CT angiogra-
phy during and outside office hours (chapter 10). We found that image quality was 
lower in patients presenting outside office hours, and the number of non-evaluable 
segments due to artefacts was significantly higher. This could not be explained by differ-
ences in clinical characteristics, type of scanner, acquisition parameters or beta-blocker 
administration. Probably other unidentified confounders, or a combination of factors 
may explain the lower image quality of CT scans acquired outside office hours. A trend 
towards higher heart rates in the group seen outside office hours was found (64 vs 69 
bpm, p=0.095), or maybe the experience of technicians and workflow pressure in the ED 
during off-hours, could have played a role in the image quality as well.
Besides the finding that image quality of CT scans acquired during off-hours was 
lower, we found that patients presenting outside office hours had a longer length of 
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stay with the tendency to be admitted more frequently (67, 68). This was consistent with 
previous observations and can be explained by logistic reasons, such as the accessibility 
to testing and staffing, next to unfavourable clinical characteristics of patients present-
ing outside office hours (67, 68). The 24/7 implementation of coronary CT angiography 
on the ED is a challenge, and requires state-of-the-art scanner technology, sufficiently 
trained staff and time for preparation and optimization of the procedure.
FUTURE PERSPECTIVES
The COURAGE and FAME trials (47, 48, 69) showed that revascularization does not benefit 
every patient with angiographic CAD, but should be reserved for those with objective 
myocardial ischemia. Invasive angiography, without proper ischemia testing leads to 
over-treatment. In the field of non-invasive ischemia testing there are multiple modali-
ties available. Functional assessment with CT-MPI may have practical advantages, as it 
can be performed in conjunction with CTA, and allows for a comprehensive assessment 
of anatomy and function like we showed in this dissertation. The high radiation dose, 
relatively complicated scan protocol and the requirement of specific CT equipment for a 
dynamic CT-MPI scan can slow down the implementation in daily practice of the regular 
cardiology clinic. However, as scanner and data processing technology further develop, 
the comfort of use and radiation exposure of dynamic CT-MPI will likely improve and will 
become easier accessible.
Besides functional assessment with CT, there are more established stress imaging 
techniques available. For example, cardiovascular magnetic resonance (MR) perfusion 
imaging has demonstrated the highest accuracy of all non-invasive testing. In the MR-
INFORM trial, Nagel et al [in press](70) showed that MR-perfusion guided management of 
patients with stable angina is non inferior for MACE at one year compared with invasive 
angiography and FFR. This was the first trial to show that MR-perfusion imaging could 
guide patient management in a high-risk population with the same effectiveness as 
invasive angiography with FFR. The advantages of an MR-based work up are the absence 
of radiation, as well as gaining potentially relevant information on anatomy, contractile 
function and myocardial structure in a single session. However, MR-perfusion is a time-
consuming technique of which the cost-effectiveness still needs to be investigated.
Another non-invasive testing modality for myocardial ischemia is PET imaging. Da-
nad et al determined the diagnostic value of CTA, SPECT and PET imaging compared 
against invasive FFR(71). They found that PET yielded the highest diagnostic accuracy, 
outperforming CTA and SPECT and unexpectedly a hybrid diagnostic approach, com-
bining anatomy and functional assessment did not improve accuracy compared to PET 
alone. However, before PET can be used as standard gatekeeper in the work up of stable 
CAD, some drawbacks need to be overcome. The image quality with the currently used 
isotope is not sufficient to perform a standard segmental perfusion analysis and also the 
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high costs and duration of a PET exam are not ideal for a gatekeeper function in large 
groups of patients.
There is still ongoing debate what is the best non-invasive gatekeeper that provides 
anatomical and functional information and accurately predicts significant flow impair-
ment compared with the gold-standard invasive FFR. While the technical strengths and 
weaknesses of each technique are known, as well as the diagnostic accuracy and prog-
nostic power, there are also other important variables influencing the choice of a test, 
some of which are availability and waiting times, local expertise and radiation exposure. 
Another very important variable is the cost of each test which varies tremendously be-
tween countries and is very difficult to standardize. Long-term cost-effectiveness is dif-
ficult to establish, depends on the local conditions and may conflict with the economic 
incentives within health care systems. Patients are different and it is unlikely that one 
specific test is the best choice for each patient in every clinical context.
So what is the next step from here? The important and clinically relevant question 
for the practicing physicians is how to match each patient with its own clinical char-
acteristics with each test to improve clinical care. Thus, the important challenge for 
clinical research would be to develop well-defined patient groups for which physicians 
can be advised about the best test choice based on group’s clinical characteristics, the 
diagnostic accuracy of the test, and the specific data required from the test. Robust trial 
evidence is needed to find the best non-invasive imaging test for each patient. Con-
versely, we are not likely to see many large-scale randomized controlled trials in imaging 
because of the high cost of performing them and non-imaging factors that contribute 
to outcomes, including downstream use of test information and less than optimum 
post-test patient care strategies, are difficult to control. It is therefore likely that we will 
see more pragmatic trials with varied clinical endpoints. But it will be challenging to 
compare the different clinical endpoints for their effectiveness, safety, or efficiency.
Currently an international landmark trial named ISCHEMIA has recently completed 
recruitment and the results will be published in the upcoming years(72). Five thousand 
patients with stable angina and at least moderate ischemia were randomized between 
invasive angiography or optimal medical treatment and followed for four years. The 
primary aim is to determine if an initial strategy with invasive angiography and revas-
cularization together with medical therapy will reduce events compared to a strategy 
of medical therapy alone (with cath lab referral reserved for failed medical treatment). 
Where prior trials in stable CAD showed that an index strategy of optimal medical 
therapy alone was safe and equally effective as PCI with optimal medical therapy, this 
trial will possibly offer great opportunities for imaging to be a core component and 
decision trigger for the clinical management of stable CAD and may potentially provide 
evidence to alter the current evaluation strategy.
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Technical developments of functional assessments in cardiac CT
The possibility of imaging myocardial enhancement during hyperemia using CT has 
been demonstrated repeatedly(35, 39, 45, 73), but only with the introduction of wider 
detector-row CT systems has it become feasible to perform dynamic MPI in clinical prac-
tice(33, 40). Up to now dynamic CT-MPI had only been tested in single-center studies 
(33, 40), however the international multicenter SPECIFIC trial is currently recruiting pa-
tients referred for invasive angiography and performs dynamic CT-MPI before invasive 
angiography. The aim is to determine the diagnostic accuracy of dynamic CT-MPI for 
the detection of hemodynamically relevant coronary stenosis as determined by invasive 
FFR. Results are expected in 2019. Meanwhile cardiac CT technology is developing and 
the latest CT systems provide higher temporal resolution, wider detector coverage, bet-
ter tissue resolution and lower radiation doses. Whether these improvements in scanner 
technology, as well as the development of user-independent tools for interpretation, will 
benefit the performance and applicability of CT-MPI will need to be further investigated.
Apart from dynamic CT-MPI, and well-known established functional modalities, sev-
eral other CT-based functional assessment techniques have emerged. For static CT-MPI 
the diagnostic performance and incremental value over CTA has been demonstrated in 
single- and multicenter trials (35, 37-39, 45, 74), with potential for diagnostic improve-
ment using dual-energy techniques (41), or hybrid systems that combine CT with PET 
or SPECT.
An alternative approach to estimating the functional severity of angiographic CAD 
is by model-based calculation of the fractional flow reserve (FFR) using computational 
fluid dynamics. CTA based FFR (CT-FFR) computes coronary flow parameters from con-
ventional CT angiograms(75, 76). While CT-FFR is not a direct physiological measure-
ment, and relies on sufficient CT quality, the lack of additional testing and radiation 
exposure are obvious advantages, that can make it a fruitful functional tool in the future. 
The PLATFORM study demonstrated how CTA combined with CT-FFR can improve the 
diagnostic yield of invasive angiography(77). The few direct comparisons published to 
date suggest a comparable and partially complementary performance of CT-MPI and 
CT-FFR (46, 78, 79). In the future, the simultaneous assessment of coronary anatomy and 
functional severity of CAD has the potential to function as a reliable “one stop shop”. 
With further advancements of cardiac CT, such as improved diagnostic accuracy, radia-
tion reduction, artifact reduction, reduced susceptibility to motion artifacts, a wider ac-
ceptance of cardiac CT in the work-up of suspected stable CAD can be expected.
While work presented in this theses answered many questions, undoubtedly it raised 
even more questions as mentioned in this chapter. The coming years will reveal how 
the above mentioned different non-invasive testing modalities of suspected CAD have 
moved forward.
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NEDERLANDSE SAMENVATTING
Cardiale CT (“computed tomography”) heeft zich het afgelopen decennium ontwikkeld 
tot een volwaardige diagnostische test in het opsporen van mogelijke vernauwingen in 
de kransslagaders (“coronair lijden”). Cardiale CT is de overkoepelende naam voor een 
aantal CT onderzoeken van het hart. Vaak begint het CT onderzoek met een CT-calcium-
score. Dit is een “blanco” CT scan zonder contrastmiddel, waarbij de calciumafzetting in 
de vaatwanden gedetecteerd en vervolgens gekwantificeerd kan worden volgens de 
Agatston-methode(1). Calciumscores zijn sterk geassocieerd met de graad en ernst van 
aderverkalking(2-4) en worden tegenwoordig het meest gebruikt als risico-stratificatie 
bij asymptomatische patiënten. Maar de hoge sensitiviteit en negatief voorspellende 
waarde van de CT-calciumscore maken de test ook uitermate geschikt om bij patiënten 
met pijn op de borst klachten vernauwingen in de kransslagaders mee uit te sluiten. Een 
voordeel van deze methode is dat er geen contrasttoediening nodig is en de stralings-
dosis en kosten zo lager zijn(5). Meerdere observationele studies hebben aangetoond 
dat in patiënten met een laag tot intermediair risico op coronair lijden een negatieve 
calciumscore, ernstige aderverkalking zeer zeldzaam is(6-8).
Na een CT-calciumscore kan een coronair CT angiografie (CCTA) volgen. Tijdens de 
CCTA wordt jodiumhoudend contrastmiddel in de bloedvaten van de patiënt geïnjec-
teerd om zo de binnenkant van de kransslagaders zichtbaar te maken en daarmee de 
ernst van de aderverkalking en vernauwingen te beoordelen. CCTA heeft een hoge 
sensitiviteit en negatief voorspellende waarde voor het detecteren van angiografische 
vernauwingen(9, 10). CCTA is echter beperkt in zijn vermogen om het hemodynamisch 
belang van vernauwingen in de kransslagaders te beoordelen.
De anatomische ernst van een vernauwing is een slechte voorspeller van de hemody-
namische ernst van een vernauwing, daarom wordt in de richtlijnen een functionele be-
oordeling van intermediaire vernauwingen aanbevolen(11, 12). CT-myocardiale perfusie 
(CT-MPI) is een derde CT techniek waarmee naast de anatomische informatie van de 
CCTA ook functionele informatie verkregen kan worden. CT-MPI wordt uitgevoerd onder 
toediening van adenosine, waardoor toegenomen bloedtoevoer (hyperemie) naar het 
hartspierweefsel ontstaat(13). Door verschillen in contrast-toevoer in het myocard tus-
sen gebieden achter een vernauwde kransslagader die minder goed doorbloed worden, 
en gebieden die normaal doorbloed worden, kan een perfusie (doorbloedings-) defect 
opgespoord worden(14). Hiermee kunnen de hemodynamische consequenties van een 
anatomische vernauwing in een kransslagader beoordeeld worden, dit noemen we een 
functionele beoordeling. Deze perfusie techniek is gevalideerd in single-center studies 
en heeft een diagnostische nauwkeurigheid die ten minste vergelijkbaar is met een 
nucleaire SPECT scan. Daarnaast is ook de stralingsdosis vergelijkbaar met een SPECT 
scan, met als voordeel dat CT ook anatomische informatie over de kransslagaders geeft. 
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Hierdoor kan cardiale CT een belangrijke rol als “poortwachters functie” vervullen voor 
patiënten zonder hemodynamisch belangrijke aderverkalking en zo doorverwijzing 
naar invasieve katheterisatie (angiografie) voorkomen.
Het doel van dit proefschrift was het onderzoeken van de waarde van cardiale CT bij 
patiënten met een verdenking op vernauwingen in de kransslagaders. We beschreven 
de effectiviteit, de (kosten-) efficiëntie en veiligheid van cardiale CT als diagnostische 
test om vernauwingen in de kransslagaders op te sporen en vergeleken deze met de 
momenteel standaard functionele test methode.
Hoofdstuk 1 is de algemene inleiding van dit proefschrift waarin het doel en de inde-
ling ervan worden beschreven. In hoofdstuk 2 wordt een overzicht van de technische 
aspecten van cardiale CT beschreven. Onder andere de acquisitie, de evaluatie van data 
en de klinische toepassingen van CT zoals beschreven in de huidige richtlijnen komen 
aan bod.
CT-calciumscan en coronair CT-angiografie bij patiënten met stabiele angina 
pectoris
Hoofdstuk 3 is gericht op de klinische toepassing van cardiale CT in poliklinische 
patiënten met pijn op de borst klachten met een verdenking op vernauwingen in de 
kransslagaders. In 4 ziekenhuizen in regio Rijnmond werden 350 patiënten met stabiele 
pijn op de borst gerandomiseerd tussen een cardiale CT-scan of een standaard functio-
nele test volgens de huidige richtlijnen (de CRESCENT studie). Het cardiale CT protocol 
startte met een CT-calciumscan en in patiënten met vooraf een laag tot intermediair 
risico op vernauwde kransslagaders sloot de afwezigheid van calcium vernauwingen in 
de kransslagaders uit(15). Patiënten met een hoge calcium score (>400) ondergingen 
daarna een functionele test. In de standaard test groep ondergingen de meeste patiën-
ten een fietstest. De belangrijkste bevinding was dat in de CT groep na één jaar meer 
patiënten van hun pijn op de borst klachten af waren. Dit werd mogelijk verklaard door 
de betere diagnostische kwaliteiten van CT, waardoor een meer passende behandeling 
gekozen konden worden, waardoor de klachten sneller en beter verdwenen. Mogelijk 
speelt tevens mee dat artsen en mogelijk ook patiënten meer gerustgesteld waren na 
een negatieve CT scan, in vergelijking met een negatieve functionele test. Ondanks dat 
de studie niet berekend was op het aantonen van verschillen in mortaliteit of hartin-
farcten, werd in de CT groep opgeteld een lager aantal dood, hartinfarct, beroerte, late 
revascularisaties en ongeplande ziekenhuisbezoeken gevonden (3.3% vs 10.2%). Een 
nadeel van CT is het gebruik van röntgen straling, echter door het gebruik van de CT-
calciumscan als triage middel voor de volgende testen en tevens de hedendaagse CT-
apparatuur en dosis verlagende technieken was de cumulatieve stralingsdosis niet meer 
dan 10% hoger vergeleken met de functionele test groep. Op het gebied van efficiëntie 
bleek na CT de diagnose sneller bereikt, waren hier minder diagnostische onderzoeken 
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voor nodig, waaronder ook geen stijging van het aantal invasieve katheterisaties en 
waren de kosten lager vergeleken met de standaard functionele test.
Vrouwen en hart en vaatziekten is de laatste jaren een controversieel onderwerp, 
onder andere omdat blijkt dat de mortaliteit onder vrouwen hoger is (16). Dit heeft te 
maken met een vaak niet-typische presentatie bij vrouwen, een hogere prevalentie van 
verkrampingen in de kransslagvaten (vasospasmen) en meer ziekte in de kleine haarvaat-
jes van het hart (microvasculair vaatlijden), evenals de minder accurate diagnostische 
functionele testen bij vrouwen. Hierom lijkt cardiale CT, waarbij de aanwezigheid van 
aderverkalking direct gevisualiseerd wordt, een uitermate geschikte test voor vrouwen. 
Hoofdstuk 4 breidt voort op hoofdstuk 3 en beschrijft de verschillen tussen man en 
vrouw in de prestatie van cardiale CT in vergelijking met de functionele diagnostische 
test. Cardiale CT bleek meer efficiënt bij vrouwen wat betreft een kortere tijd tot de 
uiteindelijke diagnose en daarbij bleken minder extra diagnostische testen nodig.
In hoofdstuk 5 presenteren we de prospectieve, multicenter, gerandomiseerde 
IsoCOR studie. Door technische ontwikkelingen kunnen de kransslagaders van het 
hart tegenwoordig gescand worden met lagere “buis spanningen” (kV). Hierdoor is de 
stralingsdosis verlaagd, maar het vergroot ook de aankleuring (attenuatie)-verschillen 
tussen jodium en de weke delen. Hierdoor kan contrastmiddel met een lagere jo-
dium concentratie geïnjecteerd worden en hiermee voldoende contrastaankleuring 
verkregen worden. Iso-osmolaire contrast middelen, dus met een osmolariteit gelijk 
aan bloedplasma, veroorzaken minder hartritme versnellingen en aritmiëen, wat uit-
eindelijk zou kunnen zorgen voor een betere CT beeldkwaliteit (17-21). In de IsoCOR 
studie, werden 306 patiënten in de regio Rijnmond gerandomiseerd en vergeleken 
we de aankleuring van de kransslagaders door twee verschillende contrastmiddelen: 
iso-osmolair iodixanol-270 mg I/ml (Visipaque) en laag-osmolair iopromide 300mg I/ml 
(Ultravist). Beide contrast middelen werden met gelijke jodium aanvoersnelheden ge-
injecteerd en we vonden een aankleuring van de kransslagaders die met iodixanol-270 
niet inferieur was aan iopromide-300 (476 ± 160 Hounsfield Units (HU) vs 454 ± 158 HU). 
Omdat de osmolariteit van contrastmiddel ook geassocieerd is met een aantal klinische 
effecten, zoals een gevoel van warmte, pijn, en hartritme versnellingen, werd dit in de 
IsoCOR studie ook onderzocht. Patiënten in de iodixanol-270 groep ervoeren significant 
minder warmte-discomfort (72% vs. 86%), maar er werden geen verschillen in hartritme 
geobjectiveerd. Er dient te worden opgemerkt dat bijna de helft van alle patiënten 
een bètablokker kregen toegediend voor de CT scan, maar in vergelijkbare aantallen 
in beide groepen. Tenslotte werd er geen verschil in beeldkwaliteit gevonden tussen 
beide contrastmiddelen.
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CT-myocard perfusie bij patiënten met stabiele angina pectoris
Verminderde doorbloeding van de hartspier (myocardiale perfusie) veroorzaakt door 
vernauwingen in de kransslagaders blijkt meer uitgesproken te zijn in het subendo-
cardium, de diepste laag van de hartspier (22). Dit wordt mogelijk verklaard door een 
vermindering in diastolische perfusie tijd, hogere weefsel drukken tijdens contractie in 
de hartspier ter plaatse, en verschillen in de coronaire haarvaatjes (microvasculatuur)
(22, 23). De hoge spatiele resolutie van CT maakt het mogelijk onderscheid te maken 
tussen subendocard en subepicard. Een methode om de gevoeligheid van subendocard 
voor ischemie uit te drukken is de transmurale perfusie ratio (TPR). De hypothese van 
hoofdstuk 6 was dat deze ratio de diagnostische prestatie van CT-MPI kon verbeteren, 
omdat de TPR minder gevoelig is voor lagere absolute bloedstroom, omdat het een 
relatieve index is. We vergeleken de additionele waarde van TPR alleen en in combi-
natie met de normale myocardiale bloedstroom (MBF) waardes in dynamische CT-MPI. 
Er werden 43 patiënten, en 94 myocardiale territoria geanalyseerd. De “area under the 
receiver operator curve” was significant groter voor MBF vergeleken met TPR, en ook 
de toevoeging van TPR aan MBF bracht geen toegevoegde waarde. Terwijl sommige 
studies de toegevoegde waarde van TPR aan het detecteren van ischemie laten zien(24), 
zijn er ook recentere studies die aantonen dat een visuele beoordeling van ischemie 
beter presteert dan TPR (25). Wij concludeerden dat TPR in dynamische CT-MPI geen 
toegevoegde waarde heeft. Deze negatieve uitkomst kan mogelijk verklaard worden 
doordat de endocardiale zone direct aangrenzend aan de linker ventrikel vatbaar is voor 
artefacten, zoals “beam hardening” en “partial voluming”, wat subtiele perfusie defecten 
heeft kunnen vervagen.
In hoofdstuk 7 presenteren we de CRESCENT-II studie: een prospectieve, multicenter, 
gerandomiseerde studie waarin de effectiviteit , de efficiëntie en de veiligheid van cardi-
ale CT onderzocht werd in vergelijking met een standaard functionele test strategie. De 
CRESCENT-II studie verschilde van de CRESCENT-I studie wat betreft de CT-strategie. In 
CRESCENT-II werd er gestart met een CT-calciumscan, gevolgd door CCTA als er calcium 
gedetecteerd werd. Patiënten met een significante stenose op CCTA ondergingen ook 
een zogenaamde perfusie scan (CT-MPI) om de hemodynamische ernst van de vernau-
wing te bepalen. In de functionele test groep onderging 95% als eerste test een fietstest.
Het doel van het uitvoeren van niet-invasieve diagnostische onderzoeken in patiënten 
met een verdenking op een vernauwing in de kransslagaders is om op een betrouwbare 
wijze vernauwingen uit te sluiten. Een invasieve katheterisatie (angiografie) waarbij uit-
eindelijk géén vernauwingen zichtbaar blijken te zijn, beschouwen we als een falende 
poortwachters functie van de diagnostische testen die hieraan vooraf zijn gegaan. In 
de CRESCENT-II studie was het primaire eindpunt het aantal invasieve katheterisaties 
zónder significant vernauwde kransslagaders (13), dit aantal bleek significant lager in 
de CT groep vergeleken met de standaard functionele test (1.5% vs 7.2%). In 34% van 
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de patiënten met een >50% vernauwing in één van de kransslagaders op CCTA werd 
myocard ischemie toch uitgesloten door middel van een perfusie scan (CT-MPI). Hier-
mee heeft CT-MPI een belangrijke rol in de CT-strategie als “poortwachter” voor door-
verwijzing naar invasieve katheterisatie. In tegenstelling tot onze verwachtingen was 
het aantal invasieve katheterisaties niet verhoogd in de CT groep, daarnaast bleken in 
de CT groep een hoger aantal invasieve katheterisaties mét significante vernauwingen 
opgespoord te worden (88% vs 50%) (26-28). Tenslotte bleek een CT strategie snel-
ler tot een diagnose te leiden en waren daar minder extra diagnostische testen voor 
nodig. Een nadeel van cardiale CT is de straling, met name CT-MPI gaat gepaard met 
een hogere stralingsdosis. In onze studie was de gemiddelde stralingsdosis van CT-MPI 
10.6±6.3mSv. Maar omdat CT-MPI enkel nodig was in 22% van de CT patiënten, was 
de gemiddelde cumulatieve stralingsdosis in de CT groep 5.6±6.3mSv. Dit was hoger 
vergeleken met de functionele test groep, waarin de meesten primair een fietstest 
ondergingen en uiteindelijk slechts 37% een tweede test nodig had die straling betrof 
(nucleaire SPECT scan, danwel katheterisatie). De conclusie van de CRESCENT-II studie 
was dat bij patiënten met verdenking op vernauwde kransslagaders een cardiale CT, 
met stapsgewijze uitvoering van CT-calciumscan, CCTA, en CT-MPI, een snel, veilig en 
efficiënt alternatief is voor de functionele test.
Coronair-CT angiografie bij patiënten met verdenking op een acuut hartinfarct 
(ACS)
Het laatste deel van het proefschrift gaat over CT (CCTA) bij patiënten met verdenking 
op een ACS (“hartinfarct”). Het is in deze patiënten groep op de spoedeisende hulp 
belangrijk om een ACS, of een andere levensbedreigende aandoening, met zekerheid 
uit te sluiten. Aan de andere kant is het belangrijk hierin een efficiënte strategie te 
hanteren, omdat er wereldwijd grote aantallen patiënten zich zo presenteren en vele 
daarvan blijken uiteindelijk geen hartinfarct of andere ernstige aandoening te hebben. 
Meerdere studies hebben recent aangetoond dat CT veilige en efficiëntere diagnostiek 
is op de spoedeisende hulp bij patiënten met acute pijn op de borst in vergelijking 
met de oude standaard (29-32). Echter zijn deze studies niet uitgevoerd ten tijde van 
de “high sensitivity troponines” (hs-troponine). Troponine is een stof die vrijkomt uit 
beschadigd hartspierweefsel, zoals tijdens een hartinfarct. De nieuwe hs-troponine zijn 
zeer gevoelig en kunnen daarmee hartspierschade nog sneller detecteren. In hoofdstuk 
8 worden de resultaten van de prospectieve, multicenter gerandomiseerde BEACON 
studie beschreven. 500 patiënten met acute pijn op de borst verdacht voor ACS werden 
gerandomiseerd tussen een diagnostische strategie aangevuld met CT, danwel de 
momenteel standaard optimale zorg. In beide groepen waren de hs-troponine beschik-
baar. Belangrijkste exclusie criterium was de behoefte aan acute revascularisatie. We 
concludeerden dat een diagnostische strategie met CT op de spoedeisende hulp veilig 
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is en gepaard gaat met minder poliklinische diagnostische testen in een later stadium 
en lagere kosten. Echter, in de huidige tijd met de beschikbaarheid van hs-troponine 
worden er door CT niet meer patiënten geïdentificeerd die een revascularisatie behoe-
ven, tevens verkort het de duur in het ziekenhuis niet en leidt het ook niet tot sneller 
ontslag van de spoedeisende hulp.
Zoals ook beschreven in hoofdstuk 4 worden hart en vaatziekten nog vaak onderkend 
in vrouwen. In hoofdstuk 9 worden de verschillen tussen man en vrouw onderzocht in 
klinische effectiviteit tussen de CT en de standaard strategie in patiënten met acute pijn 
op de borst op de spoedeisende hulp. Vrouwen bleken minder vaak vernauwingen in de 
kransslagaders te hebben en werden minder vaak gediagnosticeerd met hartinfarcten 
(ACS) vergeleken met mannen. Wat betreft de effectiviteit, bleken er geen additionele 
voordelen aan een CT strategie te zitten voor vrouwen. In tegenstelling leken er in voor-
gaande studies wel voordelen te zitten aan een vroege CT-scan bij vrouwen met acute 
pijn op de borst (33). Het verschil in uitkomst kan te maken hebben met de nieuwe 
beschikbaarheid van de hs-troponine.
Nu voor patiënten met acute pijn op de borst CT op de spoedeisende hulp zich aan 
het ontwikkelen is als mogelijk nieuwe strategie, hebben we in hoofdstuk 10 de ver-
schillen in beeld kwaliteit van CT gedurende de dag en nacht beoordeeld. Het 24uur 
per dag bieden van de mogelijkheid tot cardiale CT op een spoedeisende hulp gaat 
namelijk gepaard met enige uitdagingen, zoals de beschikbaarheid van geavanceerde 
scanners en ervaren personeel, maar ook wat betreft patiënt karakteristieken en de 
ernst van ziekte (34, 35). In het coördinerend centrum van de Beacon studie, het Eras-
mus MC, werden patiënten 24uur per dag, 7 dagen per week geïncludeerd. Van deze 
118 patiënten, waarvan 75% zich presenteerde tijdens normale kantoortijden, en 25% 
daarbuiten, hebben we de beeldkwaliteit van CT onderzocht. De beeldkwaliteit bleek 
significant lager in de diensten ten opzichte van de normale kantoortijden, tevens bleek 
het aantal niet-beoordeelbare segmenten tijdens diensten hoger. Dit werd niet ver-
klaard door klinische karakteristieken, type scanner, acquisitie parameters of bètablok-
ker toediening. Mogelijk dat een combinatie van andere onbekende “confounders” een 
rol hebben gespeeld in de lagere beeldkwaliteit tijdens diensturen. Er werd een trend 
naar een hogere hartfrequentie gezien tijdens de diensturen (64 vs 69, p=0.095), wat 
mogelijk meegespeeld heeft. Tevens kan de ervaring van de CT-laboranten en de werk-
druk tijdens diensten op de spoedeisende hulp meegespeeld hebben, maar dit werd in 
deze studie niet onderzocht. Naast de mindere beeldkwaliteit tijdens diensten, bleek 
dat patiënten die zich buiten kantooruren presenteerden langer op de spoedeisende 
hulp verbleven en vaker in het ziekenhuis werden opgenomen. Dit is in lijn met eerdere 
studies en kan verklaard worden door logistieke redenen, zoals de beschikbaarheid van 
diagnostiek en personeel, naast de ongunstige klinische kenmerken van patiënten die 
zich buiten kantoortijden presenteren(34, 35). Om CT 24/7 beschikbaar te maken op 
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een spoedeisende hulp is state-of-the-art scanner technologie vereist, voldoende goed 
opgeleid personeel met verstand van cardiale CT en met tijd voor voorbereiding en 
optimalisatie van de procedure.
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PHD PORTFOLIO
year Workload
(ECTS)
1. PhD training
General academic and research skills
Introduction to clinical research, NIHES Erasmus MC 2013 0.9
CCO2 Biostatistical methods I: basic principles, NIHES Erasmus MC 2013 5.7
Instellingsgebonden regelgeving en stralingshygiëne niveau 5A, Erasmus 
MC
2013 1.25
Open Clinica training 2014 0.3
English biomedical writing and communication course, Erasmus MC 2014 3.0
Diagnostic research, NIHES Erasmus MC 2014 0.75
Advanced decision making, NIHES Erasmus MC 2014 1.4
Photoshop and Illustrator CS6 workshop, Erasmus MC 2014 0.3
Research integrity course, Erasmus MC 2015 0.3
In-depth courses
Cardiovascular imaging and diagnostics, COEUR Erasmus MC 2013 1.5
Cardiovascular pharmacology, COEUR Erasmus MC 2013 1.5
Cardiovascular medicine, COEUR Erasmus MC 2013 1.5
Translational electrophysiology, COEUR Erasmus MC 2013 0.4
Gender differences in cardiovascular disease 2013 0.4
Ercathan module1: functionele en toegepaste cardiale anatomie, Skillslab 
EMC
2013 0.3
Heart failure research, COEUR Erasmus MC 2014 1.5
Arrhythmia research methodology 2014 1.5
Webinar EACVI advanced cardiac CT, ESC EACVI 2015 0.3
Congenital heart disease 2015 1.5
Coeur PhD days 2014, 2016 0.8
Conferences and Symposia
RSNA Annual Meeting 2014 1.2
ECR congress 2015, 2016 2.4
ESC congress 2015 1.5
Radiologen dagen 2015 0.6
NVVC congress 2015, 2016 (2x) 1.5
SCCT winter meeting 2016 0.9
ACC Scientific Sessions 2016 0.9
SCCT Annual Scientific Meeting 2016 0.9
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2. Teaching
Lecturing
Basic + Advanced Cardiac CT workshop, K.Nieman/R.Budde Erasmus MC 2014, 2015 (2x), 2016 2.1
Siemens CT-User day, presentation about CT myocardial perfusion imaging 2016 0.3
Supervising practicals
Supervising research of 2nd year medical students 2014, 2016 0.6
TOTAAL 38
Oral presentations
2016 The Netherlands Society of Cardiology (NVVC) autumn congress, Papendal, The Netherlands
2016 American College of Cardiology (ACC) conference, Chicago, USA
2016 The Netherlands Society of Cardiology (NVVC) spring congress, Noordwijkerhout, The Netherlands
2016 European Congress of Radiology (ECR), Vienna, Austria
2016 Society of Cardiovascular Computed Tomography (SCCT) winter meeting, Istanbul, Turkey
2015 The Netherlands Society of Cardiology (NVVC) autumn congress, Papendal, The Netherlands
2015 Radiologen dagen, Rotterdam, The Netherlands
2015 European Society of Cardiology (ESC), London, UK
Moderated poster presentations
2016 Society of Cardiovascular Computed Tomography (SCCT), Orlando, USA
Poster presentations
2015 European Congress of Radiology (ECR), Vienna, Austria
2014 Radiological Society of North America (RSNA), Chicago, USA
Awards
2016 NVVC autumn, best presentation in session I: computed tomography / Cardiovascular magnetic 
resonance
2016 SCCT Istanbul, best abstract
2015 NVVC autumn, best presentation in session I: computed tomography / Cardiovascular magnetic 
resonance
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